2024 Cigna Healthcare
Comprehensive Drug List
(Formulary)

Please read:
This document contains information about
all of the drugs we cover in this plan.

HPMS Approved Formulary File Submission 00024188, Version Number 11.
This formulary was updated on 3/1/2024. For more recent information or other questions, please contact Cigna Healthcare Customer
Service, at 1-800-668-3813 (TTY users should call 711), 8 a.m. – 8 p.m. local time, 7 days a week October - March, Monday to Friday
April - September. Messaging service used weekends, after hours and on federal holidays, or visit CignaMedicare.com.
The Formulary and pharmacy network may change at any time. For a complete list of Contract/PBP numbers this document applies to,
please refer to the back cover of this document.

March 2024
24_F_01_MAPD_01_V03
INT_24_1010203_C_Final_1_c

Note to existing customers: This formulary has changed since last year. Please review this document to make sure
that it still contains the drugs you take.
When this drug list (formulary) refers to “we,” “us,” or “our,” it means Cigna Healthcare. When it refers to “plan”
or “our plan,” it means Cigna Preferred GA Medicare (HMO), Cigna Preferred DC Medicare (HMO), Cigna Preferred
Medicare (HMO), Cigna Preferred Plus Medicare (HMO), Cigna Premier Medicare (HMO-POS), Cigna True Choice
Medicare (PPO), Cigna True Choice Access Medicare (PPO), Cigna True Choice DE Medicare (PPO), Cigna True
Choice Savings Medicare (PPO), Cigna True Choice Plus Medicare (PPO), Cigna Preferred Savings Medicare (HMO),
Cigna Alliance Medicare (HMO).
This document includes a list of the drugs (formulary) for our plans, which is current as of March 2024. For an
updated formulary, please contact us. Our contact information, along with the date we last updated the formulary,
appears on the front and back cover pages.
You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy
network, and/or copayments/coinsurance may change on January 1, 2025, and from time to time during the year.
What is the Cigna Healthcare Comprehensive Drug List?
A drug list is a list of covered drugs selected by Cigna
Healthcare in consultation with a team of health care providers,
which represents the prescription therapies believed to be a
necessary part of a quality treatment program. Cigna Healthcare
will generally cover the drugs listed in our drug list as long as
the drug is medically necessary, the prescription is filled at a
Cigna Healthcare network pharmacy, and other plan rules are
followed. For more information on how to fill your prescriptions,
please review your Evidence of Coverage (EOC).

– If we make such a change, you or your prescriber can ask
us to make an exception and continue to cover the brand
name drug for you. The notice we provide you will also
include information on how to request an exception, and
you can also find information in the section entitled “How do
I request an exception to the Cigna Healthcare Drug List?”
• Drugs removed from the market. If the Food and Drug
Administration (FDA) deems a drug on our drug list to be
unsafe or the drug’s manufacturer removes the drug from the
market, we will immediately remove the drug from our drug
list and provide notice to customers who take the drug.

Can the Drug List (formulary) change?
Most changes in drug coverage happen on January 1, but we
may add or remove drugs on the drug list during the year, move
them to different cost-sharing tiers, or add new restrictions. We
must follow Medicare rules in making these changes.

• Other changes. We may make other changes that affect
customers currently taking a drug. For instance, we may
add a generic drug that is not new to the market to replace
a brand name drug currently on the drug list, or add new
restrictions to the brand name drug or move it to a different
cost-sharing tier or both. Or we may make changes based
on new clinical guidelines and/or studies. If we remove drugs
from our drug list, add prior authorization, quantity limits, and/
or step therapy restrictions on a drug or move a drug to a
higher cost-sharing tier, we must notify affected customers
of the change at least 30 days before the change becomes
effective, or at the time the customer requests a refill of the
drug, at which time the customer will receive a 30-day supply
of the drug.

Changes that can affect you this year. In the below cases,
you will be affected by coverage changes during the year:
• New generic drugs. We may immediately remove a brand
name drug on our drug list if we are replacing it with a new
generic drug that will appear on the same or lower costsharing tier and with the same or fewer restrictions. Also,
when adding the new generic drug, we may decide to keep
the brand name drug on our drug list, but immediately move
it to a different cost-sharing tier or add new restrictions. If you
are currently taking that brand name drug, we may not tell
you in advance before we make that change, but we will later
provide you with information about the specific change(s) we
have made.
March 2024

– If we make these other changes, you or your prescriber
can ask us to make an exception and continue to cover the
brand name drug for you. The notice we provide you will
also include information on how to request an exception,
1

What are generic drugs?
Cigna Healthcare covers both brand name drugs and generic
drugs. A generic drug is approved by the FDA as having the
same active ingredient as the brand name drug. Generally,
generic drugs cost less than brand name drugs.

– and you can find information in the section below titled
“How do I request an exception to the Cigna Healthcare
Drug List?”
Changes that will not affect you if you are currently taking
the drug. Generally, if you are taking a drug on our 2024 drug
list that was covered at the beginning of the year, we will not
discontinue or reduce coverage of the drug during the 2024
coverage year except as described above. This means these
drugs will remain available at the same cost-sharing and with
no new restrictions for those customers taking them for the
remainder of the coverage year. You will not get direct notice
this year about changes that do not affect you. However, on
January 1 of the next year, such changes would affect you, and
it is important to check the drug list for the new benefit year for
any changes to drugs.

Are there any restrictions on my coverage?
Some covered drugs may have additional requirements or limits
on coverage. These requirements and limits may include:
• Prior Authorization: Cigna Healthcare requires you or your
doctor to get prior authorization for certain drugs. This means
that you will need to get approval from Cigna Healthcare
before you fill these prescriptions. If you don’t get approval,
Cigna Healthcare may not cover the drug.
• Quantity Limits: For certain drugs, Cigna Healthcare limits
the amount of the drug that Cigna Healthcare will cover. For
example, Cigna Healthcare allows for 1 tablet per day for
atorvastatin 40mg. This applies to a standard one-month
supply (for total quantity of 30 per 30 days) or three-month
supply (for total quantity of 90 per 90 days).

The enclosed drug list is current as of March 2024. To get
updated information about the drugs covered by Cigna
Healthcare, please contact us. Our contact information appears
on the front and back cover pages. If there are significant
changes made to the printed drug list within the covered year,
you may be notified by mail identifying the changes. Drug lists
located on our website are reviewed and updated on a monthly
basis.

• Step Therapy: In some cases, Cigna Healthcare requires you
to first try certain drugs to treat your medical condition before
we will cover another drug for that condition. For example, if
Drug A and Drug B both treat your medical condition, Cigna
Healthcare may not cover Drug B unless you try Drug A first.
If Drug A does not work for you, Cigna Healthcare will then
cover Drug B.

How do I use the Drug List?
There are two ways to find your drug within the drug list:
Medical Condition
The drug list begins on page 13. The drugs in this drug list
are grouped into categories depending on the type of medical
conditions that they are used to treat. For example, drugs
used to treat a heart condition are listed under the category,
“CARDIOVASCULAR, HYPERTENSION / LIPIDS.” If you know
what your drug is used for, look for the category name in the list
that begins on page 13. Then look under the category name for
your drug.

• Non-Extended Days Supply: For certain drugs, Cigna
Healthcare limits the amount of the drug that Cigna
Healthcare will cover to only a 30-day supply or less, at
one time. For example, customers who have not had any
recent fill of opioid pain medications within the past 108 days
(referred to as “opioid naïve”) are limited to a maximum of 7
days’ supply of opioid pain medication. Customers who have
received a recent fill of an opioid pain medication (not opioid
naïve) are limited to up to a month’s supply of that medication
at one time. Other high cost drugs may be subject to a nonextended day supply restriction, as well.

Covered Drug Index
If you are not sure what category to look under, you should look
for your drug in the Covered Drugs Index that begins on page
66. The Covered Drugs Index provides an alphabetical list of all
of the drugs included in this document. Both brand name drugs
and generic drugs are listed in the Index. Look in the Index and
find your drug. Next to your drug, you will see the page number
where you can find coverage information. Turn to the page
listed in the Covered Drug Index and find the name of your drug
in the drug name column of the list.

March 2024

You can find out if your drug has any additional requirements
or limits by looking in the drug list that begins on page 13. You
can also get more information about the restrictions applied to
specific covered drugs by visiting our website. We have posted
online documents that explain our prior authorization and step
therapy restrictions. You may also ask us to send you a copy.
Our contact information, along with the date we last updated the
drug list, appears on the front and back cover pages.

2

You can ask Cigna Healthcare to make an exception to these
restrictions or limits or for a list of other, similar drugs that may
treat your health condition. See the section, “How do I request
an exception to the Cigna Healthcare drug list?” on page 3 for
information about how to request an exception.

show it to your doctor and ask them to prescribe a similar
drug that is covered by Cigna Healthcare.
• You can ask Cigna Healthcare to make an exception and
cover your drug. See the next section for information about
how to request an exception.

Options for Maintenance Medications
Taking the medications prescribed by your doctor (or other
prescriber) is important to your health.

How do I request an exception to the Cigna Healthcare
Drug List?
You can ask Cigna Healthcare to make an exception to our
coverage rules. There are several types of exceptions that you
can ask us to make.

We are committed to helping you control your chronic conditions
by making it easy for you to receive your maintenance
medications. There are several ways we can work together
to accomplish this goal:

• You can ask us to cover a drug even if it is not on our drug
list. If approved, this drug will be covered at a pre-determined
cost-sharing level, and you would not be able to ask us to
provide the drug at a lower cost-sharing level.

• Talk with your doctor about whether a 90-day supply of your
ongoing, stable medications may be appropriate. Taking
these medications every day as prescribed is important for
your overall health, and getting 90-day prescriptions of these
medications can help ensure that you do not miss a dose.

• You can ask us to waive coverage restrictions or limits on
your drug. For example, for certain drugs, Cigna Healthcare
limits the amount of the drug that we will cover. If your drug
has a quantity limit, you can ask us to waive the limit and
cover a greater amount.

• You can receive a 90-day supply at most retail pharmacies or
through one of our mail-order pharmacies.
• Talk to your pharmacist if you are experiencing any new
challenges with your maintenance medications.

• You can ask us to cover a formulary drug at a lower costsharing level, unless the drug is on the specialty tier. If
approved, this would lower the amount you must pay for
your drug. This applies to the following circumstances:

How can I use my prescription drug coverage to save
money on my medications?
There may be opportunities for you to save money on your
medications using your Cigna Healthcare coverage.

– If the drug you’re taking is a brand name drug, you can
ask us to cover your drug at the cost-sharing amount
that applies to the lowest tier that contains brand name
alternatives for treating your condition.

• Ask your doctor (or other prescriber) if there are any lowercost generic alternatives available for any of your current
medications.

– If the drug you’re taking is a generic drug, you can ask us
to cover your drug at the cost-sharing amount that applies
to the lowest tier that contains either brand or generic
alternatives for treating your condition.

• Some plans may offer a $0 copay for Tier 1 and Tier 2 generic
drugs filled at a preferred retail and/or mail-order pharmacies.
Refer to your Evidence of Coverage (EOC) for your plan’s
specific cost-sharing amounts.

– If the drug you’re taking is a biological product, you can
ask us to cover your drug at the cost-sharing amount that
applies to the lowest tier that contains biological product
alternatives for treating your condition.

• Explore whether the ‘CMS Extra Help’ program may offer
additional financial support for your medications.
• If your medication is not covered in the Cigna Healthcare drug
list, talk with your doctor about alternative medications which
are covered on the drug list.

Please note, if we grant your request to cover a drug that is
not on our drug list, you may not ask us to provide this drug
at a lower cost-sharing level.
Generally, Cigna Healthcare will only approve your request for
an exception if the alternative drug is included in our drug list,
the lower cost-sharing drug or additional utilization restrictions
would not be as effective in treating your condition and/or would
cause you to have adverse medical effects.

What if my drug is not on the Drug List?
If your drug is not included in this drug list, you should first
contact Customer Service and ask if your drug is covered. If
you learn that Cigna Healthcare does not cover your drug, you
have two options:

You should contact us to ask us for an initial coverage decision
for a drug list, tiering or utilization restriction exception. When

• You can ask Customer Service for a list of similar drugs that
are covered by Cigna Healthcare. When you receive the list,
March 2024

3

you request a drug list, tiering or utilization restriction
exception you should submit a statement from your
prescriber or doctor supporting your request. Generally,
we must make our decision within 72 hours of getting your
prescriber’s supporting statement. You can request an
expedited (fast) exception if you or your doctor believe that your
health could be seriously harmed by waiting up to 72 hours for
a decision. If your request to expedite is granted, we must give
you a decision no later than 24 hours after we get a supporting
statement from your doctor or other prescriber.

If you are a resident of a long-term care facility and you need a
drug that is not on our drug list or if your ability to get your drugs
is limited, but you are past the first 90 days of membership in
our plan, we will cover a 31-day emergency supply of that drug
while you pursue a drug list exception.
In order to accommodate unexpected transitions of our
customers that do not leave time for advanced planning, such
as level-of-care changes due to discharge from a hospital to a
nursing facility or to a home, Cigna Healthcare will allow a onetime 31-day supply (unless the prescription is written for fewer
days).

What do I do before I can talk to my doctor about changing
my drugs or requesting an exception?
As a new or existing customer in our plan you may be taking
drugs that are not on our drug list. Or, you may be taking a drug
that is on our drug list but your ability to get it is limited. For
example, you may need a prior authorization from us before
you can fill your prescription. You should talk to your doctor
to decide if you should switch to an appropriate drug that we
cover or request a drug list exception so that we will cover the
drug you take. While you talk to your doctor to determine the
right course of action for you, we may cover your drug up to a
30-day supply, in certain cases during the first 90 days you are
a customer of our plan.

Cigna Healthcare’s Drug List
The comprehensive drug list that begins on page 13 provides
coverage information about all of the drugs covered by Cigna
Healthcare. If you have trouble finding your drug in the list, turn
to the Covered Drug Index that begins on page 66.
The first column of the chart lists the drug name. Brand name
drugs are capitalized (e.g., TRELEGY ELLIPTA) and generic
drugs are listed in lower-case italics (e.g., atorvastatin).
The information in the Requirements/Limits column tells you if
Cigna Healthcare has any special requirements for coverage of
your drug.
We provide quantity limits on certain drugs which are indicated
with a QL in the Covered Drugs by Category list on page 13
along with the amount dispensed per the days supplied. (For
example: atorvastatin 40mg QL 30/30; this means the drug
atorvastatin 40mg is limited to 30 tablets per 30 days. For 90day supplies, this quantity limit would be expanded to 90 tablets
per 90 days).

For each of your drugs that is not on our drug list or if your
ability to get your drugs is limited, we will cover a temporary
30-day supply. If your prescription is written for fewer days,
we’ll allow refills to provide up to a maximum 30-day supply of
medication. After your first 30-day supply, we will not pay for
these drugs without a drug list exception, even if you have been
a customer of the plan less than 90 days.

For more information
For more detailed information about your Cigna Healthcare prescription drug coverage, please review your
Evidence of Coverage (EOC) and other plan materials. To access a copy of your most recent EOC, go to
CignaMedicare.com/resources.
If you have questions about Cigna Healthcare, please contact us. Our contact information, along with the date
we last updated the drug list, appears on the front and back cover pages.
If you have general questions about Medicare prescription drug coverage, please call Medicare at
1-800-MEDICARE (1-800-633-4227), 24 hours a day, 7 days a week. TTY users should call 1-877-486-2048.
Or, visit http://www.medicare.gov.

March 2024

4

The following Cigna Healthcare plans offer 100-day extended supplies for certain medications. If your plan is listed below,
please refer to your Evidence of Coverage (EOC) for more information about this coverage. To access a copy of your most
recent EOC, go to CignaMedicare.com/resources.
PLAN NAME

PBP NUMBER

PLAN NAME

PBP NUMBER

Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)

H0672-001-000
H0672-003-000
H0672-004-000
H0672-005-000
H0672-006-000
H0672-007-000
H0672-008-000

Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)

H0672-011-000
H0672-013-000
H0672-014-000
H0672-016-000
H0672-017-000
H7849-015-000
H7849-088-000

Gap Coverage
The following plans offer additional prescription drug coverage in the coverage gap in the tier listed. If your plan is listed below, please
refer to your Evidence of Coverage (EOC) for more information about this coverage. To access a copy of your most recent EOC, go to
CignaMedicare.com/resources.
PLAN NAME

PBP NUMBER

TIER

Cigna Preferred GA Medicare (HMO)
Cigna Preferred GA Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)

H0439-003-001
H0439-003-002
H0439-006-000
H0439-007-000
H0439-008-000
H0439-009-000
H0439-010-000
H0439-011-000
H0439-013-000
H0672-001-000
H0672-003-000
H0672-004-000

Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs

Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Alliance Medicare (HMO)

H0672-005-000
H0672-006-000
H0672-007-000
H0672-008-000
H0672-011-000
H0672-013-000
H0672-014-000
H0672-016-000
H0672-017-000
H2108-022-000
H2108-036-000

Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs

March 2024

5

PLAN NAME

PBP NUMBER

TIER

Cigna Preferred DC Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Medicare (HMO)

H2108-040-000
H2108-042-001
H2108-042-002
H3949-030-000
H3949-031-000
H3949-032-000
H3949-034-000
H3949-035-000
H3949-045-000
H3949-046-000
H3949-047-000
H3949-048-000
H3949-049-000

Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage

Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Premier Medicare (HMO-POS)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Alliance Medicare (HMO)

H3949-050-000
H4407-027-000
H4407-028-000
H4407-030-001
H4407-030-002
H4407-030-003
H4513-026-000
H4513-030-000
H4513-036-000
H4513-037-000
H4513-038-000
H4513-049-001
H4513-049-002
H4513-049-003
H4513-049-004
H4513-049-005
H4513-050-000
H4513-051-000
H4513-052-000
H4513-059-000
H4513-061-001
H4513-061-002
H4513-061-003
H4513-061-004
H4513-061-005
H4513-064-000

Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage

March 2024

6

PLAN NAME

PBP NUMBER

TIER

Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Premier Medicare (HMO-POS)

H4513-068-001
H4513-068-002
H4513-068-003
H4513-073-000
H4513-074-000
H4513-083-001
H4513-083-002
H4513-083-003
H4513-083-004
H4513-083-005
H4513-083-006
H4513-083-007
H4513-084-000

Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs

Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)

H4513-085-000
H4513-086-000
H5410-018-000
H5410-024-000
H5410-026-000
H5410-027-000
H5410-028-000
H5410-029-000
H5410-030-000
H5410-037-000
H5410-039-000
H5410-040-000
H5410-041-000
H5410-043-000
H5410-044-000
H5410-048-000
H5410-050-000
H5410-051-000
H5410-052-000
H5410-053-000
H5410-054-000
H7020-004-000
H7020-006-000
H7020-008-000
H7020-009-000
H7389-001-000

Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1 and 2: Full Coverage
Tier 1 and 2: Full Coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1 and 2: Full Coverage
Tier 1 and 2: Full Coverage
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs

March 2024

7

PLAN NAME

PBP NUMBER

TIER

Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Savings Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)

H7389-002-000
H7389-003-000
H7389-004-000
H7389-008-000
H7389-011-000
H7787-001-000
H7849-001-000
H7849-002-000
H7849-003-000
H7849-006-000
H7849-013-000
H7849-014-000
H7849-015-000

Tier 1 and 2: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1 and 2: Full coverage
Tier 1: Full coverage

Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)

H7849-017-000
H7849-018-000
H7849-020-000
H7849-021-000
H7849-022-000
H7849-023-000
H7849-024-000
H7849-026-000
H7849-027-000
H7849-029-000
H7849-030-000
H7849-031-000
H7849-033-000
H7849-034-000
H7849-037-000
H7849-038-000
H7849-039-000
H7849-041-000
H7849-042-000
H7849-044-000
H7849-045-000
H7849-047-000
H7849-048-000
H7849-050-000
H7849-051-000
H7849-052-000

Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage

March 2024

8

PLAN NAME

PBP NUMBER

TIER

Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Access Medicare (PPO)
Cigna True Choice Access Medicare (PPO)
Cigna True Choice Access Medicare (PPO)
Cigna True Choice Access Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)

H7849-054-000
H7849-055-000
H7849-056-000
H7849-057-000
H7849-058-000
H7849-059-000
H7849-060-000
H7849-064-001
H7849-064-002
H7849-064-003
H7849-064-004
H7849-065-000
H7849-066-000

Tier 1: Full coverage
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1 and 2: Full coverage
Tier 1 and 2: Full coverage

Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)

H7849-067-000
H7849-068-000
H7849-070-000
H7849-071-000
H7849-076-000
H7849-077-000
H7849-080-000
H7849-081-000
H7849-082-000
H7849-083-000
H7849-084-000
H7849-085-000
H7849-087-000
H7849-088-000
H7849-101-000
H7849-102-001
H7849-102-002
H7849-102-003
H7849-102-004
H7849-103-000
H7849-104-000
H7849-105-000
H7849-106-000
H7849-107-000
H7849-108-000
H7849-109-000

Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1 and 2: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage

March 2024

9

PLAN NAME

PBP NUMBER

TIER

Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Access Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)

H7849-110-000
H7849-111-000
H7849-112-001
H7849-112-002
H7849-113-001
H7849-113-002
H7849-113-003
H7849-113-004
H7849-114-000
H7849-115-000
H7849-116-000
H7849-117-001
H7849-117-002

Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs

Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice Savings Medicare (PPO)
Cigna True Choice DE Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Plus Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna True Choice Medicare (PPO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Medicare (HMO)
Cigna Preferred Plus Medicare (HMO)

H7849-118-000
H7849-119-000
H7849-120-000
H7849-121-000
H7849-123-000
H7849-124-001
H7849-124-002
H7849-125-000
H7849-127-000
H7849-128-000
H7849-129-000
H7849-130-000
H7849-131-000
H7849-132-000
H7849-133-001
H7849-133-002
H7849-133-003
H7849-134-001
H7849-134-002
H9460-001-000
H9725-008-000
H9725-010-000
H9725-011-000

Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Full coverage
Tier 1: Partial coverage for Excluded Drugs
Tier 1: Partial coverage for Excluded Drugs

For insulins that are covered by our plans, you will pay only $35 for each 30-day script and $0 for each covered adult vaccine.
March 2024

10

What is a preferred network pharmacy?
If your plan has preferred network pharmacies, you
will typically save money by using these pharmacies.
Your prescription drug costs (like a copay or coinsurance)
will typically be less at a preferred network pharmacy
because it has a preferred agreement with your plan. If you
need help finding a network pharmacy, please call Customer
Service at 1-800-668-3813 (TTY 711), or you can visit
Cigna.com/member-resources for the most current
Pharmacy Directory.

description of the majority of the drugs in the tier. It does not
mean that there are only brand-name drugs in this tier.
Tier 4 - Non-Preferred Drugs: This tier includes higher-priced
brand name drugs and generic drugs not in a preferred tier.
There may be lower-cost alternatives for you. Ask your doctor
about switching to a covered drug on a lower tier.
Tier 5 - Specialty Tier drugs: This tier includes high-cost
drugs. For most plans, you will pay a percentage of total drug
costs in this tier, called coinsurance. Drugs in Tier 5 are the
most expensive drugs on the drug list.

Drug Tier and Cost-Sharing
Cigna Healthcare covers both brand name drugs and generic
drugs. The amount you pay for a prescription drug depends
on which tier your drug is in. In general, the higher the tier
number, the higher your cost for the drug.

Cost-sharing amounts for each tier vary by Cigna Healthcare
plan. Refer to your Evidence of Coverage (EOC) for your
plan’s specific cost-sharing amounts. To access a copy of your
most recent EOC, visit CignaMedicare.com/resources.

Tier 1 - Preferred Generic Drugs: This tier includes
commonly prescribed generic drugs. Drugs in Tier 1 will
typically be your most affordable option.

Cigna Healthcare is not always able to keep all generic
medications in the Preferred Generic and Generic drug tiers.
Some generic medications may be in Tier 3, Tier 4 or Tier 5.

Tier 2 - Generic Drugs: This tier includes generic drugs, but
generally cost a little more than preferred generic drugs. Drugs
in Tier 2 typically have low copayments.

For customers receiving Extra Help: Your Low Income
Subsidy (LIS) copay level will be based on how the Food
and Drug Administration (FDA) classifies certain drugs. Due
to this, a generic drug may receive a preferred brand copay,
or a preferred brand drug may receive a generic drug copay.
Please see your LIS Rider for additional information on these
copay levels. Or call Customer Service for further clarification
regarding a specific drug.

Tier 3 - Preferred Brand Drugs: This tier includes preferred
brand-name drugs as well as some generic drugs. Keep in
mind that the tier name “Preferred Brand Drugs” is just a

Drug List Key:
B/D – This prescription drug has a Part B versus D
administrative prior authorization requirement. This drug
may be covered under Medicare Part B or D depending on
circumstances.

October 1 – March 31, 8 a.m. – 8 p.m. local time,
7 days a week. From April 1 – September 30, Monday –
Friday 8 a.m. – 8 p.m. local time. Messaging service used
weekends, after hours, and on federal holidays, or visit
CignaMedicare.com/resources.

EX – Excluded Drug. This prescription drug is not normally
covered in a Medicare Prescription Drug Plan. The amount
you pay when you fill a prescription for this drug does not
count towards your total drug costs (that is, the amount you
pay does not help you qualify for catastrophic coverage).
In addition, if you are receiving extra help to pay for your
prescriptions, you will not get any extra help to pay for this
drug.

NDS – Non-extended day supply medication. This drug is
only available for a one month supply.
PA – This drug requires prior authorization
QL – This drug has quantity limits
ST – This drug has step therapy requirements
V – This vaccine is provided at no cost when used based on
recommendations by the Centers for Disease Control and
Prevention’s (CDC) Advisory Committee on Immunization
Practices (ACIP).

GC – We provide additional coverage of the prescription
drugs in this tier in the coverage gap. Please refer to our
Evidence of Coverage for more information about this
coverage.

Generally all medications on the drug list are available
through mail-order, except when special circumstances
or situations prohibit mailing a particular medication to
your home.

LA – Limited Availability. This prescription may be
available only at certain pharmacies. For more information
consult your Pharmacy Directory or call Customer
Service at 1-800-668-3813 (TTY users should call 711),
March 2024

11

Drug List Table of Contents:
The drugs on the drug list are grouped into categories depending on the type of medical condition they are used to treat.
If you know what your drug is used for, look for the category name in the list below. Then look under the category name
within the drug list for your drug.
Page
ANTI - INFECTIVES....................................................................................................................................................................13
ANTINEOPLASTIC / IMMUNOSUPPRESSANT DRUGS.........................................................................................................19
AUTONOMIC / CNS DRUGS, NEUROLOGY / PSYCH............................................................................................................27
CARDIOVASCULAR, HYPERTENSION / LIPIDS.....................................................................................................................37
DERMATOLOGICALS/TOPICAL THERAPY............................................................................................................................41
DIAGNOSTICS / MISCELLANEOUS AGENTS.........................................................................................................................44
EAR, NOSE / THROAT MEDICATIONS.....................................................................................................................................46
ENDOCRINE/DIABETES............................................................................................................................................................46
GASTROENTEROLOGY............................................................................................................................................................50
IMMUNOLOGY, VACCINES / BIOTECHNOLOGY....................................................................................................................52
MISCELLANEOUS SUPPLIES..................................................................................................................................................54
MUSCULOSKELETAL / RHEUMATOLOGY.............................................................................................................................55
OBSTETRICS / GYNECOLOGY................................................................................................................................................56
OPHTHALMOLOGY...................................................................................................................................................................59
RESPIRATORY AND ALLERGY................................................................................................................................................61
UROLOGICALS..........................................................................................................................................................................63
VITAMINS, HEMATINICS / ELECTROLYTES...........................................................................................................................63

March 2024

12

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME
acyclovir oral tablet
acyclovir sodium intravenous
solution
adefovir
amantadine hcl
APRETUDE
APTIVUS
atazanavir oral capsule 150
mg, 300 mg
atazanavir oral capsule 200 mg
BARACLUDE ORAL
SOLUTION
BIKTARVY
CABENUVA
CIMDUO
COMPLERA
darunavir oral tablet 600 mg
darunavir oral tablet 800 mg
DELSTRIGO
DESCOVY
DOVATO
EDURANT
efavirenz oral capsule 200 mg
efavirenz oral capsule 50 mg
efavirenz oral tablet
efavirenz-emtricitabin-tenofov
efavirenz-lamivu-tenofov disop
oral tablet 400‑300‑300 mg
efavirenz-lamivu-tenofov disop
oral tablet 600‑300‑300 mg
emtricitabine
emtricitabine-tenofovir (tdf) oral
tablet 100‑150 mg, 167‑250
mg, 200‑300 mg
emtricitabine-tenofovir (tdf) oral
tablet 133‑200 mg
EMTRIVA ORAL SOLUTION
entecavir

ANTI - INFECTIVES
ANTIFUNGAL AGENTS
ABELCET
amphotericin b
amphotericin b liposome
caspofungin intravenous recon
soln 50 mg
caspofungin intravenous recon
soln 70 mg
clotrimazole mucous
membrane
CRESEMBA ORAL
fluconazole
fluconazole in nacl (iso-osm)
flucytosine
griseofulvin microsize
griseofulvin ultramicrosize
itraconazole oral capsule
itraconazole oral solution
ketoconazole oral
micafungin
nystatin oral suspension
nystatin oral tablet
posaconazole oral
tablet,delayed release (dr/ec)
terbinafine hcl oral
voriconazole intravenous
voriconazole oral suspension
for reconstitution
voriconazole oral tablet
ANTIVIRALS
abacavir oral solution
abacavir oral tablet
abacavir-lamivudine
acyclovir oral capsule
acyclovir oral suspension 200
mg/5 ml

4
4
5
5

PA
PA
PA; NDS
PA; NDS

4

PA

2
5
2
4
5
4
4
4
5
2
5
2
3
5
2
5
5

NDS
PA
NDS

QL (120/30)
NDS
NDS

QL (96/30); NDS
PA; NDS
NDS

4
3
4
3
2
4

QL (960/30)
QL (60/30)
QL (30/30)

DRUG REQUIREMENTS/
TIER LIMITS
2
4

B/D PA

4
3
5
5
3

NDS
QL (120/30); NDS
QL (30/30)

3
5

QL (60/30)
QL (630/30); NDS

5
5
5
5
5
5
5
5
5
5
4
3
4
5
5

NDS
NDS
NDS
QL (30/30); NDS
QL (60/30); NDS
QL (30/30); NDS
NDS
QL (30/30); NDS
NDS
QL (30/30); NDS
QL (120/30)
QL (180/30)
QL (30/30)
QL (30/30); NDS
QL (30/30); NDS

5

NDS

3
4

QL (30/30)
QL (30/30)

5

QL (30/30); NDS

4
4

QL (680/28)
QL (30/30)

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

13

Covered Drugs By Category
DRUG NAME
EPCLUSA ORAL PELLETS IN
PACKET 150‑37.5 MG
EPCLUSA ORAL PELLETS IN
PACKET 200‑50 MG
EPCLUSA ORAL TABLET
200‑50 MG
EPCLUSA ORAL TABLET
400‑100 MG
etravirine
EVOTAZ
famciclovir
fosamprenavir
FUZEON SUBCUTANEOUS
RECON SOLN
GENVOYA
HARVONI ORAL PELLETS IN
PACKET 33.75‑150 MG
HARVONI ORAL PELLETS IN
PACKET 45‑200 MG
HARVONI ORAL TABLET
45‑200 MG
HARVONI ORAL TABLET
90‑400 MG
INTELENCE ORAL TABLET
25 MG
ISENTRESS HD
ISENTRESS ORAL POWDER
IN PACKET
ISENTRESS ORAL TABLET
ISENTRESS ORAL TABLET,
CHEWABLE 100 MG
ISENTRESS ORAL TABLET,
CHEWABLE 25 MG
JULUCA
LAGEVRIO (EUA)
lamivudine oral solution
lamivudine oral tablet 100 mg,
300 mg
lamivudine oral tablet 150 mg

DRUG REQUIREMENTS/
TIER LIMITS
5
5
5
5
4
5
3
5
5
5
5

PA; QL (28/28);
NDS
PA; QL (56/28);
NDS
PA; QL (56/28);
NDS
PA; QL (28/28);
NDS
QL (60/30)
QL (30/30); NDS
QL (60/30)
QL (120/30); NDS
QL (60/30); NDS

4

QL (30/30); NDS
PA; QL (28/28);
NDS
PA; QL (56/28);
NDS
PA; QL (56/28);
NDS
PA; QL (28/28);
NDS
QL (120/30)

5
4

NDS
QL (60/30)

5
5

QL (120/30); NDS
QL (180/30); NDS

3

QL (180/30)

5
3
3
3

NDS
QL (40/180)
QL (900/30)
QL (30/30)

3

QL (60/30)

5
5
5

DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

lamivudine-zidovudine
LEXIVA ORAL SUSPENSION
lopinavir-ritonavir oral solution
lopinavir-ritonavir oral tablet
100‑25 mg
lopinavir-ritonavir oral tablet
200‑50 mg
maraviroc oral tablet 150 mg
maraviroc oral tablet 300 mg
MAVYRET ORAL PELLETS IN
PACKET
MAVYRET ORAL TABLET

3
4
3
4

QL (60/30)
QL (1575/28)

4

QL (120/30)

5
5
5

nevirapine oral suspension
nevirapine oral tablet
nevirapine oral tablet extended
release 24 hr 100 mg
nevirapine oral tablet extended
release 24 hr 400 mg
NORVIR ORAL POWDER IN
PACKET
ODEFSEY
oseltamivir
PAXLOVID ORAL TABLETS,
DOSE PACK 150‑100 MG*
PAXLOVID ORAL TABLETS,
DOSE PACK 300 MG (150 MG
X 2)-100 MG*
PIFELTRO
PREVYMIS ORAL
PREZCOBIX
PREZISTA ORAL
SUSPENSION
PREZISTA ORAL TABLET
150 MG
PREZISTA ORAL TABLET
75 MG
RETROVIR INTRAVENOUS

4
3
4

QL (60/30); NDS
QL (120/30); NDS
PA; QL (168/28);
NDS
PA; QL (84/28);
NDS
QL (1200/30)
QL (60/30)
QL (90/30)

4

QL (30/30)

5

QL (300/30)

4
5
3
3

QL (30/30); NDS

3

QL (30/180)

5
5
5
5

NDS
QL (30/30); NDS
QL (30/30); NDS
QL (400/30); NDS

4

QL (240/30)

3

QL (480/30)

QL (20/180)

4
*$0 cost share for Paxlovid

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

14

Covered Drugs By Category
DRUG NAME
REYATAZ ORAL POWDER IN
PACKET
ribavirin oral capsule
ribavirin oral tablet 200 mg
rimantadine
ritonavir
RUKOBIA
SELZENTRY ORAL
SOLUTION
SELZENTRY ORAL TABLET
25 MG
SELZENTRY ORAL TABLET
75 MG
STRIBILD
SUNLENCA
SYMTUZA
tenofovir disoproxil fumarate
TIVICAY ORAL TABLET 10 MG
TIVICAY ORAL TABLET
25 MG, 50 MG
TIVICAY PD
TRIUMEQ
TRIUMEQ PD
TRIZIVIR
TROGARZO
TYBOST
valacyclovir oral tablet 1 gram
valacyclovir oral tablet 500 mg
valganciclovir oral recon soln
valganciclovir oral tablet
VEKLURY
VEMLIDY
VIRACEPT ORAL TABLET
250 MG
VIRACEPT ORAL TABLET
625 MG
VIREAD ORAL POWDER

DRUG REQUIREMENTS/
TIER LIMITS
5
3
3
2
3
5
5

DRUG NAME

QL (240/30); NDS

QL (360/30)
NDS
NDS

3
5

NDS

5
5
5
4
4
5

QL (30/30); NDS
NDS
NDS
QL (30/30)
QL (60/30)
QL (60/30); NDS

5
5
5
5
5
3
2
2
5
3
5
5
5

QL (180/30); NDS
QL (30/30); NDS
QL (300/30); NDS
QL (60/30); NDS
NDS

4

QL (120/30)

5

QL (240/30); NDS

QL (120/30)
QL (60/30)
NDS
QL (4/180); NDS
NDS
QL (270/30); NDS

DRUG REQUIREMENTS/
TIER LIMITS

VIREAD ORAL TABLET
150 MG, 200 MG, 250 MG
VOSEVI

5

QL (30/30); NDS

5

PA; QL (28/28);
NDS

XOFLUZA ORAL TABLET
40 MG, 80 MG
zidovudine oral capsule
zidovudine oral syrup
zidovudine oral tablet
CEPHALOSPORINS
cefaclor oral capsule
cefaclor oral suspension for
reconstitution 125 mg/5 ml, 250
mg/5 ml, 375 mg/5 ml
cefaclor oral tablet extended
release 12 hr
cefadroxil oral capsule
cefadroxil oral suspension for
reconstitution 250 mg/5 ml, 500
mg/5 ml
cefadroxil oral tablet
CEFAZOLIN IN DEXTROSE
(ISO-OS) INTRAVENOUS
PIGGYBACK 1 GRAM/50 ML,
2 GRAM/100 ML,
2 GRAM/50 ML
cefazolin injection recon soln
1 gram, 10 gram, 100 gram, 2
gram, 300 g, 500 mg
cefazolin intravenous recon
soln 1 gram
CEFAZOLIN INTRAVENOUS
RECON SOLN 2 GRAM,
3 GRAM
cefdinir oral capsule
cefdinir oral suspension for
reconstitution
CEFEPIME IN DEXTROSE 5%
CEFEPIME IN DEXTROSE,
ISO-OSM

4
4
3
3
2
3
3
3
3
3
4

4
4
4
2
3
4
4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

15

QL (180/30)
QL (1680/28)
QL (60/30)

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

cefepime injection
4
cefepime intravenous
4
PA
cefixime
4
cefoxitin
4
PA
CEFOXITIN IN DEXTROSE,
4
PA
ISO-OSM
cefpodoxime
2
cefprozil
2
ceftazidime
4
PA
ceftriaxone
4
ceftriaxone in dextrose,iso-os
4
cefuroxime axetil oral tablet
2
cefuroxime sodium injection
4
PA
recon soln 750 mg
cefuroxime sodium intravenous
4
PA
cephalexin oral capsule 250
1
mg, 500 mg
cephalexin oral suspension for
2
reconstitution
tazicef
4
PA
TEFLARO
5
PA; NDS
ERYTHROMYCINS / OTHER MACROLIDES
azithromycin intravenous
4
PA
AZITHROMYCIN ORAL
3
PACKET
azithromycin oral suspension
2
for reconstitution
azithromycin oral tablet
1
clarithromycin oral suspension
3
for reconstitution
clarithromycin oral tablet
2
clarithromycin oral tablet
2
extended release 24 hr
DIFICID ORAL SUSPENSION
5
QL (136/10); NDS
FOR RECONSTITUTION
DIFICID ORAL TABLET
5
QL (20/10); NDS
ery-tab oral tablet,delayed
3
release (dr/ec) 250 mg, 333 mg

DRUG REQUIREMENTS/
TIER LIMITS

erythrocin (as stearate) oral
4
tablet 250 mg
erythrocin intravenous recon
4
soln 500 mg
erythromycin ethylsuccinate
3
oral suspension for
reconstitution 200 mg/5 ml
erythromycin ethylsuccinate
3
oral tablet
erythromycin oral tablet
4
erythromycin oral
3
tablet,delayed release (dr/ec)
MISCELLANEOUS ANTIINFECTIVES
albendazole
5
amikacin injection solution
4
1,000 mg/4 ml, 500 mg/2 ml
ARIKAYCE
5
atovaquone
4
atovaquone-proguanil
2
aztreonam injection recon soln
3
1 gram
aztreonam injection recon soln
5
2 gram
bacitracin intramuscular
4
CAYSTON
5
chloramphenicol sod succinate
chloroquine phosphate
clindamycin hcl
CLINDAMYCIN IN 0.9% SOD
CHLOR
clindamycin in 5% dextrose
clindamycin palmitate hcl
clindamycin pediatric
clindamycin phosphate injection
COARTEM
colistin (colistimethate na)
cycloserine

4
2
2
4
4
4
4
4
4
5
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

16

PA

NDS
PA
PA; LA; NDS

PA
PA; NDS
PA; LA; QL (84/28);
NDS

PA
PA

PA
QL (24/30)
PA; NDS
NDS

Covered Drugs By Category
DRUG NAME
dapsone oral
daptomycin
DAPTOMYCIN IN 0.9% SOD
CHLOR
emverm
ertapenem
ethambutol
FIRVANQ
gentamicin in nacl (iso-osm)
intravenous piggyback 100
mg/100 ml, 100 mg/50 ml, 120
mg/100 ml, 60 mg/50 ml, 80
mg/100 ml, 80 mg/50 ml
gentamicin injection solution 40
mg/ml
gentamicin sulfate (ped) (pf)
hydroxychloroquine
imipenem-cilastatin
isoniazid oral solution
isoniazid oral tablet
ivermectin oral
lincomycin
linezolid in dextrose 5%
linezolid oral suspension for
reconstitution
linezolid oral tablet
LINEZOLID-0.9% SODIUM
CHLORIDE
mefloquine
meropenem intravenous recon
soln 1 gram, 500 mg
MEROPENEM-0.9% SODIUM
CHLORIDE
METRO I.V.
metronidazole in nacl (iso-os)
metronidazole oral tablet
neomycin
nitazoxanide

DRUG REQUIREMENTS/
TIER LIMITS
3
5
5
5
4
3
4
4

DRUG NAME

NDS
NDS
NDS

QL (450/10)
PA

4

PA

4
2
4
4
2
3
4
4
5

PA

4
4

QL (60/30)
PA

PA
PA
PA
QL (1800/30); NDS

2
4
4
4
4
2
2
5

PA
PA

QL (20/10); NDS

DRUG REQUIREMENTS/
TIER LIMITS

ORBACTIV
paromomycin
pentamidine inhalation
pentamidine injection
polymyxin b sulfate
praziquantel
PRIFTIN
primaquine
pyrazinamide
pyrimethamine
quinine sulfate
rifabutin
rifampin intravenous
rifampin oral
SIRTURO ORAL TABLET
100 MG
SIRTURO ORAL TABLET
20 MG
SIVEXTRO INTRAVENOUS
SIVEXTRO ORAL
streptomycin
tigecycline
tobramycin in 0.225% nacl

5
4
3
3
4
4
4
3
4
5
4
4
5
2
5

PA; QL (3/30); NDS

4

PA; LA

5
5
5
5
5

tobramycin sulfate
TRECATOR
VANCOMYCIN IN 0.9%
SODIUM CHL INTRAVENOUS
PIGGYBACK
VANCOMYCIN IN DEXTROSE
5% INTRAVENOUS
PIGGYBACK
vancomycin injection
vancomycin intravenous recon
soln 1,000 mg, 1.25 gram, 10
gram, 5 gram, 500 mg, 750 mg
VANCOMYCIN INTRAVENOUS
RECON SOLN 1.5 GRAM

4
3
4

PA; QL (6/28); NDS
QL (6/28); NDS
PA; NDS
PA; NDS
B/D PA; QL
(280/28); NDS
PA

4
4
4
4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

17

B/D PA; QL (1/28)
PA

PA; NDS
PA; QL (42/7)
NDS
PA; LA; NDS

Covered Drugs By Category
DRUG NAME
vancomycin oral capsule 125
mg
vancomycin oral capsule 250
mg
vancomycin oral recon soln 25
mg/ml
VANCOMYCIN-DILUENT
COMBO NO.1
XIFAXAN ORAL TABLET
550 MG
PENICILLINS
amoxicillin oral capsule
amoxicillin oral suspension for
reconstitution
amoxicillin oral tablet
amoxicillin oral tablet,chewable
125 mg, 250 mg
amoxicillin-pot clavulanate oral
suspension for reconstitution
amoxicillin-pot clavulanate oral
tablet
amoxicillin-pot clavulanate oral
tablet extended release 12 hr
amoxicillin-pot clavulanate oral
tablet,chewable
ampicillin oral capsule 500 mg
ampicillin sodium
ampicillin-sulbactam
AUGMENTIN ORAL
SUSPENSION FOR
RECONSTITUTION
125‑31.25 MG/5 ML
BICILLIN L-A
dicloxacillin
NAFCILLIN IN DEXTROSE
ISO-OSM
nafcillin injection
nafcillin intravenous recon soln
2 gram

DRUG REQUIREMENTS/
TIER LIMITS
3

PA; QL (40/10)

3

PA; QL (80/10)

4

QL (450/10)

DRUG NAME
oxacillin injection
penicillin g potassium
penicillin v potassium oral
recon soln
penicillin v potassium oral tablet
pfizerpen-g
piperacillin-tazobactam
ZOSYN IN DEXTROSE (ISOOSM)
QUINOLONES
ciprofloxacin hcl oral tablet 100
mg
ciprofloxacin hcl oral tablet 250
mg, 500 mg, 750 mg
ciprofloxacin in 5% dextrose
ciprofloxacin oral
suspension,microcapsule recon
500 mg/5 ml
levofloxacin in d5w
levofloxacin oral solution
levofloxacin oral tablet
moxifloxacin oral
MOXIFLOXACIN-SOD.ACE,
SUL-WATER
moxifloxacin-sod.chloride(iso)
SULFAS / RELATED AGENTS
sulfadiazine
sulfamethoxazole-trimethoprim
intravenous
sulfamethoxazole-trimethoprim
oral suspension
sulfamethoxazole-trimethoprim
oral tablet
TETRACYCLINES
demeclocycline
doxy-100
doxycycline hyclate intravenous

4
5

PA; QL (90/30);
NDS

1
1
1
1
2
2
4
2
2
4
4
5

PA
PA
NDS

4
2
4

PA

4
4

PA
PA

PA

DRUG REQUIREMENTS/
TIER LIMITS
4
4
1
2
4
4
4

18

PA

3
1
4
4

PA

4
4
2
4
4

PA

4

PA

4
4

PA

PA

4
1
4
4
4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

PA
PA

PA
PA

Covered Drugs By Category
DRUG NAME
doxycycline hyclate oral
capsule
doxycycline hyclate oral tablet
100 mg, 20 mg
doxycycline monohydrate oral
capsule 100 mg, 50 mg
doxycycline monohydrate oral
capsule,ir - delay rel,biphase
doxycycline monohydrate oral
suspension for reconstitution
doxycycline monohydrate oral
tablet
minocycline oral capsule
minocycline oral tablet
mondoxyne nl oral capsule 100
mg
NUZYRA INTRAVENOUS
NUZYRA ORAL
tetracycline
URINARY TRACT AGENTS
fosfomycin tromethamine
methenamine hippurate
nitrofurantoin macrocrystal
nitrofurantoin monohyd/m-cryst
trimethoprim

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

1

abiraterone oral tablet 500 mg

5

1

ABRAXANE
ADCETRIS
adstiladrin
AKEEGA

5
5
5
5

ALECENSA

5

ALIQOPA
ALUNBRIG ORAL TABLET
180 MG, 90 MG
ALUNBRIG ORAL TABLET
30 MG
ALUNBRIG ORAL TABLETS,
DOSE PACK
anastrozole
arsenic trioxide
AUGTYRO

5
5

AYVAKIT

5

azacitidine
azathioprine oral tablet 100 mg,
75 mg
azathioprine oral tablet 50 mg
azathioprine sodium
BALVERSA
BAVENCIO
BELEODAQ
bendamustine
BENDEKA
BESPONSA
bexarotene
bicalutamide
BLENREP
bleomycin

5
3

2
4
2
3
2
2
2
5
5
2

PA; NDS
NDS

4
2
2
3
2

ANTINEOPLASTIC / IMMUNOSUPPRESSANT DRUGS
ADJUNCTIVE AGENTS
leucovorin calcium injection
leucovorin calcium oral
mesna
MESNEX ORAL
XGEVA

DRUG REQUIREMENTS/
TIER LIMITS

4
3
4
5
5

B/D PA
NDS
PA; QL (1.7/28);
NDS
ANTINEOPLASTIC / IMMUNOSUPPRESSANT DRUGS
abiraterone oral tablet 250 mg
5
PA; QL (120/30);
NDS

5
5
1
5
5

2
4
5
5
5
5
5
5
5
2
5
4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

19

PA; QL (60/30);
NDS
PA; NDS
PA; NDS
PA; QL (4/90); NDS
PA; QL (60/30);
NDS
PA; QL (240/30);
NDS
PA; NDS
PA; QL (30/30);
NDS
PA; QL (60/30);
NDS
PA; QL (60/365);
NDS
B/D PA; NDS
PA; QL (240/30);
NDS
PA; LA; QL (30/30);
NDS
B/D PA; NDS
B/D PA
B/D PA
B/D PA
PA; LA; NDS
PA; NDS
B/D PA; NDS
B/D PA; NDS
B/D PA; NDS
PA; NDS
PA; NDS
PA; NDS
B/D PA

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

BLINCYTO INTRAVENOUS
KIT
BORTEZOMIB INJECTION
BORTEZOMIB INTRAVENOUS
RECON SOLN
BOSULIF ORAL TABLET
100 MG
BOSULIF ORAL TABLET
400 MG, 500 MG
BRAFTOVI ORAL CAPSULE
75 MG
BRUKINSA
BUSULFAN
CABOMETYX

5

B/D PA; NDS

COPIKTRA

5

5
5

PA; NDS
PA; NDS

COSMEGEN
COTELLIC

5
5

5

5

B/D PA; NDS

5

B/D PA; NDS

3
3

B/D PA
B/D PA

5

3

B/D PA

CALQUENCE
(ACALABRUTINIB MAL)
CAPRELSA ORAL TABLET
100 MG
CAPRELSA ORAL TABLET
300 MG
carboplatin intravenous solution
carmustine intravenous recon
soln 100 mg
cisplatin intravenous solution
cladribine
clofarabine
COLUMVI

5

4
4
4
5
4
4
4
4
5
5
5
4
5

COMETRIQ ORAL CAPSULE
100 MG/DAY(80 MG X1‑20 MG
X1)
COMETRIQ ORAL CAPSULE
140 MG/DAY(80 MG X1‑20 MG
X3)
COMETRIQ ORAL CAPSULE
60 MG/DAY (20 MG X 3/DAY)

5

cyclophosphamide intravenous
recon soln
CYCLOPHOSPHAMIDE
INTRAVENOUS SOLUTION
200 MG/ML
cyclophosphamide intravenous
solution 500 mg/ml
cyclophosphamide oral capsule
cyclophosphamide oral tablet
25 mg
CYCLOPHOSPHAMIDE ORAL
TABLET 50 MG
cyclosporine intravenous
cyclosporine modified
cyclosporine oral capsule
CYRAMZA
cytarabine
cytarabine (pf)
dacarbazine
dactinomycin
DANYELZA
DARZALEX
DARZALEX FASPRO
daunorubicin
DAURISMO ORAL TABLET
100 MG
DAURISMO ORAL TABLET
25 MG
decitabine
docetaxel intravenous solution
160 mg/16 ml (10 mg/ml), 160
mg/8 ml (20 mg/ml), 80 mg/8
ml (10 mg/ml)

5

CALQUENCE

PA; QL (90/30);
NDS
PA; QL (30/30);
NDS
PA; LA; QL
(180/30); NDS
PA; LA; NDS
B/D PA; NDS
PA; LA; QL (30/30);
NDS
PA; LA; QL (60/30);
NDS
PA; LA; QL (60/30);
NDS
PA; LA; QL (60/30);
NDS
PA; LA; QL (30/30);
NDS
B/D PA
B/D PA

PA; LA; QL (60/30);
NDS
B/D PA; NDS
PA; LA; QL (63/28);
NDS
B/D PA; NDS

B/D PA
B/D PA
B/D PA
PA; NDS
B/D PA
B/D PA
B/D PA
B/D PA
PA; NDS
PA; NDS
PA; NDS
B/D PA
PA; QL (30/30);
NDS
PA; QL (60/30);
NDS
B/D PA; NDS
B/D PA; NDS

5
5
5
5
5

5
5
4
4
4
4
4
5

B/D PA
B/D PA
B/D PA
PA; QL (30/21);
NDS
PA; QL (56/28);
NDS

5

PA; QL (112/28);
NDS

5

PA; QL (84/28);
NDS

5
5
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

20

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

docetaxel intravenous solution
20 mg/2 ml (10 mg/ml), 20 mg/
ml (1 ml), 80 mg/4 ml (20 mg/
ml)
doxorubicin intravenous recon
soln 50 mg
doxorubicin intravenous
solution
doxorubicin, peg-liposomal
DROXIA
ELIGARD
ELIGARD (3 MONTH)
ELIGARD (4 MONTH)
ELIGARD (6 MONTH)
ELREXFIO
ELZONRIS
EMCYT
EMPLICITI INTRAVENOUS
RECON SOLN 300 MG
EMPLICITI INTRAVENOUS
RECON SOLN 400 MG
ENHERTU
ENVARSUS XR
epirubicin intravenous solution
EPKINLY
ERBITUX
ERIVEDGE

4

ERLEADA

5

erlotinib oral tablet 100 mg, 150
mg
erlotinib oral tablet 25 mg

5

ETOPOPHOS
etoposide intravenous
everolimus (antineoplastic) oral
tablet

4
3
5

4

B/D PA

B/D PA

4

B/D PA

5
3
4
4
4
4
5
5
5
4

B/D PA; NDS

5

PA; NDS

5
4
4
5
5
5

PA; NDS
B/D PA
B/D PA
PA; NDS
B/D PA; NDS
PA; QL (30/30);
NDS
PA; QL (120/30);
NDS
PA; QL (30/30);
NDS
PA; QL (60/30);
NDS
B/D PA
B/D PA
PA; QL (30/30);
NDS

5

DRUG NAME

PA
PA
PA
PA
PA; NDS
PA; NDS
NDS
PA

DRUG REQUIREMENTS/
TIER LIMITS

everolimus (antineoplastic) oral
tablet for suspension 2 mg
everolimus (antineoplastic) oral
tablet for suspension 3 mg, 5
mg
everolimus
(immunosuppressive) oral
tablet 0.25 mg
everolimus
(immunosuppressive) oral
tablet 0.5 mg, 0.75 mg, 1 mg
EVOMELA
exemestane
EXKIVITY

5

FARYDAK
FIRMAGON KIT W DILUENT
SYRINGE SUBCUTANEOUS
RECON SOLN 120 MG
FIRMAGON KIT W DILUENT
SYRINGE SUBCUTANEOUS
RECON SOLN 80 MG
floxuridine
fludarabine
fluorouracil intravenous
FOLOTYN
FOTIVDA

5
5

PA; LA; QL
(120/30); NDS
PA; QL (6/21); NDS
B/D PA; NDS

4

B/D PA

4
4
4
5
5

FRUZAQLA ORAL CAPSULE
1 MG
FRUZAQLA ORAL CAPSULE
5 MG
fulvestrant
FYARRO
GAVRETO

5

GAZYVA
gefitinib

5
5

gemcitabine

4

B/D PA
B/D PA
B/D PA
B/D PA; NDS
PA; LA; QL (21/28);
NDS
PA; QL (84/28);
NDS
PA; QL (21/28);
NDS
B/D PA; NDS
PA; LA; NDS
PA; LA; QL
(120/30); NDS
PA; NDS
PA; QL (30/30);
NDS
B/D PA

5
4

B/D PA

5

B/D PA; NDS

5
2
5

PA; NDS

5
5
5
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

21

PA; QL (150/30);
NDS
PA; QL (56/28);
NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

gengraf
GILOTRIF

4
5

GLEOSTINE
HALAVEN
hydroxyurea
IBRANCE

4
5
2
5

ICLUSIG

5

idarubicin
IDHIFA

4
5

ifosfamide intravenous recon
soln 1 gram
IFOSFAMIDE INTRAVENOUS
RECON SOLN 3 GRAM
ifosfamide intravenous solution
imatinib oral tablet 100 mg

4

PA; QL (21/28);
NDS
PA; QL (30/30);
NDS
B/D PA
PA; LA; QL (30/30);
NDS
B/D PA

4

B/D PA

4
5

B/D PA
PA; QL (180/30);
NDS
PA; QL (60/30);
NDS
PA; QL (120/30);
NDS
PA; QL (30/30);
NDS
PA; QL (324/30);
NDS
PA; QL (30/30);
NDS
PA; NDS
PA; LA; NDS
B/D PA; NDS
PA; QL (180/30);
NDS
PA; QL (120/30);
NDS
PA; QL (5/28); NDS

imatinib oral tablet 400 mg

5

IMBRUVICA ORAL CAPSULE
140 MG
IMBRUVICA ORAL CAPSULE
70 MG
IMBRUVICA ORAL
SUSPENSION
IMBRUVICA ORAL TABLET
140 MG, 280 MG, 420 MG
IMFINZI
IMJUDO
INFUGEM
INLYTA ORAL TABLET 1 MG

5

INLYTA ORAL TABLET 5 MG

5

INQOVI

5

5
5
5
5
5
5
5

DRUG NAME

B/D PA
PA; QL (30/30);
NDS
PA; NDS

DRUG REQUIREMENTS/
TIER LIMITS

INREBIC

5

irinotecan
IXEMPRA
JAKAFI

4
5
5

JAYPIRCA
JEMPERLI
JEVTANA
KADCYLA
kemoplat
KEYTRUDA
KIMMTRAK
KISQALI FEMARA CO-PACK
ORAL TABLET 200 MG/
DAY(200 MG X 1)-2.5 MG
KISQALI FEMARA CO-PACK
ORAL TABLET 400 MG/
DAY(200 MG X 2)-2.5 MG
KISQALI FEMARA CO-PACK
ORAL TABLET 600 MG/
DAY(200 MG X 3)-2.5 MG
KISQALI ORAL TABLET
200 MG/DAY (200 MG X 1)
KISQALI ORAL TABLET
400 MG/DAY (200 MG X 2)
KISQALI ORAL TABLET
600 MG/DAY (200 MG X 3)
KLISYRI
KOSELUGO ORAL CAPSULE
10 MG
KOSELUGO ORAL CAPSULE
25 MG
KRAZATI

5
5
5
5
4
5
5
5

KYPROLIS
lapatinib

5
5

5

PA; QL (70/28);
NDS

5

PA; QL (91/28);
NDS

5

PA; QL (21/28);
NDS
PA; QL (42/28);
NDS
PA; QL (63/28);
NDS
ST; QL (5/30)
PA; QL (240/30);
NDS
PA; QL (120/30);
NDS
PA; QL (180/30);
NDS
B/D PA; NDS
PA; QL (180/30);
NDS

5
5
4
5
5
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

22

PA; LA; QL
(120/30); NDS
B/D PA
B/D PA; NDS
PA; QL (60/30);
NDS
PA; NDS
PA; NDS
B/D PA; NDS
PA; NDS
B/D PA
PA; NDS
PA; NDS
PA; QL (49/28);
NDS

Covered Drugs By Category
DRUG NAME
lenalidomide oral capsule 10
mg, 15 mg, 25 mg, 5 mg
LENALIDOMIDE ORAL
CAPSULE 2.5 MG, 20 MG
LENVIMA ORAL CAPSULE
10 MG/DAY (10 MG X 1), 4 MG
LENVIMA ORAL CAPSULE
12 MG/DAY (4 MG X 3),
18 MG/DAY (10 MG X 1‑4 MG
X2), 24 MG/DAY(10 MG X
2‑4 MG X 1)
LENVIMA ORAL CAPSULE
14 MG/DAY(10 MG X 1‑4 MG
X 1), 20 MG/DAY (10 MG X 2),
8 MG/DAY (4 MG X 2)
letrozole
LEUKERAN
leuprolide (3 month)
leuprolide subcutaneous kit
LIBTAYO
LONSURF ORAL TABLET
15‑6.14 MG
LONSURF ORAL TABLET
20‑8.19 MG
LOQTORZI
LORBRENA ORAL TABLET
100 MG
LORBRENA ORAL TABLET
25 MG
LUMAKRAS ORAL TABLET
120 MG
LUMAKRAS ORAL TABLET
320 MG
LUNSUMIO
LUPRON DEPOT
LUPRON DEPOT (3 MONTH)
LUPRON DEPOT (4 MONTH)
LUPRON DEPOT (6 MONTH)

DRUG REQUIREMENTS/
TIER LIMITS
5
5
5
5

5

2
4
4
4
5
5
5
5
5
5
5
5
5
5
4
4
4

DRUG NAME

PA; QL (28/28);
NDS
PA; QL (28/28);
NDS
PA; QL (30/30);
NDS
PA; QL (90/30);
NDS

PA; QL (60/30);
NDS

PA
PA
PA; NDS
PA; QL (100/28);
NDS
PA; QL (80/28);
NDS
PA; NDS
PA; QL (30/30);
NDS
PA; QL (90/30);
NDS
PA; QL (240/30);
NDS
PA; QL (90/30);
NDS
PA; LA; NDS
PA; NDS
PA
PA
PA

DRUG REQUIREMENTS/
TIER LIMITS

LUPRON DEPOT-PED
(3 MONTH) INTRAMUSCULAR
SYRINGE KIT 11.25 MG
LUPRON DEPOT-PED
(3 MONTH) INTRAMUSCULAR
SYRINGE KIT 30 MG
LUPRON DEPOT-PED
INTRAMUSCULAR KIT
LUPRON DEPOT-PED
INTRAMUSCULAR SYRINGE
KIT
LYNPARZA

4

PA

5

PA; NDS

5

PA; NDS

4

PA

5

LYSODREN
LYTGOBI ORAL TABLET 4 MG

5
5

LYTGOBI ORAL TABLET 4 MG
(4X 4 MG TB)
LYTGOBI ORAL TABLET 4 MG
(5X 4 MG TB)
MARGENZA
MATULANE
megestrol oral suspension 400
mg/10 ml (10 ml), 400 mg/10
ml (40 mg/ml), 800 mg/20 ml
(20 ml)
megestrol oral tablet
MEKINIST ORAL RECON
SOLN
MEKINIST ORAL TABLET
0.5 MG
MEKINIST ORAL TABLET
2 MG
MEKTOVI

5

PA; QL (120/30);
NDS
NDS
PA; LA; QL (90/30);
NDS
PA; LA; QL
(120/30); NDS
PA; LA; QL
(150/30); NDS
PA; NDS
NDS
PA

melphalan
melphalan hcl
mercaptopurine
methotrexate sodium (pf)
methotrexate sodium injection

4
5
2
4
4

5
5
5
3

3
5
5
5
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

23

PA
PA; QL (1350/30);
NDS
PA; QL (90/30);
NDS
PA; QL (30/30);
NDS
PA; LA; QL
(180/30); NDS
B/D PA
B/D PA; NDS
B/D PA
B/D PA

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

methotrexate sodium oral
mitomycin intravenous
mitoxantrone
MONJUVI
mycophenolate mofetil (hcl)
mycophenolate mofetil oral
capsule
mycophenolate mofetil oral
suspension for reconstitution
mycophenolate mofetil oral
tablet
mycophenolate sodium
MYLOTARG
nelarabine
NERLYNX
nilutamide
NINLARO
NIPENT
NUBEQA

1
5
4
5
4
2

B/D PA; NDS
B/D PA
PA; NDS
B/D PA
B/D PA

5

B/D PA; NDS

2

B/D PA

2
5
5
5
5
5
4
5

NULOJIX
octreotide acetate injection
solution 1,000 mcg/ml, 100
mcg/ml, 200 mcg/ml, 50 mcg/ml
octreotide acetate injection
solution 500 mcg/ml
octreotide acetate injection
syringe
ODOMZO

5
4

B/D PA
PA; NDS
B/D PA; NDS
PA; LA; NDS
NDS
PA; QL (3/28); NDS
B/D PA
PA; LA; QL
(120/30); NDS
B/D PA; NDS
PA

5

PA; NDS

4

PA

5

OJJAARA

5

ONCASPAR
ONIVYDE
ONUREG

5
5
5

OPDIVO
OPDUALAG

5
5

PA; LA; QL (30/30);
NDS
PA; QL (30/30);
NDS
B/D PA; NDS
PA; NDS
PA; QL (14/28);
NDS
PA; NDS
PA; NDS

DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

ORGOVYX

5

ORSERDU
oxaliplatin
paclitaxel
PACLITAXEL PROTEINBOUND
PADCEV
pazopanib

5
4
4
5

PEMAZYRE

5

pemetrexed disodium
intravenous recon soln
PERJETA
PHESGO
PIQRAY
POLIVY
POMALYST

5

PORTRAZZA
POTELIGEO
PROGRAF INTRAVENOUS
PROGRAF ORAL GRANULES
IN PACKET
PURIXAN
QINLOCK

4
5
4
4

RETEVMO ORAL CAPSULE
40 MG
RETEVMO ORAL CAPSULE
80 MG
REVLIMID

5

REZLIDHIA

5

REZUROCK

5

5
5

5
5
5
5
5

4
5

5
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

24

PA; LA; QL (30/28);
NDS
PA; NDS
B/D PA
B/D PA
PA; NDS
PA; NDS
PA; QL (120/30);
NDS
PA; LA; QL (14/21);
NDS
PA; NDS
PA; NDS
PA; NDS
PA; NDS
PA; NDS
PA; LA; QL (21/28);
NDS
B/D PA
PA; NDS
B/D PA
B/D PA
PA; LA; QL (90/30);
NDS
PA; LA; QL
(180/30); NDS
PA; LA; QL
(120/30); NDS
PA; LA; QL (28/28);
NDS
PA; QL (60/30);
NDS
PA; LA; QL (30/30);
NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

romidepsin intravenous recon
soln
ROMIDEPSIN INTRAVENOUS
SOLUTION
ROZLYTREK ORAL CAPSULE
100 MG
ROZLYTREK ORAL CAPSULE
200 MG
ROZLYTREK ORAL PELLETS
IN PACKET
RUBRACA

5

PA; NDS

5

PA; NDS

5

RUXIENCE
RYBREVANT
RYDAPT

5
5
5

RYLAZE
SANDIMMUNE ORAL
SOLUTION
SANDOSTATIN LAR
DEPOT INTRAMUSCULAR
SUSPENSION, EXTENDED
REL RECON
SARCLISA
SCEMBLIX ORAL TABLET
20 MG
SCEMBLIX ORAL TABLET
40 MG
SIGNIFOR
SIMULECT
sirolimus oral solution
sirolimus oral tablet
SOLTAMOX
SOMATULINE DEPOT
sorafenib

5
4

PA; QL (150/30);
NDS
PA; QL (90/30);
NDS
PA; QL (360/30);
NDS
PA; LA; QL
(120/30); NDS
PA; NDS
PA; NDS
PA; QL (224/28);
NDS
B/D PA; NDS
B/D PA

5

PA; NDS

SPRYCEL ORAL TABLET
100 MG, 140 MG, 50 MG,
80 MG

5

5
5
5

5
5
5
5
5
5
4
5
5
5

DRUG NAME

PA; NDS
PA; QL (600/30);
NDS
PA; QL (300/30);
NDS
PA; NDS
B/D PA; NDS
B/D PA; NDS
B/D PA
NDS
PA; NDS
PA; QL (120/30);
NDS
PA; QL (30/30);
NDS

DRUG REQUIREMENTS/
TIER LIMITS

SPRYCEL ORAL TABLET
20 MG, 70 MG
STIVARGA

5

sunitinib malate

5

TABLOID
TABRECTA
tacrolimus oral
TAFINLAR ORAL CAPSULE

4
5
2
5

TAFINLAR ORAL TABLET FOR
SUSPENSION
TAGRISSO

5

TALVEY
TALZENNA ORAL CAPSULE
0.1 MG, 0.35 MG, 0.5 MG,
0.75 MG, 1 MG
TALZENNA ORAL CAPSULE
0.25 MG
tamoxifen
TASIGNA ORAL CAPSULE
150 MG, 200 MG
TASIGNA ORAL CAPSULE
50 MG
TAZVERIK
TECENTRIQ
TECVAYLI
TEMODAR INTRAVENOUS
temsirolimus
TEPMETKO

5
5

THALOMID ORAL CAPSULE
100 MG, 50 MG
THALOMID ORAL CAPSULE
150 MG, 200 MG
thiotepa
TIBSOVO

5

5

5

5
2
5
5
5
5
5
5
5
5

5
4
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

25

PA; QL (60/30);
NDS
PA; QL (84/28);
NDS
PA; QL (30/30);
NDS
PA; NDS
B/D PA
PA; QL (120/30);
NDS
PA; QL (840/28);
NDS
PA; LA; QL (30/30);
NDS
PA; NDS
PA; QL (30/30);
NDS
PA; QL (90/30);
NDS
PA; QL (112/28);
NDS
PA; QL (120/30);
NDS
PA; LA; NDS
PA; NDS
PA; NDS
B/D PA; NDS
B/D PA; NDS
PA; LA; QL (60/30);
NDS
PA; QL (28/28);
NDS
PA; QL (56/28);
NDS
PA
PA; NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

TIVDAK
topotecan intravenous recon
soln
topotecan intravenous solution
toremifene
TRAZIMERA
TREANDA
TRELSTAR INTRAMUSCULAR
SUSPENSION FOR
RECONSTITUTION
tretinoin (antineoplastic)
TRIPTODUR
TRODELVY
TRUQAP

5
5

PA; NDS
B/D PA; NDS

4
5
5
5
4

B/D PA
NDS
PA; NDS
B/D PA; NDS
PA

5
4
5
5

TUKYSA ORAL TABLET
150 MG
TUKYSA ORAL TABLET
50 MG
TURALIO ORAL CAPSULE
125 MG
UNITUXIN
valrubicin
VANFLYTA

5

VECTIBIX
VENCLEXTA ORAL TABLET
10 MG
VENCLEXTA ORAL TABLET
100 MG
VENCLEXTA ORAL TABLET
50 MG
VENCLEXTA STARTING PACK

5
4

NDS
PA; QL (1/168)
PA; NDS
PA; QL (64/28);
NDS
PA; LA; QL
(120/30); NDS
PA; LA; QL
(300/30); NDS
PA; LA; QL
(120/30); NDS
PA; NDS
B/D PA
PA; QL (56/28);
NDS
PA; NDS
PA; LA; QL (60/30)

VERZENIO

5

vinblastine
vincristine
vinorelbine

4
4
4

5
5
5
4
5

5
5
5

DRUG NAME

PA; LA; QL
(120/30); NDS
PA; LA; QL (30/30);
NDS
PA; LA; QL
(84/365); NDS
PA; LA; QL (60/30);
NDS
B/D PA
B/D PA
B/D PA

DRUG REQUIREMENTS/
TIER LIMITS

VITRAKVI ORAL CAPSULE
100 MG
VITRAKVI ORAL CAPSULE
25 MG
VITRAKVI ORAL SOLUTION

5

VIZIMPRO

5

VONJO

5

VOTRIENT

5

VYXEOS
WELIREG

5
5

XALKORI ORAL CAPSULE

5

XALKORI ORAL PELLET
150 MG
XALKORI ORAL PELLET
20 MG, 50 MG
XATMEP
XERMELO

5

XOSPATA
XPOVIO ORAL TABLET
100 MG/WEEK (50 MG X 2),
40 MG/WEEK (40 MG X 1),
40MG TWICE WEEK (40 MG X
2), 60 MG/WEEK (60 MG X 1),
60MG TWICE WEEK (120 MG/
WEEK), 80 MG/WEEK (40 MG
X 2), 80MG TWICE WEEK
(160 MG/WEEK)
XTANDI ORAL CAPSULE

5
5

XTANDI ORAL TABLET 40 MG

5

XTANDI ORAL TABLET 80 MG

5

YERVOY

5

5
5

5
4
5

5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

26

PA; LA; QL (60/30);
NDS
PA; LA; QL
(180/30); NDS
PA; LA; QL
(300/30); NDS
PA; QL (30/30);
NDS
PA; QL (120/30);
NDS
PA; QL (120/30);
NDS
B/D PA; NDS
PA; LA; QL (90/30);
NDS
PA; QL (60/30);
NDS
PA; QL (180/30);
NDS
PA; QL (120/30);
NDS
PA
PA; LA; QL (84/28);
NDS
PA; LA; NDS
PA; LA; NDS

PA; QL (120/30);
NDS
PA; QL (120/30);
NDS
PA; QL (60/30);
NDS
PA; NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

YONDELIS
ZALTRAP
ZANOSAR
ZEJULA ORAL CAPSULE

5
4
4
5

ZEJULA ORAL TABLET

5

ZELBORAF

5

ZEPZELCA
ZIRABEV
ZOLADEX
ZOLINZA

5
5
4
5

ZYDELIG

5

ZYKADIA

5

ZYNLONTA
ZYNYZ

5
5

DRUG NAME

PA; NDS
B/D PA
B/D PA
PA; LA; QL (90/30);
NDS
PA; LA; QL (30/30);
NDS
PA; QL (240/30);
NDS
PA; NDS
PA; NDS
B/D PA
PA; QL (120/30);
NDS
PA; QL (60/30);
NDS
PA; QL (90/30);
NDS
PA; NDS
PA; NDS

AUTONOMIC / CNS DRUGS, NEUROLOGY / PSYCH
ANTICONVULSANTS
APTIOM ORAL TABLET
200 MG
APTIOM ORAL TABLET
400 MG
APTIOM ORAL TABLET
600 MG, 800 MG
BRIVIACT INTRAVENOUS
BRIVIACT ORAL SOLUTION
BRIVIACT ORAL TABLET
carbamazepine oral capsule, er
multiphase 12 hr
carbamazepine oral suspension
100 mg/5 ml
carbamazepine oral tablet
carbamazepine oral tablet
extended release 12 hr

5

QL (180/30); NDS

5

QL (90/30); NDS

5

QL (60/30); NDS

5
5
5
2

NDS
QL (600/30); NDS
QL (60/30); NDS

2
2
2

DRUG REQUIREMENTS/
TIER LIMITS

carbamazepine oral
tablet,chewable
CELONTIN ORAL CAPSULE
300 MG
clobazam oral suspension
clobazam oral tablet 10 mg
clobazam oral tablet 20 mg
clonazepam oral tablet 0.5 mg,
1 mg
clonazepam oral tablet 2 mg
clonazepam oral
tablet,disintegrating 0.125 mg,
0.25 mg
clonazepam oral
tablet,disintegrating 0.5 mg, 1
mg
clonazepam oral
tablet,disintegrating 2 mg
DIACOMIT
diazepam rectal
dilantin
divalproex oral capsule,
delayed rel sprinkle
divalproex oral tablet extended
release 24 hr
divalproex oral tablet,delayed
release (dr/ec)
EPIDIOLEX
epitol
EPRONTIA
ethosuximide
felbamate
FINTEPLA

2

fosphenytoin
FYCOMPA ORAL
SUSPENSION
FYCOMPA ORAL TABLET
10 MG, 12 MG, 8 MG

3
5

QL (720/30); NDS

5

QL (30/30); NDS

3
4
4
4
2

PA; QL (480/30)
PA; QL (120/30)
PA; QL (60/30)
QL (120/30)

2
2

QL (300/30)
QL (90/30)

2

QL (120/30)

2

QL (300/30)

5
4
3
2

LA; NDS

3
2
5
2
4
3
4
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

27

PA; LA; NDS
PA

PA; LA; QL
(360/30); NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

FYCOMPA ORAL TABLET
2 MG
FYCOMPA ORAL TABLET
4 MG, 6 MG
gabapentin oral capsule 100
mg, 300 mg
gabapentin oral capsule 400
mg
gabapentin oral solution
gabapentin oral tablet 600 mg
gabapentin oral tablet 800 mg
lacosamide intravenous
lacosamide oral solution
lacosamide oral tablet 100 mg,
150 mg, 200 mg
lacosamide oral tablet 50 mg
lamotrigine oral tablet
lamotrigine oral tablet extended
release 24hr
lamotrigine oral tablet,
chewable dispersible
lamotrigine oral
tablet,disintegrating
lamotrigine oral tablets,dose
pack
levetiracetam in nacl (iso-os)
intravenous piggyback 1,000
mg/100 ml, 1,500 mg/100 ml,
500 mg/100 ml
levetiracetam intravenous
levetiracetam oral
methsuximide
NAYZILAM

4

QL (60/30)

5

QL (60/30); NDS

2

QL (360/30)

2

QL (270/30)

4
2
2
5
3
3

QL (2160/30)
QL (180/30)
QL (120/30)
QL (1200/30); NDS
QL (1200/30)
QL (60/30)

3
2
2

QL (120/30)

oxcarbazepine
phenobarbital oral elixir
phenobarbital oral tablet
phenobarbital sodium injection
solution

2
3
3
3

DRUG NAME

2
2
2
4

3
2
3
5

PA; QL (10/30);
NDS
PA; QL (1500/30)
PA; QL (120/30)

DRUG REQUIREMENTS/
TIER LIMITS

phenytoin oral suspension
phenytoin oral tablet,chewable
phenytoin sodium extended
phenytoin sodium intravenous
solution
pregabalin oral capsule 100
mg, 150 mg, 25 mg, 50 mg, 75
mg
pregabalin oral capsule 200 mg
pregabalin oral capsule 225
mg, 300 mg
pregabalin oral solution
primidone oral tablet 125 mg
primidone oral tablet 250 mg,
50 mg
roweepra oral tablet 500 mg
rufinamide oral suspension
rufinamide oral tablet 200 mg
rufinamide oral tablet 400 mg
SPRITAM
subvenite
subvenite starter (blue) kit
subvenite starter (green) kit
subvenite starter (orange) kit
SYMPAZAN

2
2
2
3

tiagabine
topiramate oral capsule,
sprinkle
topiramate oral
capsule,extended release 24hr
topiramate oral tablet
valproate sodium
valproic acid
valproic acid (as sodium salt)
VALTOCO

4
2

PA

4

PA

2
3
2
2
5

PA

2

QL (120/30)

2
2

QL (90/30)
QL (60/30)

3
4
2

QL (900/30)

2
5
3
5
4
2
2
2
2
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

28

PA; NDS
PA
PA; NDS

PA; QL (60/30);
NDS

PA; QL (10/30);
NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

vigabatrin

5

vigadrone

5

XCOPRI MAINTENANCE
PACK ORAL TABLET 250MG/
DAY(150 MG X1‑100MG
X1), 350 MG/DAY (200 MG
X1‑150MG X1)
XCOPRI ORAL TABLET
100 MG
XCOPRI ORAL TABLET
150 MG, 200 MG
XCOPRI ORAL TABLET 50 MG

5

XCOPRI TITRATION PACK
ORAL TABLETS, DOSE PACK
12.5 MG (14)- 25 MG (14)
XCOPRI TITRATION PACK
ORAL TABLETS, DOSE PACK
150 MG (14)- 200 MG (14),
50 MG (14)- 100 MG (14)
ZONISADE
zonisamide
ZTALMY

4

ANTIPARKINSONISM AGENTS
benztropine injection
benztropine oral
bromocriptine
carbidopa
carbidopa-levodopa oral tablet
carbidopa-levodopa oral tablet
extended release
carbidopa-levodopa oral
tablet,disintegrating
carbidopa-levodopaentacapone
DHIVY
entacapone

5
5
5

PA; LA; QL
(180/30); NDS
PA; LA; QL
(180/30); NDS
PA; QL (56/28);
NDS

PA; QL (56/365);
NDS

5
2
5

PA; NDS
PA
PA; LA; QL
(1080/30); NDS

PA

2
3
4
4

DRUG REQUIREMENTS/
TIER LIMITS

ONGENTYS
3
pramipexole oral tablet
2
pramipexole oral tablet
4
extended release 24 hr
rasagiline
3
ropinirole oral tablet
2
RYTARY
4
ST
selegiline hcl
3
tolcapone
5
NDS
trihexyphenidyl
2
PA
MIGRAINE / CLUSTER HEADACHE THERAPY
AIMOVIG AUTOINJECTOR
3
PA; QL (1/30)
AJOVY AUTOINJECTOR
3
PA; QL (1.5/30)
AJOVY SYRINGE
3
PA; QL (1.5/30)
dihydroergotamine nasal
5
PA; QL (8/28); NDS
ergotamine-caffeine
3
migergot
5
NDS
naratriptan
2
QL (18/28)
NURTEC ODT
3
PA; QL (16/30)
rizatriptan oral tablet
2
QL (36/28)
rizatriptan oral
3
QL (36/28)
tablet,disintegrating
sumatriptan nasal spray,non4
QL (18/28)
aerosol 20 mg/actuation
sumatriptan nasal spray,non4
QL (36/28)
aerosol 5 mg/actuation
sumatriptan succinate oral
2
QL (18/28)
SUMATRIPTAN SUCCINATE
4
QL (8/28)
SUBCUTANEOUS
CARTRIDGE
sumatriptan succinate
4
QL (8/28)
subcutaneous pen injector
sumatriptan succinate
4
QL (8/28)
subcutaneous solution
MISCELLANEOUS NEUROLOGICAL THERAPY
ADLARITY
4
ST; QL (4/28)
AUSTEDO ORAL TABLET
5
PA; LA; QL
12 MG, 9 MG
(120/30); NDS

PA; QL (120/30);
NDS
PA; QL (60/30);
NDS
PA; QL (240/30);
NDS
PA; QL (56/365)

5

4
2
4
4
2
3

DRUG NAME

ST

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

29

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

AUSTEDO ORAL TABLET
6 MG
AUSTEDO XR ORAL TABLET
EXTENDED RELEASE 24 HR
12 MG
AUSTEDO XR ORAL TABLET
EXTENDED RELEASE 24 HR
24 MG
AUSTEDO XR ORAL TABLET
EXTENDED RELEASE 24 HR
6 MG
AUSTEDO XR TITRATION
KT(WK1‑4)
BRIUMVI

5

dalfampridine
dimethyl fumarate oral
capsule,delayed release(dr/ec)
120 mg
dimethyl fumarate oral
capsule,delayed release(dr/ec)
120 mg (14)- 240 mg (46)
dimethyl fumarate oral
capsule,delayed release(dr/ec)
240 mg
donepezil oral tablet 10 mg
donepezil oral tablet 5 mg
donepezil oral
tablet,disintegrating 10 mg
donepezil oral
tablet,disintegrating 5 mg
fingolimod

3
5

FIRDAPSE
galantamine oral capsule,ext
rel. pellets 24 hr
galantamine oral solution
galantamine oral tablet
glatiramer subcutaneous
syringe 20 mg/ml

5
4

5
5

PA; LA; QL (60/30);
NDS
PA; LA; QL
(120/30); NDS
PA; LA; QL (60/30);
NDS

5

PA; LA; QL
(240/30); NDS

5

PA; QL (84/365);
NDS
PA; QL (24/168);
NDS
PA; QL (60/30)
PA; QL (14/30);
NDS

5

5

PA; QL (120/365);
NDS

5

PA; QL (60/30);
NDS

1
1
2

QL (60/30)
QL (30/30)
QL (60/30)

2

QL (30/30)

5

PA; QL (30/30);
NDS
PA; LA; NDS
QL (30/30)

4
4
5

DRUG NAME

QL (200/30)
QL (60/30)
PA; QL (30/30);
NDS

DRUG REQUIREMENTS/
TIER LIMITS

glatiramer subcutaneous
syringe 40 mg/ml
glatopa subcutaneous syringe
20 mg/ml
glatopa subcutaneous syringe
40 mg/ml
INGREZZA

5

INGREZZA INITIATION PACK

5

KESIMPTA PEN

5

memantine oral
capsule,sprinkle,er 24hr
memantine oral solution
memantine oral tablet 10 mg
memantine oral tablet 5 mg
MEMANTINE ORAL TABLETS,
DOSE PACK
NAMZARIC
NUEDEXTA
OCREVUS
RADICAVA
rivastigmine
rivastigmine tartrate
tetrabenazine oral tablet 12.5
mg
tetrabenazine oral tablet 25 mg

4

PA; QL (12/28);
NDS
PA; QL (30/30);
NDS
PA; QL (12/28);
NDS
PA; LA; QL (30/30);
NDS
PA; LA; QL
(56/365); NDS
PA; QL (1.2/28);
NDS
PA

3
2
2
2

PA; QL (300/30)
PA; QL (60/30)
PA; QL (90/30)
PA; QL (98/365)

3
5
5
5
4
4
5

PA
PA; NDS
PA; NDS
PA; NDS

TYSABRI
VUMERITY

5
5

ZEPOSIA

5

ZEPOSIA STARTER KIT (28DAY)
ZEPOSIA STARTER PACK
(7-DAY)

5

5
5
5

5

5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

30

QL (60/30)
PA; QL (240/30);
NDS
PA; QL (120/30);
NDS
PA; NDS
PA; QL (120/30);
NDS
PA; QL (30/30);
NDS
PA; QL (56/365);
NDS
PA; QL (14/365);
NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

MUSCLE RELAXANTS / ANTISPASMODIC THERAPY
baclofen oral tablet
1
cyclobenzaprine oral tablet 10
3
PA
mg, 5 mg
dantrolene oral
4
methocarbamol oral tablet 500
2
PA
mg, 750 mg
pyridostigmine bromide oral
5
NDS
syrup
pyridostigmine bromide oral
3
tablet 60 mg
pyridostigmine bromide oral
4
tablet extended release
tizanidine oral capsule
4
tizanidine oral tablet
2
NARCOTIC ANALGESICS
acetaminophen-codeine oral
2
QL (4500/30); NDS
solution 120‑12 mg/5 ml
acetaminophen-codeine oral
2
QL (360/30); NDS
tablet 300‑15 mg, 300‑30 mg
acetaminophen-codeine oral
2
QL (180/30); NDS
tablet 300‑60 mg
buprenorphine
4
QL (4/28); NDS
buprenorphine hcl injection
5
NDS
buprenorphine hcl sublingual
3
PA
endocet
3
QL (360/30); NDS
fentanyl
4
QL (10/30); NDS
fentanyl citrate (pf) injection
4
NDS
solution
FENTANYL CITRATE (PF)
4
NDS
INJECTION SYRINGE
50 MCG/ML
fentanyl citrate buccal lozenge
5
PA; QL (120/30);
on a handle 1,200 mcg, 1,600
NDS
mcg, 400 mcg, 600 mcg, 800
mcg
fentanyl citrate buccal lozenge
4
PA; QL (120/30);
on a handle 200 mcg
NDS

hydrocodone-acetaminophen
oral solution 7.5‑325 mg/15 ml
hydrocodone-acetaminophen
oral tablet 10‑300 mg, 7.5‑300
mg
hydrocodone-acetaminophen
oral tablet 10‑325 mg, 5‑325
mg, 7.5‑325 mg
hydrocodone-ibuprofen
hydromorphone oral liquid
hydromorphone oral tablet
INFUMORPH P/F
methadone injection solution
methadone oral solution 10
mg/5 ml
methadone oral solution 5 mg/5
ml
methadone oral tablet 10 mg
methadone oral tablet 5 mg
morphine (pf) injection solution
0.5 mg/ml, 1 mg/ml
morphine concentrate oral
solution
MORPHINE INJECTION
SOLUTION
MORPHINE INJECTION
SYRINGE 2 MG/ML, 4 MG/ML
morphine intravenous solution
10 mg/ml, 4 mg/ml, 8 mg/ml
morphine oral solution
morphine oral tablet
morphine oral tablet extended
release
oxycodone oral concentrate
oxycodone oral solution
oxycodone oral tablet 10 mg,
15 mg, 20 mg, 30 mg
oxycodone oral tablet 5 mg

DRUG REQUIREMENTS/
TIER LIMITS
4

QL (5550/30); NDS

3

QL (390/30); NDS

3

QL (360/30); NDS

3
4
3
5
4
4

QL (50/30); NDS
QL (2400/30); NDS
QL (180/30); NDS
B/D PA; NDS
NDS
QL (600/30); NDS

4

QL (1200/30); NDS

3
3
4

QL (120/30); NDS
QL (240/30); NDS
NDS

3

QL (900/30); NDS

4

NDS

4

NDS

4

NDS

3
3
3

QL (900/30); NDS
QL (180/30); NDS
QL (120/30); NDS

4
4
3

QL (180/30); NDS
QL (1200/30); NDS
QL (180/30); NDS

3

QL (360/30); NDS

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

31

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

oxycodone-acetaminophen oral
tablet 10‑325 mg, 2.5‑325 mg,
5‑325 mg, 7.5‑325 mg
oxymorphone oral tablet
extended release 12 hr
NON-NARCOTIC ANALGESICS
buprenorphine-naloxone
sublingual film 12‑3 mg
buprenorphine-naloxone
sublingual film 2‑0.5 mg
buprenorphine-naloxone
sublingual film 4‑1 mg, 8‑2 mg
buprenorphine-naloxone
sublingual tablet 2‑0.5 mg
buprenorphine-naloxone
sublingual tablet 8‑2 mg
butorphanol nasal
celecoxib
diclofenac potassium oral tablet
50 mg
diclofenac sodium oral
diclofenac sodium topical drops
diclofenac sodium topical gel
1%
diclofenac sodium topical
solution in metered-dose pump
diflunisal
EC-NAPROXEN
etodolac
flurbiprofen oral tablet 100 mg
ibu
ibuprofen oral suspension
ibuprofen oral tablet 400 mg,
600 mg, 800 mg
KLOXXADO
meloxicam oral tablet 15 mg
meloxicam oral tablet 7.5 mg
nabumetone

3

QL (360/30); NDS

4

QL (90/30); NDS

4

QL (60/30)

4

QL (360/30)

4

QL (90/30)

2

QL (360/30)

2

QL (90/30)

4
2
2

QL (10/28); NDS
QL (60/30)

2
4
3

QL (300/28)
QL (1000/28)

4

PA; QL (224/28)

DRUG NAME

naloxone injection solution
2
naloxone injection syringe 1
2
mg/ml
naloxone nasal
3
naltrexone
2
naproxen oral suspension
3
naproxen oral tablet
1
naproxen oral tablet,delayed
2
release (dr/ec)
naproxen sodium oral tablet
4
275 mg, 550 mg
oxaprozin oral tablet
4
salsalate
2
sulindac
2
tramadol oral tablet 50 mg
2
tramadol-acetaminophen
2
VIVITROL
5
ZIMHI
4
ZUBSOLV SUBLINGUAL
3
TABLET 0.7‑0.18 MG,
1.4‑0.36 MG, 11.4‑2.9 MG,
2.9‑0.71 MG, 5.7‑1.4 MG
ZUBSOLV SUBLINGUAL
3
TABLET 8.6‑2.1 MG
PSYCHOTHERAPEUTIC DRUGS
ABILIFY ASIMTUFII
5
INTRAMUSCULAR
SUSPENSION, EXTENDED
REL SYRING 720 MG/2.4 ML
ABILIFY ASIMTUFII
5
INTRAMUSCULAR
SUSPENSION, EXTENDED
REL SYRING 960 MG/3.2 ML
ABILIFY MAINTENA
5
alprazolam oral tablet 0.25 mg,
2
0.5 mg, 1 mg
alprazolam oral tablet 2 mg
2

2
2
4
2
1
2
1
3
1
1
2

DRUG REQUIREMENTS/
TIER LIMITS

QL (60/30)

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

32

QL (240/30); NDS
QL (240/30); NDS
NDS
QL (30/30)

QL (60/30)
QL (2.4/56); NDS

QL (3.2/56); NDS

QL (1/28); NDS
QL (120/30)
QL (150/30)

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

alprazolam oral
tablet,disintegrating 0.25 mg,
0.5 mg, 1 mg
alprazolam oral
tablet,disintegrating 2 mg
amitriptyline
amoxapine
aripiprazole oral solution
aripiprazole oral tablet 10 mg,
15 mg, 2 mg, 5 mg
aripiprazole oral tablet 20 mg,
30 mg
aripiprazole oral
tablet,disintegrating
ARISTADA INITIO
ARISTADA INTRAMUSCULAR
SUSPENSION, EXTENDED
REL SYRING 1,064 MG/3.9 ML
ARISTADA INTRAMUSCULAR
SUSPENSION, EXTENDED
REL SYRING 441 MG/1.6 ML
ARISTADA INTRAMUSCULAR
SUSPENSION, EXTENDED
REL SYRING 662 MG/2.4 ML
ARISTADA INTRAMUSCULAR
SUSPENSION, EXTENDED
REL SYRING 882 MG/3.2 ML
armodafinil
asenapine maleate sublingual
tablet 10 mg, 2.5 mg
asenapine maleate sublingual
tablet 5 mg
atomoxetine oral capsule 10
mg, 18 mg, 25 mg, 40 mg
atomoxetine oral capsule 100
mg, 60 mg, 80 mg
AUVELITY

3

QL (90/30)

3

QL (150/30)

BELSOMRA

3

3
3
4
3

QL (60/30)

3

QL (30/30)

5

QL (60/30); NDS

5
5

QL (4.8/365); NDS
QL (3.9/56); NDS

5

QL (1.6/28); NDS

5

QL (2.4/28); NDS

5

QL (3.2/28); NDS

3
4

PA; QL (30/30)
QL (60/30)

4

QL (90/30)

4

QL (60/30)

4

QL (30/30)

5

ST; QL (60/30);
NDS
QL (30/30)

DRUG NAME
bupropion hcl oral tablet 100
mg
bupropion hcl oral tablet 75 mg
bupropion hcl oral tablet
extended release 24 hr 150 mg
bupropion hcl oral tablet
extended release 24 hr 300 mg
bupropion hcl oral tablet
sustained-release 12 hr 100 mg
bupropion hcl oral tablet
sustained-release 12 hr 150
mg, 200 mg
buspirone
CAPLYTA
chlorpromazine injection
chlorpromazine oral
citalopram oral solution
citalopram oral tablet 10 mg,
20 mg
citalopram oral tablet 40 mg
clomipramine
clorazepate dipotassium oral
tablet 15 mg
clorazepate dipotassium oral
tablet 3.75 mg
clorazepate dipotassium oral
tablet 7.5 mg
clozapine oral tablet
clozapine oral
tablet,disintegrating 100 mg,
12.5 mg, 150 mg, 25 mg
clozapine oral
tablet,disintegrating 200 mg
desipramine
desvenlafaxine succinate oral
tablet extended release 24 hr
100 mg
desvenlafaxine succinate oral
tablet extended release 24 hr
25 mg

DRUG REQUIREMENTS/
TIER LIMITS
2

QL (120/30)

2
2

QL (180/30)
QL (90/30)

2

QL (30/30)

2

QL (120/30)

2

QL (60/30)

2
5
4
2
3
1

33

QL (60/30)

1
4
3

QL (30/30)

3

QL (90/30)

3

QL (360/30)

QL (180/30)

3
4
5

NDS

3
4

QL (120/30)

4

QL (60/30)

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

QL (30/30); NDS

Covered Drugs By Category
DRUG NAME
desvenlafaxine succinate oral
tablet extended release 24 hr
50 mg
dexmethylphenidate oral tablet
dextroamphetamine sulfate oral
capsule, extended release
dextroamphetamine sulfate oral
solution
dextroamphetamine sulfate oral
tablet 10 mg, 15 mg, 20 mg, 30
mg, 5 mg
dextroamphetamineamphetamine oral
capsule,extended release 24hr
dextroamphetamineamphetamine oral tablet 10 mg
dextroamphetamineamphetamine oral tablet 12.5
mg, 30 mg, 7.5 mg
dextroamphetamineamphetamine oral tablet 15 mg
dextroamphetamineamphetamine oral tablet 20 mg
dextroamphetamineamphetamine oral tablet 5 mg
diazepam injection
diazepam intensol
diazepam oral concentrate
diazepam oral solution
diazepam oral tablet
doxepin oral capsule
doxepin oral concentrate
doxepin oral tablet
duloxetine oral capsule,delayed
release(dr/ec) 20 mg, 60 mg
duloxetine oral capsule,delayed
release(dr/ec) 30 mg
EMSAM
escitalopram oxalate oral
solution

DRUG REQUIREMENTS/
TIER LIMITS
4

DRUG NAME

QL (90/30)

3
4
5

QL (1800/30); NDS

4
4

QL (60/30)

3

QL (180/30)

3

QL (60/30)

3

QL (120/30)

3

QL (90/30)

3

QL (360/30)

2
2
2
2
2
3
3
3
2

QL (360/30)
QL (360/30)
QL (1800/30)
QL (180/30)

QL (30/30)
QL (60/30)

2

QL (120/30)

5
3

QL (30/30); NDS
QL (600/30)

DRUG REQUIREMENTS/
TIER LIMITS

escitalopram oxalate oral tablet
10 mg, 5 mg
escitalopram oxalate oral tablet
20 mg
FANAPT ORAL TABLET 1 MG,
10 MG, 12 MG, 2 MG, 4 MG,
6 MG
FANAPT ORAL TABLET 8 MG

1

QL (60/30)

1

QL (30/30)

5

PA; QL (60/30);
NDS

5

FANAPT ORAL TABLETS,
DOSE PACK
FETZIMA ORAL CAPSULE,
EXT REL 24HR DOSE PACK
FETZIMA ORAL CAPSULE,
EXTENDED RELEASE 24 HR
fluoxetine (pmdd)
fluoxetine oral capsule 10 mg
fluoxetine oral capsule 20 mg,
40 mg
fluoxetine oral capsule,delayed
release(dr/ec)
fluoxetine oral solution
fluoxetine oral tablet 10 mg, 20
mg
fluphenazine decanoate
fluphenazine hcl injection
fluphenazine hcl oral
concentrate
fluphenazine hcl oral elixir
fluphenazine hcl oral tablet
fluvoxamine oral tablet 100 mg,
25 mg
fluvoxamine oral tablet 50 mg
guanfacine oral tablet extended
release 24 hr
haloperidol decanoate
haloperidol lactate injection
haloperidol lactate oral

4

PA; QL (90/30);
NDS
PA; QL (16/365)

4

ST; QL (56/365)

4

ST; QL (30/30)

3
1
1

QL (120/30)
QL (120/30)
QL (90/30)

3

QL (4/28)

2
3

QL (120/30)

4
4
4
4
2
2

QL (90/30)

2
4

QL (120/30)
QL (30/30)

4
4
2

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

34

Covered Drugs By Category
DRUG NAME
haloperidol oral tablet 0.5 mg, 1
mg, 2 mg, 5 mg
haloperidol oral tablet 10 mg,
20 mg
imipramine hcl
INVEGA HAFYERA
INTRAMUSCULAR SYRINGE
1,092 MG/3.5 ML
INVEGA HAFYERA
INTRAMUSCULAR SYRINGE
1,560 MG/5 ML
INVEGA SUSTENNA
INTRAMUSCULAR SYRINGE
117 MG/0.75 ML
INVEGA SUSTENNA
INTRAMUSCULAR SYRINGE
156 MG/ML
INVEGA SUSTENNA
INTRAMUSCULAR SYRINGE
234 MG/1.5 ML
INVEGA SUSTENNA
INTRAMUSCULAR SYRINGE
39 MG/0.25 ML
INVEGA SUSTENNA
INTRAMUSCULAR SYRINGE
78 MG/0.5 ML
INVEGA TRINZA
INTRAMUSCULAR SYRINGE
273 MG/0.88 ML
INVEGA TRINZA
INTRAMUSCULAR SYRINGE
410 MG/1.32 ML
INVEGA TRINZA
INTRAMUSCULAR SYRINGE
546 MG/1.75 ML
INVEGA TRINZA
INTRAMUSCULAR SYRINGE
819 MG/2.63 ML
lithium carbonate
lithium citrate
lorazepam injection solution

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

1
2
3
4

QL (3.5/180)

4

QL (5/180)

5

QL (0.75/28); NDS

5

QL (1/28); NDS

5

QL (1.5/28); NDS

4

QL (0.25/28)

5

QL (0.5/28); NDS

4

QL (0.88/90)

4

QL (1.32/90)

5

QL (1.75/90); NDS

5

QL (2.63/90); NDS

2
2
4

DRUG REQUIREMENTS/
TIER LIMITS

lorazepam injection syringe 2
mg/ml
lorazepam intensol
lorazepam oral concentrate
lorazepam oral syringe
lorazepam oral tablet 0.5 mg,
1 mg
lorazepam oral tablet 2 mg
loxapine succinate
lurasidone oral tablet 120 mg,
20 mg, 40 mg, 60 mg
lurasidone oral tablet 80 mg
MARPLAN
metadate er
methylphenidate hcl oral tablet
methylphenidate hcl oral tablet
extended release
methylphenidate hcl oral tablet
extended release 24hr 18 mg,
18 mg (bx rating), 27 mg, 27
mg (bx rating), 36 mg, 36 mg
(bx rating), 54 mg, 54 mg (bx
rating)
mirtazapine oral tablet
mirtazapine oral
tablet,disintegrating
modafinil oral tablet 100 mg
modafinil oral tablet 200 mg
molindone oral tablet 10 mg,
25 mg
molindone oral tablet 5 mg
nefazodone
nortriptyline oral capsule
nortriptyline oral solution
NUPLAZID

4

olanzapine intramuscular
olanzapine oral tablet 10 mg,
2.5 mg, 5 mg, 7.5 mg

4
3

3
3
3
2

QL (150/30)
QL (150/30)
QL (150/30)
QL (90/30)

2
2
4

QL (150/30)

4
4
3
3
3

QL (60/30)
QL (180/30)

35

QL (90/30)

3

2
3
4
4
2
4
4
2
3
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

QL (30/30)

QL (30/30)
PA; QL (30/30)
PA; QL (60/30)

PA; QL (30/30);
NDS
QL (30/30)
QL (60/30)

Covered Drugs By Category
DRUG NAME
olanzapine oral tablet 15 mg,
20 mg
olanzapine oral
tablet,disintegrating 10 mg, 5
mg
olanzapine oral
tablet,disintegrating 15 mg, 20
mg
olanzapine-fluoxetine
oxazepam
paliperidone oral tablet
extended release 24hr 1.5 mg,
9 mg
paliperidone oral tablet
extended release 24hr 3 mg,
6 mg
paroxetine hcl oral suspension
paroxetine hcl oral tablet 10 mg
paroxetine hcl oral tablet 20
mg, 40 mg
paroxetine hcl oral tablet 30 mg
paroxetine hcl oral tablet
extended release 24 hr
perphenazine
perphenazine-amitriptyline
PERSERIS
phenelzine
pimozide
protriptyline
quetiapine oral tablet 100 mg,
25 mg, 50 mg
quetiapine oral tablet 150 mg,
200 mg
quetiapine oral tablet 300 mg,
400 mg
quetiapine oral tablet extended
release 24 hr 150 mg, 200 mg
quetiapine oral tablet extended
release 24 hr 300 mg, 400 mg,
50 mg

DRUG REQUIREMENTS/
TIER LIMITS
3

QL (30/30)

4

QL (60/30)

4

QL (30/30)

4
2
4

QL (120/30)
PA; QL (30/30)

4

PA; QL (60/30)

4
1
1

QL (900/30)
QL (180/30)
QL (30/30)

1
3

QL (60/30)
QL (60/30)

4
4
5
3
4
4
2

DRUG NAME
QUILLICHEW ER ORAL
TABLET, CHEW, IR-ER.
BIPHASIC24HR 20 MG, 30 MG
QUILLICHEW ER ORAL
TABLET, CHEW, IR-ER.
BIPHASIC24HR 40 MG
ramelteon
REXULTI ORAL TABLET
RISPERDAL CONSTA
INTRAMUSCULAR
SUSPENSION, EXTENDED
REL RECON 12.5 MG/2 ML
RISPERDAL CONSTA
INTRAMUSCULAR
SUSPENSION, EXTENDED
REL RECON 25 MG/2 ML,
37.5 MG/2 ML, 50 MG/2 ML
risperidone oral solution
risperidone oral syringe
risperidone oral tablet 0.25 mg,
0.5 mg, 4 mg
risperidone oral tablet 1 mg
risperidone oral tablet 2 mg
risperidone oral tablet 3 mg
risperidone oral
tablet,disintegrating 0.25 mg,
0.5 mg, 4 mg
risperidone oral
tablet,disintegrating 1 mg
risperidone oral
tablet,disintegrating 2 mg
risperidone oral
tablet,disintegrating 3 mg
SECUADO
sertraline oral concentrate
sertraline oral tablet
sodium oxybate

QL (1/28); NDS

QL (120/30)

2

QL (90/30)

2

QL (60/30)

3

QL (30/30)

3

QL (60/30)

DRUG REQUIREMENTS/
TIER LIMITS
4

PA; QL (60/30)

4

PA; QL (30/30)

3
5
4

QL (30/30)
QL (30/30); NDS
QL (2/28)

5

QL (2/28); NDS

2
2
2

QL (120/30)

2
2
2
4

QL (180/30)
QL (90/30)
QL (60/30)
QL (120/30)

4

QL (180/30)

4

QL (90/30)

4

QL (60/30)

5
4
1
5

QL (30/30); NDS

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

36

QL (60/30)
PA; LA; QL
(540/30); NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

SPRAVATO NASAL SPRAY,
NON-AEROSOL 56 MG
(28 MG X 2)
SPRAVATO NASAL SPRAY,
NON-AEROSOL 84 MG
(28 MG X 3)
tasimelteon

5

PA; QL (16/28);
NDS

5

PA; QL (18/28);
NDS

temazepam oral capsule 15
mg, 30 mg
thioridazine
thiothixene
tranylcypromine
trazodone
trifluoperazine
trimipramine
TRINTELLIX
UZEDY SUBCUTANEOUS
SUSPENSION, EXTENDED
REL SYRING 100 MG/0.28 ML
UZEDY SUBCUTANEOUS
SUSPENSION, EXTENDED
REL SYRING 125 MG/0.35 ML
UZEDY SUBCUTANEOUS
SUSPENSION, EXTENDED
REL SYRING 150 MG/0.42 ML
UZEDY SUBCUTANEOUS
SUSPENSION, EXTENDED
REL SYRING 200 MG/0.56 ML
UZEDY SUBCUTANEOUS
SUSPENSION, EXTENDED
REL SYRING 250 MG/0.7 ML
UZEDY SUBCUTANEOUS
SUSPENSION, EXTENDED
REL SYRING 50 MG/0.14 ML
UZEDY SUBCUTANEOUS
SUSPENSION, EXTENDED
REL SYRING 75 MG/0.21 ML
venlafaxine oral
capsule,extended release 24hr
150 mg, 37.5 mg

3

5

DRUG NAME
venlafaxine oral
capsule,extended release 24hr
75 mg
venlafaxine oral tablet 100 mg,
25 mg, 37.5 mg
venlafaxine oral tablet 50 mg,
75 mg
VERSACLOZ
vilazodone
VRAYLAR ORAL CAPSULE
VRAYLAR ORAL CAPSULE,
DOSE PACK
zaleplon oral capsule 10 mg
zaleplon oral capsule 5 mg
ziprasidone hcl oral capsule 20
mg
ziprasidone hcl oral capsule 40
mg
ziprasidone hcl oral capsule 60
mg, 80 mg
ziprasidone mesylate
zolpidem oral tablet
ZURZUVAE
ZYPREXA RELPREVV
INTRAMUSCULAR
SUSPENSION FOR
RECONSTITUTION 210 MG,
300 MG
ZYPREXA RELPREVV
INTRAMUSCULAR
SUSPENSION FOR
RECONSTITUTION 405 MG

PA; QL (30/30);
NDS
QL (60/365)

3
4
4
1
3
4
4
5

ST; QL (30/30)
QL (0.28/28); NDS

5

QL (0.35/28); NDS

5

QL (0.42/56); NDS

5

QL (0.56/56); NDS

5

QL (0.7/56); NDS

5

QL (0.14/28); NDS

5

QL (0.21/28); NDS

1

QL (60/30)

DRUG REQUIREMENTS/
TIER LIMITS
1

QL (90/30)

2

QL (90/30)

2

QL (120/30)

5
4
5
4

NDS
QL (30/30)
QL (30/30); NDS
QL (14/365)

3
3
3

QL (60/30)
QL (30/30)
QL (180/30)

3

QL (120/30)

3

QL (60/30)

4
2
5
5

QL (6/30)
QL (30/30)
PA; NDS
PA; QL (2/28); NDS

5

PA; QL (1/28); NDS

CARDIOVASCULAR, HYPERTENSION / LIPIDS
ANTIARRHYTHMIC AGENTS
amiodarone intravenous
solution
amiodarone oral tablet 100 mg,
400 mg
amiodarone oral tablet 200 mg

4
2
1

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

37

B/D PA

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

dofetilide
3
flecainide
3
LIDOCAINE (PF)
4
INTRAVENOUS SOLUTION
lidocaine (pf) intravenous
4
syringe
mexiletine
2
pacerone oral tablet 100 mg,
2
400 mg
pacerone oral tablet 200 mg
1
propafenone oral
4
capsule,extended release 12 hr
propafenone oral tablet
2
quinidine sulfate oral tablet
2
sorine oral tablet 120 mg, 160
2
mg, 80 mg
sotalol af
2
sotalol oral
2
SOTYLIZE
4
ANTIHYPERTENSIVE THERAPY
acebutolol
2
aliskiren
4
amiloride
2
amiloride-hydrochlorothiazide
2
amlodipine
1
amlodipine-benazepril
1
amlodipine-olmesartan
1
amlodipine-valsartan
1
amlodipine-valsartan-hcthiazid
1
atenolol
1
atenolol-chlorthalidone
1
benazepril
1
benazepril-hydrochlorothiazide
1
betaxolol oral
2
bisoprolol fumarate
2
bisoprolol-hydrochlorothiazide
1
bumetanide injection
4

bumetanide oral
candesartan oral tablet 16 mg,
4 mg, 8 mg
candesartan oral tablet 32 mg
candesartan-hydrochlorothiazid
captopril
cartia xt
carvedilol
carvedilol phosphate
chlorothiazide sodium
chlorthalidone oral tablet 25
mg, 50 mg
clonidine
clonidine hcl oral tablet
diltiazem hcl intravenous
diltiazem hcl oral capsule,ext.
rel 24h degradable
diltiazem hcl oral
capsule,extended release 12 hr
diltiazem hcl oral
capsule,extended release 24 hr
diltiazem hcl oral
capsule,extended release 24hr
120 mg, 180 mg, 240 mg, 300
mg
diltiazem hcl oral tablet
diltiazem hcl oral tablet
extended release 24 hr
dilt-xr
doxazosin oral tablet 1 mg, 2
mg, 4 mg
doxazosin oral tablet 8 mg
EDARBI
EDARBYCLOR
enalapril maleate oral tablet
enalapril-hydrochlorothiazide
eplerenone
ethacrynate sodium

DRUG REQUIREMENTS/
TIER LIMITS
3
1
1
1
1
2
1
3
4
2

QL (30/30)

4
1
4
2

QL (4/28)

2
2
2

2
2
2
2
2
3
3
1
1
2
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

38

QL (60/30)

QL (30/30)
QL (60/30)

NDS

Covered Drugs By Category
DRUG NAME
felodipine
fosinopril
fosinopril-hydrochlorothiazide
furosemide injection solution
furosemide oral solution 10 mg/
ml, 40 mg/5 ml (8 mg/ml)
FUROSEMIDE ORAL
SOLUTION 40 MG/4 ML
furosemide oral tablet
hydralazine injection
hydralazine oral
hydrochlorothiazide
indapamide
irbesartan
irbesartan-hydrochlorothiazide
isosorbide-hydralazine
isradipine
KERENDIA
labetalol oral
lisinopril
lisinopril-hydrochlorothiazide
losartan
losartan-hydrochlorothiazide
oral tablet 100‑12.5 mg, 100‑25
mg
losartan-hydrochlorothiazide
oral tablet 50‑12.5 mg
matzim la
metolazone
metoprolol succinate
metoprolol ta-hydrochlorothiaz
metoprolol tartrate oral
metyrosine
minoxidil oral
moexipril
nadolol
nebivolol

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

2
1
1
4
2

nicardipine intravenous solution
nicardipine oral
nifedipine oral tablet extended
release
nifedipine oral tablet extended
release 24hr
nimodipine
nisoldipine
olmesartan
olmesartan-amlodipin-hcthiazid
olmesartan-hydrochlorothiazide
ORENITRAM MONTH
1 TITRATION KT
ORENITRAM MONTH
2 TITRATION KT
ORENITRAM MONTH
3 TITRATION KT
ORENITRAM ORAL TABLET
EXTENDED RELEASE
0.125 MG
ORENITRAM ORAL TABLET
EXTENDED RELEASE
0.25 MG, 1 MG, 2.5 MG, 5 MG
perindopril erbumine
phenoxybenzamine
pindolol
prazosin
propranolol oral
capsule,extended release 24 hr
propranolol oral solution
propranolol oral tablet
quinapril
quinapril-hydrochlorothiazide
ramipril
spironolactone oral tablet
spironolacton-hydrochlorothiaz
taztia xt
telmisartan

2
1
4
2
1
1
1
1
3
3
3
2
1
1
1
1
1
2
2
1
2
1
5
2
1
3
3

QL (30/30)
QL (30/30)
QL (180/30)
PA; QL (30/30)

QL (60/30)
QL (30/30)
QL (60/30)

PA; NDS

DRUG REQUIREMENTS/
TIER LIMITS
4
4
3
3
4
4
1
1
1
5

PA; NDS

5

PA; NDS

5

PA; NDS

4

PA

5

PA; NDS

1
5
1
3
2
2
1
1
1
1
1
2
2
1

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

39

NDS

Covered Drugs By Category
DRUG NAME
telmisartan-amlodipine
telmisartan-hydrochlorothiazid
terazosin oral capsule 1 mg, 2
mg, 5 mg
terazosin oral capsule 10 mg
tiadylt er
timolol maleate oral
torsemide oral
trandolapril
triamterene-hydrochlorothiazid
valsartan oral tablet 160 mg, 40
mg, 80 mg
valsartan oral tablet 320 mg
valsartan-hydrochlorothiazide
verapamil intravenous solution
verapamil oral capsule, 24 hr er
pellet ct
verapamil oral capsule,ext rel.
pellets 24 hr 120 mg, 180 mg,
240 mg
VERAPAMIL ORAL CAPSULE,
EXT REL. PELLETS 24 HR
360 MG
verapamil oral tablet
verapamil oral tablet extended
release
COAGULATION THERAPY
aminocaproic acid oral
aspirin-dipyridamole
BRILINTA
cilostazol
clopidogrel oral tablet 300 mg
clopidogrel oral tablet 75 mg
dabigatran etexilate
dipyridamole oral
DOPTELET (10 TAB PACK)
DOPTELET (15 TAB PACK)
DOPTELET (30 TAB PACK)

DRUG REQUIREMENTS/
TIER LIMITS
1
1
1

DRUG NAME
ELIQUIS
ELIQUIS DVT-PE TREAT 30D
START
enoxaparin
fondaparinux subcutaneous
syringe 10 mg/0.8 ml, 5 mg/0.4
ml, 7.5 mg/0.6 ml
fondaparinux subcutaneous
syringe 2.5 mg/0.5 ml
HEPARIN (PORCINE) IN 5%
DEX
heparin (porcine) in nacl (pf)
heparin (porcine) injection
solution
HEPARIN (PORCINE)
INJECTION SYRINGE
5,000 UNIT/ML
HEPARIN(PORCINE) IN
0.45% NACL INTRAVENOUS
PARENTERAL SOLUTION
25,000 UNIT/250 ML,
25,000 UNIT/500 ML
heparin, porcine (pf) injection
syringe 5,000 unit/0.5 ml
HEPARIN, PORCINE (PF)
INJECTION SYRINGE
5,000 UNIT/ML
jantoven
pentoxifylline
prasugrel
PROMACTA ORAL POWDER
IN PACKET 12.5 MG
PROMACTA ORAL POWDER
IN PACKET 25 MG
PROMACTA ORAL TABLET
12.5 MG, 25 MG, 50 MG
PROMACTA ORAL TABLET
75 MG
warfarin
XARELTO

QL (30/30)

1
2
4
2
1
1
1

QL (60/30)

1
1
4
3

QL (30/30)
QL (30/30)

QL (60/30)

2
3
1
2
5
4
3
2
4
1
4
3
5
5
5

NDS
QL (60/30)

QL (30/30)

PA; LA; NDS
PA; LA; NDS
PA; LA; NDS

DRUG REQUIREMENTS/
TIER LIMITS
3
3
3
5
4
4
4
3
4
4

4
4
1
2
3
5
5
5
5
1
3

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

40

NDS

PA; QL (360/30);
NDS
PA; QL (180/30);
NDS
PA; LA; QL (30/30);
NDS
PA; LA; QL (60/30);
NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

XARELTO DVT-PE TREAT 30D 3
START
LIPID/CHOLESTEROL LOWERING AGENTS
amlodipine-atorvastatin
1
atorvastatin
1
QL (30/30)
cholestyramine (with sugar)
3
cholestyramine light
3
cholestyramine-aspartame
3
colesevelam
3
colestipol oral granules
4
colestipol oral packet
4
colestipol oral tablet
3
ezetimibe
1
QL (30/30)
ezetimibe-simvastatin
1
QL (30/30)
fenofibrate micronized oral
3
capsule 134 mg, 200 mg, 67
mg
fenofibrate nanocrystallized
3
fenofibrate oral tablet 160 mg,
2
54 mg
fenofibric acid (choline)
4
fluvastatin oral capsule 20 mg
1
QL (30/30)
fluvastatin oral capsule 40 mg
1
QL (60/30)
fluvastatin oral tablet extended
1
QL (30/30)
release 24 hr
gemfibrozil
1
icosapent ethyl
3
lovastatin oral tablet 10 mg
1
QL (30/30)
lovastatin oral tablet 20 mg, 40
1
QL (60/30)
mg
NEXLETOL
3
PA; QL (30/30)
NEXLIZET
3
PA; QL (30/30)
niacin oral tablet 500 mg
2
niacin oral tablet extended
2
release 24 hr
niacor
2
omega-3 acid ethyl esters
3

DRUG REQUIREMENTS/
TIER LIMITS

pitavastatin calcium
1
QL (30/30)
pravastatin
1
QL (30/30)
prevalite
3
REPATHA PUSHTRONEX
3
PA; QL (7/28)
REPATHA SURECLICK
3
PA; QL (6/28)
REPATHA SYRINGE
3
PA; QL (6/28)
rosuvastatin
1
QL (30/30)
simvastatin
1
QL (30/30)
MISCELLANEOUS CARDIOVASCULAR AGENTS
CORLANOR ORAL TABLET
4
PA; QL (60/30)
digoxin injection solution
4
digoxin oral solution
3
digoxin oral tablet 125 mcg
2
(0.125 mg), 250 mcg (0.25 mg)
digoxin oral tablet 62.5 mcg
4
(0.0625 mg)
ENTRESTO
3
QL (60/30)
LANOXIN PEDIATRIC
4
ranolazine
3
QL (60/30)
VERQUVO
3
PA; QL (30/30)
VYNDAMAX
5
PA; NDS
VYNDAQEL
5
PA; NDS
NITRATES
isosorbide dinitrate oral tablet
3
10 mg, 20 mg, 30 mg, 5 mg
isosorbide mononitrate oral
1
tablet
isosorbide mononitrate oral
2
tablet extended release 24 hr
nitroglycerin intravenous
4
B/D PA
nitroglycerin sublingual
2
nitroglycerin transdermal patch
2
24 hour
nitroglycerin translingual
4
DERMATOLOGICALS/TOPICAL THERAPY
ANTIPSORIATIC / ANTISEBORRHEIC
acitretin
4
PA

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

41

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

calcipotriene scalp
3
QL (120/30)
calcipotriene topical cream
4
QL (120/30)
calcipotriene topical ointment
4
QL (120/30)
CALCITRIOL TOPICAL
4
selenium sulfide topical lotion
2
SKYRIZI SUBCUTANEOUS
5
PA; QL (2/28); NDS
PEN INJECTOR
SKYRIZI SUBCUTANEOUS
5
PA; QL (2/28); NDS
SYRINGE 150 MG/ML
STELARA SUBCUTANEOUS
5
PA; QL (0.5/28);
SOLUTION
NDS
STELARA SUBCUTANEOUS
5
PA; QL (0.5/28);
SYRINGE 45 MG/0.5 ML
NDS
STELARA SUBCUTANEOUS
5
PA; QL (1/28); NDS
SYRINGE 90 MG/ML
TALTZ AUTOINJECTOR
5
PA; QL (4/28); NDS
TALTZ SYRINGE
5
PA; QL (4/28); NDS
MISCELLANEOUS DERMATOLOGICALS
ammonium lactate
3
DUPIXENT PEN
5
PA; QL (4.56/28);
SUBCUTANEOUS PEN
NDS
INJECTOR 200 MG/1.14 ML
DUPIXENT PEN
5
PA; QL (8/28); NDS
SUBCUTANEOUS PEN
INJECTOR 300 MG/2 ML
DUPIXENT SYRINGE
5
PA; QL (1.34/28);
SUBCUTANEOUS SYRINGE
NDS
100 MG/0.67 ML
DUPIXENT SYRINGE
5
PA; QL (4.56/28);
SUBCUTANEOUS SYRINGE
NDS
200 MG/1.14 ML
DUPIXENT SYRINGE
5
PA; QL (8/28); NDS
SUBCUTANEOUS SYRINGE
300 MG/2 ML
fluorouracil topical cream 0.5%
5
NDS
fluorouracil topical cream 5%
3
fluorouracil topical solution
2
glydo
3
QL (60/30)

imiquimod topical cream in
metered-dose pump
imiquimod topical cream in
packet 3.75%
imiquimod topical cream in
packet 5%
lidocaine (pf) injection solution
lidocaine hcl injection solution
lidocaine hcl laryngotracheal
lidocaine hcl mucous
membrane solution 4% (40 mg/
ml)
lidocaine topical adhesive
patch,medicated 5%
lidocaine topical ointment
lidocaine viscous
lidocaine-prilocaine topical
cream
methoxsalen
PANRETIN
pimecrolimus
podofilox topical solution
REGRANEX
SANTYL
SILVER SULFADIAZINE
SSD
tacrolimus topical
VALCHLOR
ZTLIDO
THERAPY FOR ACNE
adapalene topical gel 0.3%
amnesteem
azelaic acid
claravis
clindacin etz topical swab
clindacin p
clindamycin phosphate topical
gel

DRUG REQUIREMENTS/
TIER LIMITS
4
4
3
4
4
2
2
3

PA; QL (90/30)

4
1
4

QL (50/30)

4
5
4
2
5
4
3
3
4
5
4
4
4
4
4
2
2
4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

42

QL (30/30)
NDS
PA; QL (100/30)
PA; NDS

PA; QL (100/30)
PA; NDS
PA; QL (90/30)
QL (45/30)

QL (69/30)
QL (69/30)
QL (120/30)

Covered Drugs By Category
DRUG NAME
CLINDAMYCIN PHOSPHATE
TOPICAL GEL, ONCE DAILY
clindamycin phosphate topical
lotion
clindamycin phosphate topical
solution
clindamycin phosphate topical
swab
ery pads
erythromycin with ethanol
topical gel
erythromycin with ethanol
topical solution
erythromycin-benzoyl peroxide
isotretinoin oral capsule 10 mg,
20 mg, 30 mg, 40 mg
metronidazole topical
tazarotene topical cream
tazarotene topical gel
tretinoin microspheres
tretinoin topical cream
tretinoin topical gel 0.01%
tretinoin topical gel 0.025%,
0.05%
zenatane
TOPICAL ANESTHETICS
lidocaine hcl mucous
membrane jelly in applicator
lidocaine hcl mucous
membrane solution 2%
TOPICAL ANTIBACTERIALS
gentamicin topical cream
gentamicin topical ointment
mupirocin
mupirocin calcium
sulfacetamide sodium (acne)
TOPICAL ANTIFUNGALS
ciclodan topical solution

DRUG REQUIREMENTS/
TIER LIMITS
4

QL (120/30)

4

QL (120/30)

3

QL (120/30)

2

QL (60/30)

DRUG NAME
ciclopirox topical cream
ciclopirox topical shampoo
ciclopirox topical solution
ciclopirox topical suspension
clotrimazole topical cream
clotrimazole topical solution
clotrimazole-betamethasone
topical cream
clotrimazole-betamethasone
topical lotion
econazole
ketoconazole topical cream
ketoconazole topical shampoo
naftifine topical cream
naftifine topical gel 2%
NAFTIN TOPICAL GEL 2%
nyamyc
nystatin topical cream
nystatin topical ointment
nystatin topical powder
nystatin-triamcinolone
nystop
TOPICAL ANTIVIRALS
acyclovir topical ointment
penciclovir
TOPICAL CORTICOSTEROIDS
ala-cort topical cream 1%
alclometasone
betamethasone dipropionate
betamethasone valerate topical
cream
betamethasone valerate topical
foam
betamethasone valerate topical
lotion
betamethasone valerate topical
ointment

3
4
2
4
4
4
3
4
4
4
3
4

PA
PA
PA
PA
PA
PA

4
3

QL (60/30)

1
3
3
2
4
3

QL (60/30)
QL (44/30)
QL (30/30)

3

DRUG REQUIREMENTS/
TIER LIMITS
3
3
3
3
3
3
2

QL (90/28)
QL (120/28)
QL (6.6/28)
QL (60/28)
QL (45/28)
QL (30/28)
QL (45/28)

2

QL (60/28)

3
2
2
3
3
3
3
2
2
3
4
3

QL (85/28)
QL (60/28)
QL (120/28)
QL (60/28)
QL (60/30)
QL (60/28)
QL (180/30)
QL (30/28)
QL (30/28)
QL (180/30)
QL (60/28)
QL (180/30)

4
4

QL (30/30)
QL (5/30)

1
2
3
2
3
2
2

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

43

Covered Drugs By Category
DRUG NAME
betamethasone, augmented
clobetasol scalp
clobetasol topical cream
clobetasol topical foam
clobetasol topical gel
clobetasol topical ointment
clobetasol topical shampoo
clobetasol-emollient topical
cream
clobetasol-emollient topical
foam
clocortolone pivalate
clodan
desonide topical cream
desonide topical lotion
desonide topical ointment
desoximetasone topical cream
desoximetasone topical gel
desoximetasone topical
ointment
fluocinolone and shower cap
fluocinolone topical cream
fluocinolone topical oil
fluocinolone topical ointment
fluocinolone topical solution
fluocinonide topical cream
0.05%
fluocinonide topical cream 0.1%
fluocinonide topical gel
fluocinonide topical ointment
fluocinonide topical solution
fluticasone propionate topical
cream
fluticasone propionate topical
ointment
halobetasol propionate topical
cream

DRUG REQUIREMENTS/
TIER LIMITS
3
2
2
4
2
2
4
2

QL (100/28)
QL (120/28)
QL (100/28)
QL (120/28)
QL (120/28)
QL (236/28)
QL (120/28)

4

QL (100/28)

4
4
3
3
3
4
4
4
3
2
3
2
2
2
4
2
3
3
2

DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

halobetasol propionate topical
3
ointment
hydrocortisone butyrate topical
4
QL (120/30)
cream
hydrocortisone butyrate topical
3
QL (120/30)
ointment
hydrocortisone butyrate topical
3
QL (120/30)
solution
hydrocortisone butyr-emollient
4
QL (120/30)
hydrocortisone topical cream
1
1%, 2.5%
hydrocortisone topical lotion
2
2.5%
hydrocortisone topical ointment
2
1%, 2.5%
hydrocortisone valerate
3
mometasone topical
2
triamcinolone acetonide topical
2
cream 0.025%, 0.5%
triamcinolone acetonide topical
1
cream 0.1%
triamcinolone acetonide topical
2
lotion
triamcinolone acetonide topical
2
ointment
triderm topical cream 0.1%
1
TOPICAL SCABICIDES / PEDICULICIDES
malathion
4
permethrin
3

QL (236/28)

QL (120/30)
QL (120/30)
QL (120/30)
QL (120/30)
QL (120/30)

DIAGNOSTICS / MISCELLANEOUS AGENTS
IRRIGATING SOLUTIONS
LACTATED RINGERS
IRRIGATION
neomycin-polymyxin b gu
RINGER'S IRRIGATION
TIS-U-SOL PENTALYTE
MISCELLANEOUS AGENTS
acamprosate

2
3

4
4
4
4
2

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

44

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

anagrelide
carglumic acid
cevimeline
CHEMET
CLINIMIX 4.25%/D5W SULFIT
FREE
CUVRIOR

2
5
4
5
4

D10%-0.45% SODIUM
CHLORIDE
d2.5%-0.45% sodium chloride
d5% and 0.9% sodium chloride
d5%-0.45% sodium chloride
deferasirox oral granules in
packet
deferasirox oral tablet 180 mg,
360 mg
deferasirox oral tablet 90 mg
deferiprone
DEXTROSE 10% AND 0.2%
NACL
dextrose 10% in water (d10w)
DEXTROSE 25% IN WATER
(D25W)
dextrose 5% in water (d5w)
intravenous parenteral solution
DEXTROSE 5% IN WATER
(D5W) INTRAVENOUS
PIGGYBACK
DEXTROSE 5%-LACTATED
RINGERS
dextrose 5%-0.2% sod chloride
dextrose 5%-0.3% sod.chloride
DEXTROSE 50% IN WATER
(D50W) INTRAVENOUS
PARENTERAL SOLUTION
dextrose 50% in water (d50w)
intravenous syringe

4

5

DRUG NAME

PA; NDS
PA; NDS
B/D PA
PA; QL (300/30);
NDS

4
4
4
5

PA; NDS

5

PA; NDS

4
5
4

PA
PA; NDS

4
4
4
4
4
4
4
4
4

DRUG REQUIREMENTS/
TIER LIMITS

DEXTROSE 70% IN WATER
(D70W)
disulfiram
droxidopa oral capsule 100 mg

4

droxidopa oral capsule 200 mg,
300 mg
ENDARI

5

FERRIPROX (2 TIMES A DAY)
FERRIPROX ORAL
SOLUTION
GLASSIA
INCRELEX
levocarnitine (with sugar)
levocarnitine oral solution 100
mg/ml
LEVOCARNITINE ORAL
TABLET
LOKELMA
midodrine
nitisinone
pilocarpine hcl oral
PROLASTIN-C INTRAVENOUS
RECON SOLN
PROLASTIN-C INTRAVENOUS
SOLUTION
riluzole
risedronate oral tablet 30 mg
sevelamer carbonate oral
powder in packet 0.8 gram
sevelamer carbonate oral
powder in packet 2.4 gram
sevelamer carbonate oral tablet
sodium chloride 0.9%
intravenous parenteral solution
SODIUM CHLORIDE 0.9%
INTRAVENOUS PIGGYBACK

5
5

2
5

5

5
4
4
4

45

PA; LA; NDS
PA; LA

3
3
3
5
4
5

NDS

5

PA; NDS

3
2
4

QL (30/30)
QL (510/30)

4

QL (150/30)

4
4

QL (510/30)

4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

PA; QL (90/30);
NDS
PA; QL (180/30);
NDS
PA; QL (180/30);
NDS
PA; NDS
PA; NDS

PA; LA; NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

SODIUM CHLORIDE
IRRIGATION
sodium phenylbutyrate
sodium polystyrene sulfonate
oral powder
sps (with sorbitol) oral
trientine oral capsule 250 mg

4

TZIELD

5

VELPHORO
VELTASSA
WATER FOR IRRIGATION,
STERILE
XIAFLEX
ZOLEDRONIC ACIDMANNITOL-WATER
INTRAVENOUS PIGGYBACK
5 MG/100 ML
SMOKING DETERRENTS
bupropion hcl (smoking deter)
NICOTROL
NICOTROL NS
varenicline

5
3
4

5
3
3
5

DRUG NAME

triamcinolone acetonide dental
3
MISCELLANEOUS OTIC PREPARATIONS
acetic acid otic (ear)
2
flac otic oil
4
fluocinolone acetonide oil
4
hydrocortisone-acetic acid
2
ofloxacin otic (ear)
2
OTIC STEROID / ANTIBIOTIC
ciprofloxacin-dexamethasone
3
CORTISPORIN-TC
4
neomycin-polymyxin-hc otic
3
(ear)

PA; NDS

PA; QL (240/30);
NDS
PA; LA; QL
(14/720); NDS
NDS

5
4

PA; NDS
B/D PA

2
4
4
4

QL (60/30)

ENDOCRINE/DIABETES
ADRENAL HORMONES
cortisone
DEPO-MEDROL
dexamethasone intensol
dexamethasone oral elixir
dexamethasone oral solution
dexamethasone oral tablet
dexamethasone sodium phos
(pf) injection solution 10 mg/ml
dexamethasone sodium
phosphate injection solution
fludrocortisone
hydrocortisone oral
MEDROL ORAL TABLET 2 MG
methylpred dp
methylprednisolone acetate
methylprednisolone oral tablet
methylprednisolone oral
tablets,dose pack
methylprednisolone sodium
succ injection recon soln 125
mg, 40 mg
methylprednisolone sodium
succ intravenous

EAR, NOSE / THROAT MEDICATIONS
MISCELLANEOUS AGENTS
azelastine nasal aerosol,spray
chlorhexidine gluconate
mucous membrane
fluoride (sodium) dental
ipratropium bromide nasal
kourzeq
oralone
periogard
sodium fluoride 5000 dry mouth
sodium fluoride 5000 plus
sodium fluoride-pot nitrate

2
1
2
2
3
3
1
2
2
2

DRUG REQUIREMENTS/
TIER LIMITS

QL (60/30)

QL (30/30)

4
4
4
2
2
2
4
4
2
2
3
2
4
2
2
4
4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

46

B/D PA

B/D PA

Covered Drugs By Category
DRUG NAME
prednisolone oral solution
prednisolone sodium
phosphate oral solution 15
mg/5 ml (3 mg/ml), 15 mg/5 ml
(5 ml), 25 mg/5 ml (5 mg/ml), 5
mg base/5 ml (6.7 mg/5 ml)
prednisone intensol
prednisone oral solution
prednisone oral tablet 1 mg, 10
mg, 2.5 mg, 20 mg, 5 mg
prednisone oral tablet 50 mg
prednisone oral tablets,dose
pack
SOLU-CORTEF ACT-O-VIAL
(PF)
triamcinolone acetonide
injection suspension 40 mg/ml
ANTITHYROID AGENTS
methimazole oral tablet 10 mg,
5 mg
propylthiouracil
DIABETES THERAPY
acarbose oral tablet 100 mg
acarbose oral tablet 25 mg
acarbose oral tablet 50 mg
BAQSIMI
BYDUREON BCISE
CEQUR SIMPLICITY
CEQUR SIMPLICITY
INSERTER
CYCLOSET
diazoxide
DROPLET MICRON PEN
NEEDLE
DROPLET PEN NEEDLE
NEEDLE 30 GAUGE X 5/16"
DROPSAFE ALCOHOL PREP
PADS

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

3
3

DROPSAFE PEN NEEDLE
NEEDLE 31 GAUGE X 3/16"
FARXIGA ORAL TABLET
10 MG
FARXIGA ORAL TABLET 5 MG
glimepiride oral tablet 1 mg
glimepiride oral tablet 2 mg
glimepiride oral tablet 4 mg
glipizide oral tablet 10 mg
GLIPIZIDE ORAL TABLET
2.5 MG
glipizide oral tablet 5 mg
glipizide oral tablet extended
release 24hr 10 mg
glipizide oral tablet extended
release 24hr 2.5 mg
glipizide oral tablet extended
release 24hr 5 mg
glipizide-metformin oral tablet
2.5‑250 mg
glipizide-metformin oral tablet
2.5‑500 mg, 5‑500 mg
GLUCAGEN HYPOKIT
GLUCAGON (HCL)
EMERGENCY KIT
glucagon emergency kit
(human)
GLYXAMBI
GVOKE
GVOKE HYPOPEN 1-PACK
GVOKE HYPOPEN 2-PACK
GVOKE PFS 1-PACK
SYRINGE
GVOKE PFS 2-PACK
SYRINGE
HUMALOG JUNIOR KWIKPEN
U-100
HUMALOG KWIKPEN
INSULIN

4
2
1
2
1
4
2
2
3
2
2
2
3
3
3
3

QL (90/30)
QL (360/30)
QL (180/30)

4
5
2

QL (180/30)
NDS
QL (200/30)

2

QL (200/30)

PA; QL (4/28)
QL (10/30)
QL (1/365)

2

DRUG REQUIREMENTS/
TIER LIMITS
2

QL (200/30)

3

QL (30/30)

3
1
1
1
1
1

QL (60/30)
QL (240/30)
QL (120/30)
QL (60/30)
QL (120/30)
QL (30/30)

1
1

QL (240/30)
QL (60/30)

1

QL (240/30)

1

QL (120/30)

1

QL (240/30)

1

QL (120/30)

3
3
3
3
3
3
3
3
3
3
3

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

47

QL (30/30)

Covered Drugs By Category
DRUG NAME
HUMALOG MIX 50‑50 INSULN
U-100
HUMALOG MIX
50‑50 KWIKPEN
HUMALOG MIX
75‑25 KWIKPEN
HUMALOG MIX 75‑25(U-100)
INSULN
HUMALOG U-100 INSULIN
HUMULIN
70/30 U-100 INSULIN
HUMULIN
70/30 U-100 KWIKPEN
HUMULIN N NPH INSULIN
KWIKPEN
HUMULIN N NPH
U-100 INSULIN
HUMULIN R REGULAR
U-100 INSULN
HUMULIN R U-500 (CONC)
INSULIN
HUMULIN R U-500 (CONC)
KWIKPEN
INSULIN LISPRO
INSULIN LISPRO PROTAMINLISPRO
JANUMET
JANUMET XR ORAL TABLET,
ER MULTIPHASE 24 HR
100‑1,000 MG
JANUMET XR ORAL TABLET,
ER MULTIPHASE 24 HR
50‑1,000 MG, 50‑500 MG
JANUVIA
JARDIANCE
JENTADUETO
JENTADUETO XR ORAL
TABLET, IR - ER, BIPHASIC
24HR 2.5‑1,000 MG

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

3

JENTADUETO XR ORAL
TABLET, IR - ER, BIPHASIC
24HR 5‑1,000 MG
LANTUS SOLOSTAR
U-100 INSULIN
LANTUS U-100 INSULIN
LEVEMIR FLEXPEN
LEVEMIR U-100 INSULIN
LYUMJEV KWIKPEN
U-100 INSULIN
LYUMJEV KWIKPEN
U-200 INSULIN
LYUMJEV U-100 INSULIN
metformin oral solution
metformin oral tablet 1,000 mg
metformin oral tablet 500 mg
metformin oral tablet 850 mg
metformin oral tablet extended
release 24 hr 500 mg
metformin oral tablet extended
release 24 hr 750 mg
metformin oral tablet extended
release 24hr 1,000 mg
metformin oral tablet extended
release 24hr 500 mg
miglitol oral tablet 100 mg
miglitol oral tablet 25 mg
miglitol oral tablet 50 mg
MOUNJARO
nateglinide oral tablet 120 mg
nateglinide oral tablet 60 mg
OMNIPOD 5 G6 INTRO KIT
(GEN 5)
OMNIPOD 5 G6 PODS (GEN
5)
OMNIPOD CLASSIC PODS
(GEN 3)
OMNIPOD DASH INTRO KIT
(GEN 4)

3
3
3
3
3
3
3
3
3
5

NDS

5

NDS

3
3
3
3

QL (60/30)
QL (30/30)

3

QL (60/30)

3
3
3
3

QL (30/30)
QL (30/30)
QL (60/30)
QL (60/30)

DRUG REQUIREMENTS/
TIER LIMITS
3
3
3
3
3
3
3
3
3
1
1
1
1

QL (765/30)
QL (75/30)
QL (150/30)
QL (90/30)
QL (120/30)

1

QL (60/30)

1

ST; QL (60/30)

1

QL (150/30)

4
4
4
3
1
1
3

QL (90/30)
QL (360/30)
QL (180/30)
PA; QL (2/28)
QL (90/30)
QL (180/30)
QL (1/365)

3

QL (20/30)

3

QL (20/30)

3

QL (1/365)

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

48

QL (30/30)

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

OMNIPOD DASH PODS (GEN
4)
OMNIPOD GO PODS
OMNIPOD GO PODS
10 UNITS/DAY
OMNIPOD GO PODS
15 UNITS/DAY
OMNIPOD GO PODS
20 UNITS/DAY
OMNIPOD GO PODS
25 UNITS/DAY
OMNIPOD GO PODS
30 UNITS/DAY
OMNIPOD GO PODS
40 UNITS/DAY
OZEMPIC SUBCUTANEOUS
PEN INJECTOR 0.25 MG OR
0.5 MG (2 MG/3 ML), 1 MG/
DOSE (4 MG/3 ML), 2 MG/
DOSE (8 MG/3 ML)
PENTIPS
pioglitazone
pioglitazone-metformin
repaglinide oral tablet 0.5 mg
repaglinide oral tablet 1 mg
repaglinide oral tablet 2 mg
RYBELSUS
SOLIQUA 100/33
SYMLINPEN 120

3

QL (20/30)

3
3

QL (10/30)
QL (10/30)

3

QL (10/30)

3

QL (10/30)

3

QL (10/30)

3

QL (10/30)

3

QL (10/30)

3

PA; QL (3/28)

2
1
1
1
1
1
3
3
5

SYMLINPEN 60
SYNJARDY
SYNJARDY XR ORAL TABLET,
IR - ER, BIPHASIC 24HR
10‑1,000 MG, 12.5‑1,000 MG,
5‑1,000 MG
SYNJARDY XR ORAL TABLET,
IR - ER, BIPHASIC 24HR
25‑1,000 MG

5
3
3

QL (200/30)
QL (30/30)
QL (90/30)
QL (960/30)
QL (480/30)
QL (240/30)
PA; QL (30/30)
QL (15/25)
PA; QL (10.8/30);
NDS
PA; QL (6/30); NDS
QL (60/30)
QL (60/30)

3

DRUG NAME
TOUJEO MAX
U-300 SOLOSTAR
TOUJEO SOLOSTAR
U-300 INSULIN
TRADJENTA
TRESIBA FLEXTOUCH U-100
TRESIBA FLEXTOUCH U-200
TRESIBA U-100 INSULIN
TRIJARDY XR ORAL TABLET,
IR - ER, BIPHASIC 24HR 10‑51,000 MG, 25‑5-1,000 MG
TRIJARDY XR ORAL
TABLET, IR - ER, BIPHASIC
24HR 12.5‑2.5‑1,000 MG,
5‑2.5‑1,000 MG
TRUEPLUS INSULIN
TRUEPLUS PEN NEEDLE
TRULICITY
UNIFINE PENTIPS MAXFLOW
UNIFINE PENTIPS NEEDLE
29 GAUGE X 1/2", 31 GAUGE
X 1/4", 31 GAUGE X 3/16",
31 GAUGE X 5/16", 32 GAUGE
X 1/4", 32 GAUGE X 5/32",
33 GAUGE X 5/32"
UNIFINE PENTIPS PLUS
UNIFINE PENTIPS PLUS
MAXFLOW
V-GO 20
V-GO 30
V-GO 40
XIGDUO XR ORAL TABLET,
IR - ER, BIPHASIC 24HR
10‑1,000 MG, 10‑500 MG
XIGDUO XR ORAL TABLET,
IR - ER, BIPHASIC 24HR
2.5‑1,000 MG, 5‑1,000 MG,
5‑500 MG
XULTOPHY 100/3.6

QL (30/30)

DRUG REQUIREMENTS/
TIER LIMITS
3
3
3
3
3
3
3

QL (30/30)

3

QL (60/30)

2
2
3
2
2

QL (200/30)
QL (200/30)
PA; QL (2/28)
QL (200/30)
QL (200/30)

2
2

QL (200/30)
QL (200/30)

3
3
3
3

QL (30/30)

3

QL (60/30)

3

QL (15/30)

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

49

QL (30/30)

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

MISCELLANEOUS HORMONES
ALDURAZYME
cabergoline
calcitonin (salmon) injection
calcitonin (salmon) nasal
calcitriol intravenous solution 1
mcg/ml
calcitriol oral capsule
calcitriol oral solution
CEREZYME INTRAVENOUS
RECON SOLN 400 UNIT
CHORIONIC
GONADOTROPIN, HUMAN
INTRAMUSCULAR
cinacalcet oral tablet 30 mg, 60
mg
cinacalcet oral tablet 90 mg
danazol
desmopressin injection
desmopressin nasal spray with
pump
desmopressin nasal spray,nonaerosol 10 mcg/spray (0.1 ml)
desmopressin oral
doxercalciferol
ELAPRASE
FABRAZYME
KORLYM

5
3
5
3
4

DRUG NAME

PA; NDS
NDS

3
4
5

PA; NDS

4

PA

4

QL (60/30)

4
4
4
4

QL (120/30)

4
3
4
5
5
5

LUMIZYME
miglustat
NAGLAZYME
NATPARA

5
5
5
5

pamidronate
paricalcitol oral
RAYALDEE
sapropterin

4
4
5
5

PA; NDS
NDS
PA; QL (120/30);
NDS
PA; NDS
LA; NDS
PA; NDS
PA; LA; QL (2/28);
NDS

DRUG REQUIREMENTS/
TIER LIMITS

SOMAVERT

5

SYNAREL
testosterone cypionate
testosterone enanthate
testosterone transdermal gel
testosterone transdermal gel in
metered-dose pump 12.5 mg/
1.25 gram (1%)
testosterone transdermal gel
in packet 1% (25 mg/2.5gram),
1% (50 mg/5 gram)
TOLVAPTAN ORAL TABLET
15 MG
tolvaptan oral tablet 30 mg

5
2
3
4
4

zoledronic acid intravenous
solution
zoledronic acid-mannitolwater intravenous piggyback 4
mg/100 ml
ZOLEDRONIC AC-MANNITOL0.9NACL
THYROID HORMONES
EUTHYROX
levothyroxine oral tablet
LEVOXYL ORAL TABLET
100 MCG, 112 MCG, 125 MCG,
137 MCG, 150 MCG,
175 MCG, 200 MCG, 25 MCG,
50 MCG, 75 MCG, 88 MCG
liothyronine oral
SYNTHROID
UNITHROID

PA; QL (300/30)
PA; QL (300/30)

4

PA; QL (300/30)

5

4

PA; QL (120/30);
NDS
PA; QL (60/30);
NDS
B/D PA

4

B/D PA

4

B/D PA

5

1
1
3

2
3
3

GASTROENTEROLOGY
ANTIDIARRHEALS / ANTISPASMODICS
atropine injection solution 0.4
4
mg/ml

NDS
PA; NDS

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

PA; QL (30/30);
NDS
NDS

50

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

atropine injection syringe 0.1
4
mg/ml
atropine intravenous solution
4
0.4 mg/ml
ATROPINE INTRAVENOUS
4
SYRINGE 0.25 MG/5 ML
(0.05 MG/ML)
dicyclomine oral capsule
1
dicyclomine oral solution
3
dicyclomine oral tablet
1
diphenoxylate-atropine
3
glycopyrrolate (pf)
4
glycopyrrolate (pf) in water
4
injection
glycopyrrolate (pf) in water
4
intravenous syringe 0.4 mg/2
ml (0.2 mg/ml)
glycopyrrolate injection
4
glycopyrrolate oral tablet 1 mg,
2
2 mg
loperamide oral capsule
2
MISCELLANEOUS GASTROINTESTINAL AGENTS
alosetron
5
PA; NDS
aprepitant oral capsule 125 mg
5
B/D PA; NDS
aprepitant oral capsule 40 mg,
4
B/D PA
80 mg
aprepitant oral capsule,dose
4
B/D PA
pack
balsalazide
4
betaine
5
NDS
budesonide oral
4
capsule,delayed,extend.release
budesonide oral tablet,delayed
5
NDS
and ext.release
CLENPIQ
4
compro
2
constulose
2
CORTIFOAM
5
NDS

DRUG REQUIREMENTS/
TIER LIMITS

CREON
cromolyn oral
dronabinol
enulose
GATTEX 30-VIAL
GATTEX ONE-VIAL
gavilyte-c
generlac
granisetron hcl oral
hydrocortisone rectal
hydrocortisone topical cream
with perineal applicator
INFLECTRA

3
3
4
2
5
5
2
2
3
3
1

lactulose oral solution
LINZESS
meclizine oral tablet 12.5 mg,
25 mg
mesalamine oral
capsule,extended release 24hr
mesalamine rectal enema
mesalamine with cleansing
wipe
metoclopramide hcl oral
solution
metoclopramide hcl oral tablet
MOVANTIK
OCALIVA

2
3
2

ondansetron
ondansetron hcl (pf)
ondansetron hcl intravenous
ondansetron hcl oral solution
ondansetron hcl oral tablet 4
mg, 8 mg
palonosetron intravenous
solution 0.25 mg/5 ml

2
4
4
4
2

5

51

PA; NDS
PA; NDS

B/D PA

PA; QL (20/30);
NDS
QL (30/30)

3
4
4
2
2
4
5

4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

B/D PA; QL (60/30)

QL (30/30)
PA; LA; QL (30/30);
NDS
B/D PA

B/D PA
B/D PA

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

peg 3350-electrolytes
peg-electrolyte soln
prochlorperazine
prochlorperazine edisylate
injection solution 10 mg/2 ml (5
mg/ml)
prochlorperazine maleate
procto-med hc
proctosol hc topical
proctozone-hc
RECTIV
REMICADE

2
2
2
4

SANCUSO
scopolamine base
SKYRIZI INTRAVENOUS

5
4
5

SKYRIZI SUBCUTANEOUS
WEARABLE INJECTOR
180 MG/1.2 ML (150 MG/ML)
SKYRIZI SUBCUTANEOUS
WEARABLE INJECTOR
360 MG/2.4 ML (150 MG/ML)
SODIUM, POTASSIUM, MAG
SULFATES
SUCRAID
SUFLAVE
sulfasalazine oral tablet
SULFASALAZINE ORAL
TABLET, DELAYED RELEASE
(DR/EC)
SUTAB
TRULANCE
ursodiol oral capsule 300 mg
ursodiol oral tablet

5

2
1
1
1
4
5

5

DRUG NAME
ZENPEP ORAL CAPSULE,
DELAYED RELEASE(DR/EC)
10,000‑32,000 -42,000 UNIT,
15,000‑47,000 -63,000 UNIT,
20,000‑63,000- 84,000 UNIT,
25,000‑79,000- 105,000 UNIT,
3,000‑10,000 -14,000-UNIT,
40,000‑126,000- 168,000 UNIT,
5,000‑17,000- 24,000 UNIT
ULCER THERAPY
esomeprazole magnesium oral
capsule,delayed release(dr/ec)
famotidine oral suspension for
reconstitution
famotidine oral tablet 20 mg,
40 mg
lansoprazole oral
capsule,delayed release(dr/ec)
misoprostol
omeprazole oral
capsule,delayed release(dr/ec)
pantoprazole oral
tablet,delayed release (dr/ec)
sucralfate oral suspension
sucralfate oral tablet
TALICIA

PA; QL (20/30);
NDS
NDS
QL (10/30)
PA; QL (30/180);
NDS
PA; QL (1.2/56);
NDS
PA; QL (2.4/56);
NDS

3
5
4
2
2

PA; NDS

DRUG REQUIREMENTS/
TIER LIMITS
3

3
4
2
2

QL (60/30)

3
1

QL (60/30)

1

QL (60/30)

4
2
4

QL (168/180)

IMMUNOLOGY, VACCINES / BIOTECHNOLOGY
BIOTECHNOLOGY DRUGS
ACTIMMUNE
ARCALYST
AVONEX
BESREMI

4
4
3
4

BETASERON
SUBCUTANEOUS KIT
GENOTROPIN
GENOTROPIN MINIQUICK
NIVESTYM
NYVEPRIA

5
5
5
5
5
5
5
5
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

QL (60/30)

52

PA; NDS
PA; NDS
PA; QL (1/28); NDS
PA; LA; QL (2/28);
NDS
PA; QL (14/28);
NDS
PA; NDS
PA; NDS
PA; NDS
PA; NDS

Covered Drugs By Category
DRUG NAME
PEGASYS SUBCUTANEOUS
SOLUTION
PEGASYS SUBCUTANEOUS
SYRINGE
PLERIXAFOR
PROCRIT
REBIF (WITH ALBUMIN)
REBIF REBIDOSE
SUBCUTANEOUS PEN
INJECTOR 22 MCG/0.5 ML,
44 MCG/0.5 ML
REBIF REBIDOSE
SUBCUTANEOUS
PEN INJECTOR
8.8MCG/0.2ML-22 MCG/0.5ML
(6)
REBIF TITRATION PACK

DRUG REQUIREMENTS/
TIER LIMITS
5

PA; QL (4/28); NDS

5

PA; QL (2/28); NDS

5
4
5
5

B/D PA; NDS
PA
PA; QL (6/28); NDS
PA; QL (6/28); NDS

5

PA; QL (8.4/365);
NDS

DRUG NAME
GAMMAKED
GAMMAPLEX (WITH
SORBITOL)
GAMMAPLEX INTRAVENOUS
SOLUTION 10%
GAMUNEX-C INJECTION
SOLUTION 1 GRAM/10 ML
(10%), 10 GRAM/100 ML
(10%), 20 GRAM/200 ML
(10%), 40 GRAM/400 ML
(10%), 5 GRAM/50 ML (10%)
GAMUNEX-C INJECTION
SOLUTION 2.5 GRAM/25 ML
(10%)
GARDASIL 9 (PF)
HAVRIX (PF)
INTRAMUSCULAR SYRINGE
1,440 ELISA UNIT/ML
HAVRIX (PF)
INTRAMUSCULAR SYRINGE
720 ELISA UNIT/0.5 ML
HEPLISAV-B (PF)
HIBERIX (PF)
HIZENTRA SUBCUTANEOUS
SOLUTION 1 GRAM/5 ML
(20%)
HIZENTRA SUBCUTANEOUS
SOLUTION 10 GRAM/50 ML
(20%), 2 GRAM/10 ML (20%),
4 GRAM/20 ML (20%)
IMOVAX RABIES VACCINE
(PF)
INFANRIX (DTAP) (PF)
INTRAMUSCULAR SYRINGE
IPOL
IXIARO (PF)
JYNNEOS (PF)
KINRIX (PF)
INTRAMUSCULAR SYRINGE
MENACTRA (PF)
INTRAMUSCULAR SOLUTION

5

PA; QL (8.4/365);
NDS
RETACRIT
4
PA
ZARXIO
5
PA; NDS
ZIEXTENZO
5
PA; NDS
VACCINES / MISCELLANEOUS IMMUNOLOGICALS
ABRYSVO
3
PA; QL (1/365)
ACTHIB (PF)
3
ADACEL(TDAP ADOLESN/
3
V
ADULT)(PF)
AREXVY (PF)
3
PA; QL (1/365)
ATGAM
4
B/D PA
BCG VACCINE, LIVE (PF)
3
V
BEXSERO
3
V
BOOSTRIX TDAP
3
V
BOTOX
4
PA
DAPTACEL (DTAP
3
PEDIATRIC) (PF)
ENGERIX-B (PF)
3
B/D PA; V
ENGERIX-B PEDIATRIC (PF)
3
B/D PA; V
fomepizole
5
NDS
GAMMAGARD LIQUID
5
B/D PA; NDS

DRUG REQUIREMENTS/
TIER LIMITS
5
5

B/D PA; NDS
B/D PA; NDS

5

B/D PA; NDS

5

B/D PA; NDS

4

B/D PA

3
3

V

3
3
3
4

B/D PA; V

5

B/D PA; NDS

3

V

3
3
3
3
3

V
V
V

3

V

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

53

B/D PA

Covered Drugs By Category
DRUG NAME
MENQUADFI (PF)
MENVEO A-C-Y-W-135-DIP
(PF)
M-M-R II (PF)
OCTAGAM
PEDIARIX (PF)
PEDVAX HIB (PF)
PENTACEL (PF)
INTRAMUSCULAR KIT
15LF-48MCG-62DU
-10 MCG/0.5ML
PREHEVBRIO (PF)
PRIORIX (PF)
PROQUAD (PF)
QUADRACEL (PF)
RABAVERT (PF)
RECOMBIVAX HB (PF)
ROTARIX
ROTATEQ VACCINE
SHINGRIX (PF)
STAMARIL (PF)
TDVAX
TENIVAC (PF)
TETANUS, DIPHTHERIA TOX
PED(PF)
TICE BCG
TICOVAC
TRUMENBA
TWINRIX (PF)
TYPHIM VI
VAQTA (PF)
INTRAMUSCULAR
SUSPENSION 25 UNIT/0.5 ML
VAQTA (PF)
INTRAMUSCULAR
SUSPENSION 50 UNIT/ML

DRUG REQUIREMENTS/
TIER LIMITS
3
3

V
V

3
5
3
3
3

V
B/D PA; NDS

DRUG NAME
VAQTA (PF)
INTRAMUSCULAR SYRINGE
25 UNIT/0.5 ML
VAQTA (PF)
INTRAMUSCULAR SYRINGE
50 UNIT/ML
VARIVAX (PF)
VARIZIG
YF-VAX (PF)

DRUG REQUIREMENTS/
TIER LIMITS
3
3

V

3
4
3

V

MISCELLANEOUS SUPPLIES
3
3
3
3
3
3
3
3
3
3
3
3
3

B/D PA; V
V

4
3
3
3
3
3

B/D PA

3

V

MISCELLANEOUS SUPPLIES
ALCOHOL PADS
ASSURE ID INSULIN SAFETY
SYRINGE 1 ML 29 GAUGE X
1/2"
BD SAFETYGLIDE INSULIN
SYRINGE SYRINGE 1 ML
31 GAUGE X 15/64"
BD ULTRA-FINE NANO PEN
NEEDLE
BD ULTRA-FINE SHORT PEN
NEEDLE
GAUZE PAD TOPICAL
BANDAGE 2 X 2 "
INSULIN SYRINGE-NEEDLE
U-100 SYRINGE 0.3 ML
29 GAUGE, 1 ML 29 GAUGE X
1/2", 1/2 ML 28 GAUGE
PEN NEEDLE, DIABETIC
NEEDLE 29 GAUGE X 1/2"
TECHLITE INSULIN SYRINGE
SYRINGE 1 ML 30 GAUGE X
1/2", 1 ML 31 GAUGE X 15/64",
1 ML 31 GAUGE X 5/16
TECHLITE INSULN SYR(HALF
UNIT) SYRINGE 0.3 ML
31 GAUGE X 15/64", 0.3 ML
31 GAUGE X 5/16", 0.5 ML
30 GAUGE X 1/2", 0.5 ML
31 GAUGE X 15/64", 0.5 ML
31 GAUGE X 5/16"

V
B/D PA; V

V
V
V
V

V
V
V

2
2

QL (200/30)

2

QL (200/30)

2

QL (200/30)

2

QL (200/30)

2
2

QL (200/30)

2

QL (200/30)

2

QL (200/30)

2

QL (200/30)

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

V

54

Covered Drugs By Category
DRUG NAME
TECHLITE PEN NEEDLE
NEEDLE 29 GAUGE X 1/2",
31 GAUGE X 3/16", 31 GAUGE
X 5/16", 32 GAUGE X 1/4",
32 GAUGE X 5/32"

DRUG REQUIREMENTS/
TIER LIMITS
2

DRUG NAME

QL (200/30)

ADALIMUMAB-ADBM
SUBCUTANEOUS SYRINGE
KIT 10 MG/0.2 ML,
20 MG/0.4 ML
ADALIMUMAB-ADBM
SUBCUTANEOUS SYRINGE
KIT 40 MG/0.8 ML
ADALIMUMAB-ADBM(CF)
PEN CROHNS
ADALIMUMAB-ADBM(CF)
PEN PS-UV
BENLYSTA
CYLTEZO(CF) PEN
CYLTEZO(CF) PEN CROHN'SUC-HS
CYLTEZO(CF) PEN
PSORIASIS-UV
CYLTEZO(CF)
SUBCUTANEOUS SYRINGE
KIT 10 MG/0.2 ML,
20 MG/0.4 ML
CYLTEZO(CF)
SUBCUTANEOUS SYRINGE
KIT 40 MG/0.8 ML
ENBREL MINI
ENBREL SUBCUTANEOUS
SOLUTION
ENBREL SUBCUTANEOUS
SYRINGE
ENBREL SURECLICK
HUMIRA PEN
HUMIRA PEN CROHNSUC-HS START
HUMIRA PEN PSOR-UVEITSADOL HS
HUMIRA SUBCUTANEOUS
SYRINGE KIT 40 MG/0.8 ML
HUMIRA(CF) PEDI CROHNS
STARTER SUBCUTANEOUS
SYRINGE KIT 80 MG/0.8 ML

MUSCULOSKELETAL / RHEUMATOLOGY
GOUT THERAPY
allopurinol oral tablet 100 mg,
300 mg
colchicine oral tablet
febuxostat
MITIGARE
probenecid
probenecid-colchicine
OSTEOPOROSIS THERAPY
alendronate oral tablet 10 mg
alendronate oral tablet 35 mg,
70 mg
FORTEO
ibandronate oral
PROLIA
raloxifene
risedronate oral tablet 150 mg
risedronate oral tablet 35 mg,
35 mg (12 pack), 35 mg (4
pack)
risedronate oral tablet 5 mg
TYMLOS

1
3
3
3
2
2

QL (120/30)
ST
QL (120/30)

1
1

QL (30/30)
QL (4/28)

5

PA; QL (2.4/28);
NDS
QL (1/28)
QL (1/180)
QL (30/30)
QL (1/28)
QL (4/28)

2
4
2
2
2
2
5

OTHER RHEUMATOLOGICALS
ADALIMUMAB-ADAZ
5
ADALIMUMAB-ADBM
SUBCUTANEOUS PEN
INJECTOR KIT

5

QL (30/30)
PA; QL (1.56/30);
NDS
PA; QL (1.6/28);
NDS
PA; QL (4/28); NDS

DRUG REQUIREMENTS/
TIER LIMITS
5

PA; QL (2/28); NDS

5

PA; QL (4/28); NDS

5

5

PA; QL (12/365);
NDS
PA; QL (8/365);
NDS
PA; NDS
PA; QL (4/28); NDS
PA; QL (12/365);
NDS
PA; QL (8/365);
NDS
PA; QL (2/28); NDS

5

PA; QL (4/28); NDS

5
5

PA; QL (8/28); NDS
PA; QL (8/28); NDS

5

PA; QL (8/28); NDS

5
5
5

PA; QL (8/28); NDS
PA; QL (4/28); NDS
PA; QL (12/365);
NDS
PA; QL (8/365);
NDS
PA; QL (4/28); NDS

5
5
5
5
5

5
5
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

55

PA; QL (6/365);
NDS

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

HUMIRA(CF) PEDI CROHNS
STARTER SUBCUTANEOUS
SYRINGE KIT
80 MG/0.8 ML-40 MG/0.4 ML
HUMIRA(CF) PEN CROHNSUC-HS
HUMIRA(CF) PEN PEDIATRIC
UC
HUMIRA(CF) PEN PSOR-UVADOL HS
HUMIRA(CF) PEN
SUBCUTANEOUS PEN
INJECTOR KIT 40 MG/0.4 ML
HUMIRA(CF) PEN
SUBCUTANEOUS PEN
INJECTOR KIT 80 MG/0.8 ML
HUMIRA(CF)
SUBCUTANEOUS SYRINGE
KIT 10 MG/0.1 ML,
20 MG/0.2 ML
HUMIRA(CF)
SUBCUTANEOUS SYRINGE
KIT 40 MG/0.4 ML
HYRIMOZ PEN CROHN'S-UC
STARTER
HYRIMOZ PEN PSORIASIS
STARTER
HYRIMOZ(CF) PEDI CROHN
STARTER SUBCUTANEOUS
SYRINGE 80 MG/0.8 ML
HYRIMOZ(CF) PEDI CROHN
STARTER SUBCUTANEOUS
SYRINGE 80 MG/0.8 ML40 MG/0.4 ML
HYRIMOZ(CF) PEN

5

PA; QL (4/365);
NDS

5

PA; QL (6/365);
NDS
PA; QL (4/180);
NDS
PA; QL (6/365);
NDS
PA; QL (4/28); NDS

HYRIMOZ(CF)
SUBCUTANEOUS SYRINGE
10 MG/0.1 ML
HYRIMOZ(CF)
SUBCUTANEOUS SYRINGE
20 MG/0.2 ML

5

5
5
5
5

PA; QL (2/28); NDS

5

PA; QL (2/28); NDS

5

PA; QL (4/28); NDS

5
5
5
5

5

5

DRUG NAME

PA; QL (4.8/365);
NDS
PA; QL (3.2/365);
NDS
PA; QL (3.2/365);
NDS
PA; QL (2.4/365);
NDS

DRUG REQUIREMENTS/
TIER LIMITS

HYRIMOZ(CF)
SUBCUTANEOUS SYRINGE
40 MG/0.4 ML
leflunomide
ORENCIA CLICKJECT
ORENCIA SUBCUTANEOUS
SYRINGE 125 MG/ML
ORENCIA SUBCUTANEOUS
SYRINGE 50 MG/0.4 ML
ORENCIA SUBCUTANEOUS
SYRINGE 87.5 MG/0.7 ML
OTEZLA

5

PA; QL (1.6/28);
NDS

2
5
5

QL (30/30)
PA; QL (4/28); NDS
PA; QL (4/28); NDS

5

OTEZLA STARTER ORAL
TABLETS, DOSE PACK 10 MG
(4)-20 MG (4)-30 MG (47)
penicillamine
RIDAURA
RINVOQ ORAL TABLET
EXTENDED RELEASE 24 HR
15 MG, 30 MG
RINVOQ ORAL TABLET
EXTENDED RELEASE 24 HR
45 MG
XELJANZ ORAL SOLUTION

5

PA; QL (1.6/28);
NDS
PA; QL (2.8/28);
NDS
PA; QL (60/30);
NDS
PA; QL (110/365);
NDS

XELJANZ ORAL TABLET

5

XELJANZ XR

5

5
5

5
5
5

NDS
NDS
PA; QL (30/30);
NDS

5

PA; QL (84/180);
NDS

5

PA; QL (300/30);
NDS
PA; QL (60/30);
NDS
PA; QL (30/30);
NDS

OBSTETRICS / GYNECOLOGY
ESTROGENS / PROGESTINS
camila
deblitane
depo-estradiol
DEPO-SUBQ PROVERA 104
dotti
DUAVEE
errin

PA; QL (1.6/28);
NDS
PA; QL (0.2/28);
NDS
PA; QL (0.4/28);
NDS

3
3
4
4
2
4
3

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

56

QL (8/28)
PA

Covered Drugs By Category
DRUG NAME
estradiol oral
estradiol transdermal patch
semiweekly
estradiol transdermal patch
weekly
estradiol vaginal cream
estradiol vaginal tablet
estradiol valerate
ESTRING
fyavolv
heather
hydroxyprogesterone caproate
incassia
JENCYCLA
lyza
medroxyprogesterone
intramuscular
medroxyprogesterone oral
NORA-BE
norethindrone (contraceptive)
norethindrone acetate
norethindrone ac-eth estradiol
oral tablet 0.5‑2.5 mg-mcg
PREMARIN INJECTION
PREMARIN ORAL
PREMARIN VAGINAL
PREMPRO
progesterone micronized
sharobel
yuvafem
MISCELLANEOUS OB/GYN
clindamycin phosphate vaginal
etonogestrel-ethinyl estradiol
metronidazole vaginal
terconazole vaginal cream
0.4%

DRUG REQUIREMENTS/
TIER LIMITS
1
2

QL (8/28)

2

QL (4/28)

3
4
4
4
3
3
5
3
3
3
4

DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

TERCONAZOLE VAGINAL
2
CREAM 0.8%
terconazole vaginal suppository 3
tranexamic acid oral
3
VANDAZOLE
3
ORAL CONTRACEPTIVES / RELATED AGENTS
afirmelle
2
altavera (28)
2
alyacen 1/35 (28)
2
alyacen 7/7/7 (28)
2
amethia
2
amethyst (28)
2
apri
2
aranelle (28)
2
ashlyna
2
aubra eq
2
aurovela 1.5/30 (21)
2
aurovela 1/20 (21)
2
aurovela 24 fe
2
aurovela fe 1.5/30 (28)
2
aurovela fe 1‑20 (28)
2
aviane
2
ayuna
2
azurette (28)
2
balziva (28)
2
blisovi 24 fe
2
blisovi fe 1.5/30 (28)
2
blisovi fe 1/20 (28)
2
briellyn
2
CAMRESE
2
CAMRESE LO
2
charlotte 24 fe
2
chateal eq (28)
2
cryselle (28)
2
cyred eq
2
dasetta 1/35 (28)
2

NDS

2
3
3
3
3
4
3
3
3
3
3
4
3
4
3
2

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

57

Covered Drugs By Category
DRUG NAME
dasetta 7/7/7 (28)
daysee
desog-e.estradiol/e.estradiol
desogestrel-ethinyl estradiol
dolishale
DROSPIRENONE-E.
ESTRADIOL-LM.FA
drospirenone-ethinyl estradiol
elinest
enpresse
enskyce
estarylla
ethynodiol diac-eth estradiol
falmina (28)
finzala
gemmily
hailey
hailey 24 fe
hailey fe 1.5/30 (28)
hailey fe 1/20 (28)
iclevia
isibloom
jaimiess
jasmiel (28)
JOLESSA
joyeaux
juleber
junel 1.5/30 (21)
junel 1/20 (21)
junel fe 1.5/30 (28)
junel fe 1/20 (28)
junel fe 24
kaitlib fe
kalliga
kariva (28)
kelnor 1/35 (28)

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

2
2
2
2
2
2

kelnor 1‑50 (28)
kurvelo (28)
l norgest/e.estradiol-e.estrad
larin 1.5/30 (21)
larin 1/20 (21)
larin 24 fe
larin fe 1.5/30 (28)
larin fe 1/20 (28)
LAYOLIS FE
LEENA 28
lessina
levonest (28)
levonorgestrel-ethinyl estrad
levonorg-eth estrad triphasic
levora-28
lojaimiess
loryna (28)
low-ogestrel (28)
lo-zumandimine (28)
lutera (28)
marlissa (28)
merzee
microgestin 1.5/30 (21)
microgestin 1/20 (21)
microgestin fe 1.5/30 (28)
microgestin fe 1/20 (28)
mili
mono-linyah
necon 0.5/35 (28)
nikki (28)
noreth-ethinyl estradiol-iron
norethindrone ac-eth estradiol
oral tablet 1‑20 mg-mcg, 1.5‑30
mg-mcg
norethindrone-e.estradiol-iron
oral capsule

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
3
2
2
2
2
2
2
2
2
2
2

DRUG REQUIREMENTS/
TIER LIMITS
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

58

Covered Drugs By Category
DRUG NAME
norethindrone-e.estradiol-iron
oral tablet
NORETHINDRONE-E.
ESTRADIOL-IRON ORAL
TABLET, CHEWABLE
norgestimate-ethinyl estradiol
nortrel 0.5/35 (28)
nortrel 1/35 (21)
nortrel 1/35 (28)
nortrel 7/7/7 (28)
nylia 1/35 (28)
nylia 7/7/7 (28)
nymyo
OCELLA
philith
pimtrea (28)
portia 28
reclipsen (28)
RIVELSA
setlakin
simliya (28)
simpesse
sprintec (28)
sronyx
syeda
tarina 24 fe
tarina fe 1‑20 eq (28)
taysofy
tilia fe
tri-estarylla
tri-legest fe
tri-linyah
tri-lo-estarylla
tri-lo-marzia
tri-lo-mili
tri-lo-sprintec

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

2

tri-mili
tri-nymyo
tri-sprintec (28)
trivora (28)
tri-vylibra
tri-vylibra lo
turqoz (28)
TYBLUME
tydemy
velivet triphasic regimen (28)
vestura (28)
vienva
viorele (28)
volnea (28)
vyfemla (28)
vylibra
wera (28)
wymzya fe
zovia 1‑35 (28)
zumandimine (28)

2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

DRUG REQUIREMENTS/
TIER LIMITS
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2

OPHTHALMOLOGY
ANTIBIOTICS
AZASITE
bacitracin ophthalmic (eye)
bacitracin-polymyxin b
BESIVANCE
ciprofloxacin hcl ophthalmic
(eye)
erythromycin ophthalmic (eye)
gentamicin ophthalmic (eye)
drops
moxifloxacin ophthalmic (eye)
NATACYN
neomycin-bacitracin-polymyxin
neomycin-polymyxin-gramicidin
ofloxacin ophthalmic (eye)

3
2
2
4
2
2
2
3
3
2
2
2

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

59

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

polycin
2
polymyxin b sulf-trimethoprim
2
tobramycin ophthalmic (eye)
2
TOBREX OPHTHALMIC (EYE)
4
OINTMENT
ANTIVIRALS
trifluridine
3
ZIRGAN
4
BETA-BLOCKERS
carteolol
1
levobunolol ophthalmic (eye)
1
drops 0.5%
timolol maleate ophthalmic
1
(eye) drops
timolol maleate ophthalmic
4
(eye) gel forming solution
MISCELLANEOUS OPHTHALMOLOGICS
atropine ophthalmic (eye) drops 3
azelastine ophthalmic (eye)
2
cromolyn ophthalmic (eye)
2
cyclosporine ophthalmic (eye)
3
CYSTARAN
5
PA; NDS
epinastine
3
EYLEA
5
PA; QL (0.1/28);
NDS
LACRISERT
4
MIEBO
3
QL (3/30)
olopatadine ophthalmic (eye)
2
drops 0.1%
OXERVATE
5
PA; QL (112/56);
NDS
pilocarpine hcl ophthalmic (eye) 3
drops 1%, 2%, 4%
sulfacetamide sodium
2
ophthalmic (eye) drops
sulfacetamide-prednisolone
2
XDEMVY
5
PA; QL (10/42);
NDS

DRUG REQUIREMENTS/
TIER LIMITS

XIIDRA
3
QL (60/30)
NON-STEROIDAL ANTI-INFLAMMATORY AGENTS
bromfenac ophthalmic (eye)
3
drops 0.09%
diclofenac sodium ophthalmic
2
(eye)
flurbiprofen sodium
2
ILEVRO
3
KETOROLAC OPHTHALMIC
2
(EYE) DROPS 0.4%
ketorolac ophthalmic (eye)
2
drops 0.5%
ORAL DRUGS FOR GLAUCOMA
acetazolamide
3
acetazolamide sodium
4
methazolamide
4
OTHER GLAUCOMA DRUGS
bimatoprost ophthalmic (eye)
2
brimonidine-timolol
3
brinzolamide
4
dorzolamide
2
dorzolamide-timolol
1
latanoprost
1
LUMIGAN OPHTHALMIC
3
(EYE) DROPS 0.01%
RHOPRESSA
4
ST
ROCKLATAN
4
ST
SIMBRINZA
4
travoprost
3
STEROID-ANTIBIOTIC COMBINATIONS
neomycin-bacitracin-poly-hc
3
neomycin-polymyxin
2
b-dexameth
neomycin-polymyxin-hc
2
ophthalmic (eye)
TOBRADEX ST
3
tobramycin-dexamethasone
3

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

60

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

ZYLET
STEROIDS
dexamethasone sodium
phosphate ophthalmic (eye)
difluprednate
EYSUVIS
FLUOROMETHOLONE
INVELTYS
LOTEMAX OPHTHALMIC
(EYE) OINTMENT
LOTEMAX SM
loteprednol etabonate
ophthalmic (eye) drops,gel
loteprednol etabonate
ophthalmic (eye)
drops,suspension 0.5%
PREDNISOLONE ACETATE
prednisolone sodium
phosphate ophthalmic (eye)
SYMPATHOMIMETICS
ALPHAGAN P OPHTHALMIC
(EYE) DROPS 0.1%
apraclonidine
brimonidine ophthalmic (eye)
drops 0.1%, 0.15%
brimonidine ophthalmic (eye)
drops 0.2%

DRUG NAME

3
2
3
3
3
3
4

QL (16.6/30)

4
4
4
3
2
3
3
3
1

RESPIRATORY AND ALLERGY
ANTIHISTAMINE / ANTIALLERGENIC AGENTS
cetirizine oral solution 1 mg/ml
2
desloratadine oral tablet
2
QL (30/30)
diphenhydramine hcl injection
4
solution 50 mg/ml
EPINEPHRINE INJECTION
2
QL (2/30)
AUTO-INJECTOR
0.15 MG/0.15 ML,
0.3 MG/0.3 ML

DRUG REQUIREMENTS/
TIER LIMITS

epinephrine injection autoinjector 0.15 mg/0.3 ml, 0.3
mg/0.3 ml
epinephrine injection solution 1
mg/ml
hydroxyzine hcl oral tablet
levocetirizine oral solution
levocetirizine oral tablet
promethazine oral
promethazine rectal
suppository 12.5 mg, 25 mg
promethegan rectal suppository
25 mg, 50 mg
PULMONARY AGENTS
acetylcysteine
ADEMPAS

2

ADVAIR HFA
ALBUTEROL SULFATE
INHALATION HFA AEROSOL
INHALER 90 MCG/
ACTUATION
albuterol sulfate inhalation
hfa aerosol inhaler 90 mcg/
actuation (nda020503)
ALBUTEROL SULFATE
INHALATION HFA AEROSOL
INHALER 90 MCG/
ACTUATION (NDA020983)
albuterol sulfate inhalation
solution for nebulization
albuterol sulfate oral syrup
albuterol sulfate oral tablet
alyq

3
2

B/D PA
PA; LA; QL (90/30);
NDS
QL (12/30)
QL (17/30)

2

QL (13.4/30)

2

QL (36/30)

2

B/D PA

ambrisentan

5

ANORO ELLIPTA
arformoterol
ARNUITY ELLIPTA

3
4
3

4
3
4
2
2
4

61

PA
QL (30/30)
PA

4
3
5

2
4
5

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

QL (2/30)

PA; QL (60/30);
NDS
PA; LA; QL (30/30);
NDS
QL (60/30)
B/D PA
QL (30/30)

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

ATROVENT HFA
bosentan
BREO ELLIPTA
breyna
BROVANA
budesonide inhalation

4
5
3
4
4
3

COMBIVENT RESPIMAT
cromolyn inhalation
FASENRA
FASENRA PEN
flunisolide
fluticasone propionate nasal
fluticasone propion-salmeterol
inhalation blister with device
formoterol fumarate

3
4
5
5
3
2
2

HAEGARDA
icatibant

5
5

INCRUSE ELLIPTA
ipratropium bromide inhalation
ipratropium-albuterol
KALYDECO

3
2
2
5

levalbuterol hcl
LEVALBUTEROL TARTRATE
mometasone nasal
montelukast oral granules in
packet
montelukast oral tablet
montelukast oral
tablet,chewable
NUCALA SUBCUTANEOUS
AUTO-INJECTOR
NUCALA SUBCUTANEOUS
SYRINGE 100 MG/ML

3
4
2
3

B/D PA; QL
(120/30)
PA; LA; NDS
PA; QL (18/30);
NDS
QL (30/30)
B/D PA
B/D PA
PA; QL (56/28);
NDS
B/D PA
QL (30/30)
QL (34/30)
QL (30/30)

1
1

QL (30/30)
QL (30/30)

5

PA; LA; QL (3/28);
NDS
PA; LA; QL (3/28);
NDS

4

5

DRUG NAME

QL (25.8/30)
PA; LA; NDS
QL (60/30)
QL (10.3/30)
B/D PA
B/D PA; QL
(120/30)
QL (8/30)
B/D PA
PA; QL (1/28); NDS
PA; QL (1/28); NDS
QL (50/30)
QL (16/30)
QL (60/30)

DRUG REQUIREMENTS/
TIER LIMITS

NUCALA SUBCUTANEOUS
SYRINGE 40 MG/0.4 ML
OFEV

5

OPSUMIT
ORKAMBI ORAL GRANULES
IN PACKET
ORKAMBI ORAL TABLET

5
5

PERFOROMIST

5

pirfenidone oral tablet 267 mg

5

pirfenidone oral tablet 534 mg,
801 mg
PULMICORT

5

PULMOZYME

5

roflumilast
RYALTRIS
sajazir

4
4
5

SEREVENT DISKUS
sildenafil (pulm.hypertension)
oral tablet
SYMDEKO

3
3

tadalafil (pulm. hypertension)

5

TADLIQ

5

terbutaline
theo-24
theophylline oral tablet
extended release 12 hr
theophylline oral tablet
extended release 24 hr
TRELEGY ELLIPTA

4
4
3

5

5

4

5

62

PA; QL (56/28);
NDS
PA; QL (60/30);
NDS
PA; QL (300/30);
NDS

3
3

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

PA; LA; QL (0.4/28);
NDS
PA; QL (60/30);
NDS
PA; LA; NDS
PA; QL (56/28);
NDS
PA; QL (112/28);
NDS
B/D PA; QL
(120/30); NDS
PA; QL (270/30);
NDS
PA; QL (90/30);
NDS
B/D PA; QL
(120/30)
B/D PA; QL
(150/30); NDS
PA; QL (30/30)
ST
PA; QL (18/30);
NDS
QL (60/30)
PA; QL (90/30)

QL (60/30)

Covered Drugs By Category
DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

TRIKAFTA ORAL GRANULES
IN PACKET, SEQUENTIAL
TRIKAFTA ORAL TABLETS,
SEQUENTIAL
TYVASO
TYVASO INSTITUTIONAL
START KIT
TYVASO REFILL KIT
TYVASO STARTER KIT
VENTAVIS
VENTOLIN HFA
wixela inhub
XHANCE
XOLAIR SUBCUTANEOUS
RECON SOLN
XOLAIR SUBCUTANEOUS
SYRINGE 150 MG/ML
XOLAIR SUBCUTANEOUS
SYRINGE 75 MG/0.5 ML
YUPELRI

5

zafirlukast

4

5
5
5
5
5
5
3
2
4
5
5
5
5

DRUG NAME

PA; QL (56/28);
NDS
PA; QL (84/28);
NDS
B/D PA; NDS
B/D PA; NDS

DRUG REQUIREMENTS/
TIER LIMITS

BENIGN PROSTATIC HYPERPLASIA(BPH) THERAPY
alfuzosin
2
dutasteride
2
dutasteride-tamsulosin
4
finasteride oral tablet 5 mg
1
QL (30/30)
tamsulosin
2
QL (60/30)
MISCELLANEOUS UROLOGICALS
bethanechol chloride
2
CYSTAGON
4
LA
ELMIRON
4
K-PHOS ORIGINAL
4
potassium citrate oral tablet
4
extended release
RENACIDIN
4
sildenafil
1
EX; QL (6/30)

B/D PA; NDS
B/D PA; NDS
PA; NDS
QL (36/30)
QL (60/30)
ST; QL (32/30)
PA; LA; QL (8/28);
NDS
PA; LA; QL (8/28);
NDS
PA; LA; QL (1/28);
NDS
B/D PA; QL (90/30);
NDS
QL (60/30)

VITAMINS, HEMATINICS / ELECTROLYTES
ELECTROLYTES
calcium acetate(phosphat bind)
klor-con
KLOR-CON 10
KLOR-CON 8
klor-con m10
klor-con m15
klor-con m20
lactated ringers intravenous
magnesium sulfate in d5w
intravenous piggyback 1
gram/100 ml
magnesium sulfate in water
magnesium sulfate injection
POTASSIUM CHLORIDD5‑0.45%NACL
POTASSIUM CHLORIDE IN
0.9%NACL INTRAVENOUS
PARENTERAL SOLUTION
20 MEQ/L, 40 MEQ/L

UROLOGICALS
ANTICHOLINERGICS / ANTISPASMODICS
darifenacin
4
fesoterodine
3
QL (30/30)
GEMTESA
3
QL (30/30)
MYRBETRIQ ORAL TABLET
3
EXTENDED RELEASE 24 HR
oxybutynin chloride oral syrup
2
oxybutynin chloride oral tablet
2
5 mg
oxybutynin chloride oral tablet
2
QL (60/30)
extended release 24hr
solifenacin
2
tolterodine
3

3
2
2
2
2
2
2
4
4
4
4
4
4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

63

QL (360/30)

Covered Drugs By Category
DRUG NAME
potassium chloride in 5% dex
intravenous parenteral solution
10 meq/l
POTASSIUM CHLORIDE
IN 5% DEX INTRAVENOUS
PARENTERAL SOLUTION
20 MEQ/L
POTASSIUM CHLORIDE
IN LR-D5 INTRAVENOUS
PARENTERAL SOLUTION
20 MEQ/L
potassium chloride in water
intravenous piggyback 10
meq/100 ml, 10 meq/50 ml, 20
meq/100 ml, 20 meq/50 ml, 40
meq/100 ml
potassium chloride intravenous
potassium chloride oral
capsule, extended release
potassium chloride oral liquid
potassium chloride oral packet
potassium chloride oral tablet
extended release
potassium chloride oral
tablet,er particles/crystals
potassium chloride-0.45% nacl
POTASSIUM CHLORIDED5‑0.2%NACL INTRAVENOUS
PARENTERAL SOLUTION
20 MEQ/L
POTASSIUM CHLORIDED5‑0.9%NACL
RINGER'S INTRAVENOUS
sodium bicarbonate
intravenous syringe
sodium chloride 0.45%
intravenous
sodium chloride 3% hypertonic
SODIUM CHLORIDE 5%
HYPERTONIC
sodium chloride intravenous

DRUG REQUIREMENTS/
TIER LIMITS

DRUG NAME

DRUG REQUIREMENTS/
TIER LIMITS

TPN ELECTROLYTES
4
B/D PA
MISCELLANEOUS NUTRITION PRODUCTS
CLINIMIX 5%/D15W SULFITE
4
B/D PA
FREE
CLINIMIX 4.25%/D10W SULF
4
B/D PA
FREE
CLINIMIX 5%-D20W(SULFITE4
B/D PA
FREE)
CLINIMIX 6%-D5W (SULFITE4
B/D PA
FREE)
CLINIMIX 8%-D10W(SULFITE4
B/D PA
FREE)
CLINIMIX 8%-D14W(SULFITE4
B/D PA
FREE)
CLINIMIX E 4.25%/D10W SUL
4
B/D PA
FREE
clinisol sf 15%
4
B/D PA
ELECTROLYTE-48 IN D5W
4
INTRALIPID INTRAVENOUS
4
B/D PA
EMULSION 20%, 30%
KABIVEN
4
B/D PA
PERIKABIVEN
4
B/D PA
plenamine
4
B/D PA
PREMASOL 10%
5
B/D PA; NDS
PROSOL 20%
4
B/D PA
TRAVASOL 10%
4
B/D PA
TROPHAMINE 10%
4
B/D PA
VITAMINS / HEMATINICS
BAL-CARE DHA
3
C-NATE DHA
3
COMPLETE NATAL DHA
3
ELITE-OB
3
fluoride (sodium) oral tablet
1
fluoride (sodium) oral
1
tablet,chewable 1 mg (2.2 mg
sod. fluoride)
FOLIVANE-OB
3

4
4

4

4

4
2
4
2
2
2
4
4

4
4
4
4
4
4
4

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

64

Covered Drugs By Category
DRUG NAME
ludent fluoride oral
tablet,chewable 1 mg (2.2 mg
sod. fluoride)
M-NATAL PLUS
PNV-DHA
PNV-OMEGA
PNV-SELECT
PR NATAL 400
PR NATAL 400 EC
PR NATAL 430
PR NATAL 430 EC
PRENATAL PLUS (CALCIUM
CARB)
PRENATAL VITAMIN PLUS
LOW IRON
SE-NATAL 19 CHEWABLE
SE-NATAL-19
TARON-C DHA
TRINATAL RX 1
WESCAP-PN DHA
WESNATE DHA
westab plus
WESTGEL DHA

DRUG REQUIREMENTS/
TIER LIMITS
1
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2

CAPITALIZED = BRAND NAME DRUG
Lower case italic = Generic drug
You can find information on what the symbols and abbreviations on this table mean by going to page 11.
March 2024

65

Covered Drugs Index
DRUG

PAGE

DRUG

A

ADALIMUMAB-ADBM SUBCUTANEOUS PEN
INJECTOR KIT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
ADALIMUMAB-ADBM SUBCUTANEOUS SYRINGE KIT
10 MG/0.2 ML, 20 MG/0.4 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
ADALIMUMAB-ADBM SUBCUTANEOUS SYRINGE KIT
40 MG/0.8 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
adapalene topical gel 0.3%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
ADCETRIS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
adefovir. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
ADEMPAS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
ADLARITY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
adstiladrin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
ADVAIR HFA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
afirmelle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
AIMOVIG AUTOINJECTOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
AJOVY AUTOINJECTOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
AJOVY SYRINGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
AKEEGA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
ala-cort topical cream 1% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
albendazole. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
ALBUTEROL SULFATE INHALATION HFA AEROSOL
INHALER 90 MCG/ACTUATION. . . . . . . . . . . . . . . . . . . . . . . . . .  61
albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/
actuation (nda020503). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
ALBUTEROL SULFATE INHALATION HFA AEROSOL
INHALER 90 MCG/ACTUATION (NDA020983). . . . . . . . . . . .  61
albuterol sulfate inhalation solution for nebulization . . . . . . . .  61
albuterol sulfate oral syrup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
albuterol sulfate oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
alclometasone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
ALCOHOL PADS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
ALDURAZYME. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
ALECENSA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
alendronate oral tablet 10 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
alendronate oral tablet 35 mg, 70 mg . . . . . . . . . . . . . . . . . . . . .  55
alfuzosin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
ALIQOPA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
aliskiren. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
allopurinol oral tablet 100 mg, 300 mg . . . . . . . . . . . . . . . . . . . .  55
alosetron. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.1%. . . . . . . .  61

abacavir-lamivudine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
abacavir oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
abacavir oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
ABELCET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,
EXTENDED REL SYRING 720 MG/2.4 ML. . . . . . . . . . . . . . . .  32
ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,
EXTENDED REL SYRING 960 MG/3.2 ML. . . . . . . . . . . . . . . .  32
ABILIFY MAINTENA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
abiraterone oral tablet 250 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
abiraterone oral tablet 500 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
ABRAXANE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
ABRYSVO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
acamprosate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
acarbose oral tablet 25 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
acarbose oral tablet 50 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
acarbose oral tablet 100 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
acebutolol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
acetaminophen-codeine oral solution 120‑12 mg/5 ml. . . . . .  31
acetaminophen-codeine oral tablet 300‑15 mg,
300‑30 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
acetaminophen-codeine oral tablet 300‑60 mg . . . . . . . . . . . .  31
acetazolamide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
acetazolamide sodium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
acetic acid otic (ear) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
acetylcysteine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
acitretin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
ACTHIB (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
ACTIMMUNE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
acyclovir oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
acyclovir oral suspension 200 mg/5 ml. . . . . . . . . . . . . . . . . . . .  13
acyclovir oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
acyclovir sodium intravenous solution. . . . . . . . . . . . . . . . . . . . .  13
acyclovir topical ointment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
ADACEL(TDAP ADOLESN/ADULT)(PF) . . . . . . . . . . . . . . . . . .  53
ADALIMUMAB-ADAZ. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
ADALIMUMAB-ADBM(CF) PEN CROHNS. . . . . . . . . . . . . . . .  55
ADALIMUMAB-ADBM(CF) PEN PS-UV. . . . . . . . . . . . . . . . . . .  55
March 2024

PAGE

66

Covered Drugs Index
DRUG

PAGE

DRUG

alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg. . . . . . . . . . . . . .  32
alprazolam oral tablet 2 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
alprazolam oral tablet,disintegrating
0.25 mg, 0.5 mg, 1 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
alprazolam oral tablet,disintegrating 2 mg. . . . . . . . . . . . . . . . .  33
altavera (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
ALUNBRIG ORAL TABLET 30 MG . . . . . . . . . . . . . . . . . . . . . . .  19
ALUNBRIG ORAL TABLET 180 MG, 90 MG. . . . . . . . . . . . . . .  19
ALUNBRIG ORAL TABLETS, DOSE PACK . . . . . . . . . . . . . . .  19
alyacen 1/35 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
alyacen 7/7/7 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
alyq. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
amantadine hcl. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
ambrisentan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
amethia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
amethyst (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
amikacin injection solution 1,000 mg/4 ml, 500 mg/2 ml . . . .  16
amiloride. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
amiloride-hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
aminocaproic acid oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
amiodarone intravenous solution . . . . . . . . . . . . . . . . . . . . . . . . .  37
amiodarone oral tablet 100 mg, 400 mg. . . . . . . . . . . . . . . . . . .  37
amiodarone oral tablet 200 mg . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
amitriptyline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
amlodipine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
amlodipine-atorvastatin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
amlodipine-benazepril . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
amlodipine-olmesartan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
amlodipine-valsartan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
amlodipine-valsartan-hcthiazid . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
ammonium lactate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
amnesteem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
amoxapine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
amoxicillin oral capsule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
amoxicillin oral suspension for reconstitution . . . . . . . . . . . . . .  18
amoxicillin oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
amoxicillin oral tablet,chewable 125 mg, 250 mg. . . . . . . . . . .  18
amoxicillin-pot clavulanate oral suspension for
reconstitution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
amoxicillin-pot clavulanate oral tablet . . . . . . . . . . . . . . . . . . . . .  18
March 2024

PAGE

amoxicillin-pot clavulanate oral tablet,chewable. . . . . . . . . . . .  18
amoxicillin-pot clavulanate oral tablet extended
release 12 hr. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
amphotericin b . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
amphotericin b liposome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
ampicillin oral capsule 500 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
ampicillin sodium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
ampicillin-sulbactam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
anagrelide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
anastrozole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
ANORO ELLIPTA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
apraclonidine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
aprepitant oral capsule 40 mg, 80 mg. . . . . . . . . . . . . . . . . . . . .  51
aprepitant oral capsule 125 mg. . . . . . . . . . . . . . . . . . . . . . . . . . .  51
aprepitant oral capsule,dose pack . . . . . . . . . . . . . . . . . . . . . . . .  51
APRETUDE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
apri. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
APTIOM ORAL TABLET 200 MG. . . . . . . . . . . . . . . . . . . . . . . . .  27
APTIOM ORAL TABLET 400 MG. . . . . . . . . . . . . . . . . . . . . . . . .  27
APTIOM ORAL TABLET 600 MG, 800 MG . . . . . . . . . . . . . . . .  27
APTIVUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
aranelle (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
ARCALYST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
AREXVY (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
arformoterol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
ARIKAYCE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
aripiprazole oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 5 mg. . . . . . . . . . 33
aripiprazole oral tablet 20 mg, 30 mg . . . . . . . . . . . . . . . . . . . . .  33
aripiprazole oral tablet,disintegrating. . . . . . . . . . . . . . . . . . . . . .  33
ARISTADA INITIO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
ARISTADA INTRAMUSCULAR SUSPENSION,
EXTENDED REL SYRING 1,064 MG/3.9 ML. . . . . . . . . . . . . .  33
ARISTADA INTRAMUSCULAR SUSPENSION,
EXTENDED REL SYRING 441 MG/1.6 ML. . . . . . . . . . . . . . . .  33
ARISTADA INTRAMUSCULAR SUSPENSION,
EXTENDED REL SYRING 662 MG/2.4 ML. . . . . . . . . . . . . . . .  33
ARISTADA INTRAMUSCULAR SUSPENSION,
EXTENDED REL SYRING 882 MG/3.2 ML. . . . . . . . . . . . . . . .  33
armodafinil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
ARNUITY ELLIPTA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
67

Covered Drugs Index
DRUG

PAGE

DRUG

arsenic trioxide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
asenapine maleate sublingual tablet 5 mg. . . . . . . . . . . . . . . . .  33
asenapine maleate sublingual tablet 10 mg, 2.5 mg. . . . . . . .  33
ashlyna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
aspirin-dipyridamole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
ASSURE ID INSULIN SAFETY SYRINGE
1 ML 29 GAUGE X 1/2". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
atazanavir oral capsule 150 mg, 300 mg . . . . . . . . . . . . . . . . . .  13
atazanavir oral capsule 200 mg. . . . . . . . . . . . . . . . . . . . . . . . . . .  13
atenolol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
atenolol-chlorthalidone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
ATGAM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
atomoxetine oral capsule 10 mg, 18 mg, 25 mg, 40 mg . . . .  33
atomoxetine oral capsule 100 mg, 60 mg, 80 mg . . . . . . . . . .  33
atorvastatin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
atovaquone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
atovaquone-proguanil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
atropine injection solution 0.4 mg/ml . . . . . . . . . . . . . . . . . . . . . .  50
atropine injection syringe 0.1 mg/ml. . . . . . . . . . . . . . . . . . . . . . .  51
atropine intravenous solution 0.4 mg/ml. . . . . . . . . . . . . . . . . . .  51
ATROPINE INTRAVENOUS SYRINGE 0.25 MG/5 ML
(0.05 MG/ML) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
atropine ophthalmic (eye) drops . . . . . . . . . . . . . . . . . . . . . . . . . .  60
ATROVENT HFA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
aubra eq. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
AUGMENTIN ORAL SUSPENSION FOR
RECONSTITUTION 125‑31.25 MG/5 ML. . . . . . . . . . . . . . . . . .  18
AUGTYRO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
aurovela 1.5/30 (21) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
aurovela 1/20 (21). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
aurovela 24 fe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
aurovela fe 1.5/30 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
aurovela fe 1‑20 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
AUSTEDO ORAL TABLET 6 MG . . . . . . . . . . . . . . . . . . . . . . . . .  30
AUSTEDO ORAL TABLET 12 MG, 9 MG. . . . . . . . . . . . . . . . . .  29
AUSTEDO XR ORAL TABLET EXTENDED
RELEASE 24 HR 6 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
AUSTEDO XR ORAL TABLET EXTENDED
RELEASE 24 HR 12 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
AUSTEDO XR ORAL TABLET EXTENDED
RELEASE 24 HR 24 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
March 2024

PAGE

AUSTEDO XR TITRATION KT(WK1‑4) . . . . . . . . . . . . . . . . . . .  30
AUVELITY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
aviane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
AVONEX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
ayuna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
AYVAKIT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
azacitidine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
AZASITE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
azathioprine oral tablet 50 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
azathioprine oral tablet 100 mg, 75 mg. . . . . . . . . . . . . . . . . . . .  19
azathioprine sodium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
azelaic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
azelastine nasal aerosol,spray . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
azelastine ophthalmic (eye) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
azithromycin intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
AZITHROMYCIN ORAL PACKET. . . . . . . . . . . . . . . . . . . . . . . . .  16
azithromycin oral suspension for reconstitution . . . . . . . . . . . .  16
azithromycin oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
aztreonam injection recon soln 1 gram. . . . . . . . . . . . . . . . . . . .  16
aztreonam injection recon soln 2 gram. . . . . . . . . . . . . . . . . . . .  16
azurette (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57

B
bacitracin intramuscular. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
bacitracin ophthalmic (eye). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
bacitracin-polymyxin b . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
baclofen oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
BAL-CARE DHA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
balsalazide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
BALVERSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
balziva (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
BAQSIMI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
BARACLUDE ORAL SOLUTION . . . . . . . . . . . . . . . . . . . . . . . . .  13
BAVENCIO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
BCG VACCINE, LIVE (PF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
BD SAFETYGLIDE INSULIN SYRINGE SYRINGE
1 ML 31 GAUGE X 15/64". . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
BD ULTRA-FINE NANO PEN NEEDLE . . . . . . . . . . . . . . . . . . .  54
BD ULTRA-FINE SHORT PEN NEEDLE. . . . . . . . . . . . . . . . . .  54
68

Covered Drugs Index
DRUG

PAGE

DRUG

BELEODAQ. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
BELSOMRA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
benazepril. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
benazepril-hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
bendamustine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
BENDEKA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
BENLYSTA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
benztropine injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
benztropine oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
BESIVANCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
BESPONSA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
BESREMI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
betaine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
betamethasone, augmented. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
betamethasone dipropionate . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
betamethasone valerate topical cream. . . . . . . . . . . . . . . . . . . .  43
betamethasone valerate topical foam . . . . . . . . . . . . . . . . . . . . .  43
betamethasone valerate topical lotion. . . . . . . . . . . . . . . . . . . . .  43
betamethasone valerate topical ointment. . . . . . . . . . . . . . . . . .  43
BETASERON SUBCUTANEOUS KIT. . . . . . . . . . . . . . . . . . . . .  52
betaxolol oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
bethanechol chloride. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
bexarotene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
BEXSERO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
bicalutamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
BICILLIN L-A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
BIKTARVY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
bimatoprost ophthalmic (eye). . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
bisoprolol fumarate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
bisoprolol-hydrochlorothiazide. . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
BLENREP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
bleomycin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
BLINCYTO INTRAVENOUS KIT. . . . . . . . . . . . . . . . . . . . . . . . . .  20
blisovi 24 fe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
blisovi fe 1.5/30 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
blisovi fe 1/20 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
BOOSTRIX TDAP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
BORTEZOMIB INJECTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
BORTEZOMIB INTRAVENOUS RECON SOLN . . . . . . . . . . .  20
bosentan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
March 2024

PAGE

BOSULIF ORAL TABLET 100 MG. . . . . . . . . . . . . . . . . . . . . . . .  20
BOSULIF ORAL TABLET 400 MG, 500 MG . . . . . . . . . . . . . . .  20
BOTOX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
BRAFTOVI ORAL CAPSULE 75 MG. . . . . . . . . . . . . . . . . . . . . .  20
BREO ELLIPTA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
breyna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
briellyn. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
BRILINTA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
brimonidine ophthalmic (eye) drops 0.1%, 0.15%. . . . . . . . . .  61
brimonidine ophthalmic (eye) drops 0.2% . . . . . . . . . . . . . . . . .  61
brimonidine-timolol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
brinzolamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
BRIUMVI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
BRIVIACT INTRAVENOUS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
BRIVIACT ORAL SOLUTION. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
BRIVIACT ORAL TABLET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
bromfenac ophthalmic (eye) drops 0.09%. . . . . . . . . . . . . . . . .  60
bromocriptine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
BROVANA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
BRUKINSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
budesonide inhalation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
budesonide oral capsule,delayed,extend.release . . . . . . . . . .  51
budesonide oral tablet,delayed and ext.release. . . . . . . . . . . .  51
bumetanide injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
bumetanide oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
buprenorphine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
buprenorphine hcl injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
buprenorphine hcl sublingual. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
buprenorphine-naloxone sublingual film 2‑0.5 mg. . . . . . . . . .  32
buprenorphine-naloxone sublingual film 4‑1 mg, 8‑2 mg. . . .  32
buprenorphine-naloxone sublingual film 12‑3 mg . . . . . . . . . .  32
buprenorphine-naloxone sublingual tablet 2‑0.5 mg. . . . . . . .  32
buprenorphine-naloxone sublingual tablet 8‑2 mg. . . . . . . . . .  32
bupropion hcl oral tablet 75 mg. . . . . . . . . . . . . . . . . . . . . . . . . . .  33
bupropion hcl oral tablet 100 mg. . . . . . . . . . . . . . . . . . . . . . . . . .  33
bupropion hcl oral tablet extended release 24 hr 150 mg. . .  33
bupropion hcl oral tablet extended release 24 hr 300 mg. . .  33
bupropion hcl oral tablet sustained-release 12 hr 100 mg. . .  33
bupropion hcl oral tablet sustained-release
12 hr 150 mg, 200 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
69

Covered Drugs Index
DRUG

PAGE

DRUG

bupropion hcl (smoking deter). . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
buspirone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
BUSULFAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
butorphanol nasal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
BYDUREON BCISE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47

carbidopa-levodopa oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
carbidopa-levodopa oral tablet,disintegrating. . . . . . . . . . . . . .  29
carbidopa-levodopa oral tablet extended release . . . . . . . . . .  29
carboplatin intravenous solution . . . . . . . . . . . . . . . . . . . . . . . . . .  20
carglumic acid. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
carmustine intravenous recon soln 100 mg. . . . . . . . . . . . . . . .  20
carteolol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
cartia xt. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
carvedilol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
carvedilol phosphate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
caspofungin intravenous recon soln 50 mg. . . . . . . . . . . . . . . .  13
caspofungin intravenous recon soln 70 mg. . . . . . . . . . . . . . . .  13
CAYSTON . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
cefaclor oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
cefaclor oral suspension for reconstitution
125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml . . . . . . . . . . . . . . . . . .  15
cefaclor oral tablet extended release 12 hr . . . . . . . . . . . . . . . .  15
cefadroxil oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
cefadroxil oral suspension for reconstitution
250 mg/5 ml, 500 mg/5 ml. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
cefadroxil oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
CEFAZOLIN IN DEXTROSE (ISO-OS) INTRAVENOUS
PIGGYBACK 1 GRAM/50 ML, 2 GRAM/100 ML,
2 GRAM/50 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
cefazolin injection recon soln 1 gram, 10 gram,
100 gram, 2 gram, 300 g, 500 mg . . . . . . . . . . . . . . . . . . . . . . . .  15
cefazolin intravenous recon soln 1 gram . . . . . . . . . . . . . . . . . .  15
CEFAZOLIN INTRAVENOUS RECON SOLN 2 GRAM,
3 GRAM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
cefdinir oral capsule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
cefdinir oral suspension for reconstitution . . . . . . . . . . . . . . . . .  15
CEFEPIME IN DEXTROSE 5%. . . . . . . . . . . . . . . . . . . . . . . . . . .  15
CEFEPIME IN DEXTROSE, ISO-OSM. . . . . . . . . . . . . . . . . . . .  15
cefepime injection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
cefepime intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
cefixime. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
cefoxitin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
CEFOXITIN IN DEXTROSE, ISO-OSM . . . . . . . . . . . . . . . . . . .  16
cefpodoxime . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
cefprozil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
ceftazidime. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16

C
CABENUVA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
cabergoline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
CABOMETYX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
calcipotriene scalp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
calcipotriene topical cream. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
calcipotriene topical ointment. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
calcitonin (salmon) injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
calcitonin (salmon) nasal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
calcitriol intravenous solution 1 mcg/ml. . . . . . . . . . . . . . . . . . . .  50
calcitriol oral capsule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
calcitriol oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
CALCITRIOL TOPICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
calcium acetate(phosphat bind). . . . . . . . . . . . . . . . . . . . . . . . . . .  63
CALQUENCE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
CALQUENCE (ACALABRUTINIB MAL). . . . . . . . . . . . . . . . . . .  20
camila . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
CAMRESE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
CAMRESE LO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
candesartan-hydrochlorothiazid . . . . . . . . . . . . . . . . . . . . . . . . . .  38
candesartan oral tablet 16 mg, 4 mg, 8 mg. . . . . . . . . . . . . . . .  38
candesartan oral tablet 32 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
CAPLYTA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
CAPRELSA ORAL TABLET 100 MG. . . . . . . . . . . . . . . . . . . . . .  20
CAPRELSA ORAL TABLET 300 MG. . . . . . . . . . . . . . . . . . . . . .  20
captopril . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
carbamazepine oral capsule, er multiphase 12 hr. . . . . . . . . .  27
carbamazepine oral suspension 100 mg/5 ml. . . . . . . . . . . . . .  27
carbamazepine oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
carbamazepine oral tablet,chewable. . . . . . . . . . . . . . . . . . . . . .  27
carbamazepine oral tablet extended release 12 hr. . . . . . . . .  27
carbidopa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
carbidopa-levodopa-entacapone. . . . . . . . . . . . . . . . . . . . . . . . . .  29
March 2024

PAGE

70

Covered Drugs Index
DRUG

PAGE

DRUG

ceftriaxone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
ceftriaxone in dextrose,iso-os . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
cefuroxime axetil oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
cefuroxime sodium injection recon soln 750 mg. . . . . . . . . . . .  16
cefuroxime sodium intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . .  16
celecoxib. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
CELONTIN ORAL CAPSULE 300 MG . . . . . . . . . . . . . . . . . . . .  27
cephalexin oral capsule 250 mg, 500 mg. . . . . . . . . . . . . . . . . .  16
cephalexin oral suspension for reconstitution. . . . . . . . . . . . . .  16
CEQUR SIMPLICITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
CEQUR SIMPLICITY INSERTER. . . . . . . . . . . . . . . . . . . . . . . . .  47
CEREZYME INTRAVENOUS RECON SOLN 400 UNIT. . . .  50
cetirizine oral solution 1 mg/ml . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
cevimeline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
charlotte 24 fe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
chateal eq (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
CHEMET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
chloramphenicol sod succinate. . . . . . . . . . . . . . . . . . . . . . . . . . .  16
chlorhexidine gluconate mucous membrane. . . . . . . . . . . . . . .  46
chloroquine phosphate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
chlorothiazide sodium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
chlorpromazine injection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
chlorpromazine oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
chlorthalidone oral tablet 25 mg, 50 mg . . . . . . . . . . . . . . . . . . .  38
cholestyramine-aspartame . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
cholestyramine light . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
cholestyramine (with sugar) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
CHORIONIC GONADOTROPIN, HUMAN
INTRAMUSCULAR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
ciclodan topical solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
ciclopirox topical cream . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
ciclopirox topical shampoo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
ciclopirox topical solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
ciclopirox topical suspension . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
cilostazol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
CIMDUO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
cinacalcet oral tablet 30 mg, 60 mg. . . . . . . . . . . . . . . . . . . . . . .  50
cinacalcet oral tablet 90 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
ciprofloxacin-dexamethasone . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
ciprofloxacin hcl ophthalmic (eye). . . . . . . . . . . . . . . . . . . . . . . . .  59
March 2024

PAGE

ciprofloxacin hcl oral tablet 100 mg . . . . . . . . . . . . . . . . . . . . . . .  18
ciprofloxacin hcl oral tablet 250 mg, 500 mg, 750 mg. . . . . . . 18
ciprofloxacin in 5% dextrose. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
ciprofloxacin oral suspension,microcapsule recon
500 mg/5 ml. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
cisplatin intravenous solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
citalopram oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
citalopram oral tablet 10 mg, 20 mg. . . . . . . . . . . . . . . . . . . . . . .  33
citalopram oral tablet 40 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
cladribine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
claravis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
clarithromycin oral suspension for reconstitution. . . . . . . . . . .  16
clarithromycin oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
clarithromycin oral tablet extended release 24 hr . . . . . . . . . .  16
CLENPIQ. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
clindacin etz topical swab . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
clindacin p . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
clindamycin hcl. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
CLINDAMYCIN IN 0.9% SOD CHLOR. . . . . . . . . . . . . . . . . . . .  16
clindamycin in 5% dextrose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
clindamycin palmitate hcl. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
clindamycin pediatric . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
clindamycin phosphate injection. . . . . . . . . . . . . . . . . . . . . . . . . .  16
clindamycin phosphate topical gel . . . . . . . . . . . . . . . . . . . . . . . .  42
CLINDAMYCIN PHOSPHATE TOPICAL GEL,
ONCE DAILY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
clindamycin phosphate topical lotion. . . . . . . . . . . . . . . . . . . . . .  43
clindamycin phosphate topical solution. . . . . . . . . . . . . . . . . . . .  43
clindamycin phosphate topical swab . . . . . . . . . . . . . . . . . . . . . .  43
clindamycin phosphate vaginal . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
CLINIMIX 4.25%/D5W SULFIT FREE. . . . . . . . . . . . . . . . . . . . .  45
CLINIMIX 4.25%/D10W SULF FREE . . . . . . . . . . . . . . . . . . . . .  64
CLINIMIX 5%/D15W SULFITE FREE . . . . . . . . . . . . . . . . . . . .  64
CLINIMIX 5%-D20W(SULFITE-FREE). . . . . . . . . . . . . . . . . . . .  64
CLINIMIX 6%-D5W (SULFITE-FREE). . . . . . . . . . . . . . . . . . . . .  64
CLINIMIX 8%-D10W(SULFITE-FREE). . . . . . . . . . . . . . . . . . . .  64
CLINIMIX 8%-D14W(SULFITE-FREE). . . . . . . . . . . . . . . . . . . .  64
CLINIMIX E 4.25%/D10W SUL FREE. . . . . . . . . . . . . . . . . . . . .  64
clinisol sf 15%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
clobazam oral suspension. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
71

Covered Drugs Index
DRUG

PAGE

DRUG

clobazam oral tablet 10 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
clobazam oral tablet 20 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
clobetasol-emollient topical cream. . . . . . . . . . . . . . . . . . . . . . . .  44
clobetasol-emollient topical foam . . . . . . . . . . . . . . . . . . . . . . . . .  44
clobetasol scalp . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
clobetasol topical cream . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
clobetasol topical foam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
clobetasol topical gel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
clobetasol topical ointment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
clobetasol topical shampoo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
clocortolone pivalate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
clodan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
clofarabine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
clomipramine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
clonazepam oral tablet 0.5 mg, 1 mg. . . . . . . . . . . . . . . . . . . . . .  27
clonazepam oral tablet 2 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
clonazepam oral tablet,disintegrating 0.5 mg, 1 mg . . . . . . . .  27
clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg. . .  27
clonazepam oral tablet,disintegrating 2 mg. . . . . . . . . . . . . . . .  27
clonidine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
clonidine hcl oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
clopidogrel oral tablet 75 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
clopidogrel oral tablet 300 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
clorazepate dipotassium oral tablet 3.75 mg. . . . . . . . . . . . . . .  33
clorazepate dipotassium oral tablet 7.5 mg. . . . . . . . . . . . . . . .  33
clorazepate dipotassium oral tablet 15 mg. . . . . . . . . . . . . . . . .  33
clotrimazole-betamethasone topical cream. . . . . . . . . . . . . . . .  43
clotrimazole-betamethasone topical lotion. . . . . . . . . . . . . . . . .  43
clotrimazole mucous membrane. . . . . . . . . . . . . . . . . . . . . . . . . .  13
clotrimazole topical cream. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
clotrimazole topical solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
clozapine oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
clozapine oral tablet,disintegrating 100 mg, 12.5 mg,
150 mg, 25 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
clozapine oral tablet,disintegrating 200 mg . . . . . . . . . . . . . . . .  33
C-NATE DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
COARTEM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
colchicine oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
colesevelam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
colestipol oral granules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
March 2024

PAGE

colestipol oral packet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
colestipol oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
colistin (colistimethate na). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
COLUMVI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
COMBIVENT RESPIMAT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
COMETRIQ ORAL CAPSULE 60 MG/DAY
(20 MG X 3/DAY). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
COMETRIQ ORAL CAPSULE 100 MG/DAY
(80 MG X1‑20 MG X1). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
COMETRIQ ORAL CAPSULE 140 MG/DAY
(80 MG X1‑20 MG X3). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
COMPLERA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
COMPLETE NATAL DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
compro . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
constulose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
COPIKTRA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
CORLANOR ORAL TABLET . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
CORTIFOAM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
cortisone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
CORTISPORIN-TC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
COSMEGEN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
COTELLIC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
CREON. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
CRESEMBA ORAL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
cromolyn inhalation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
cromolyn ophthalmic (eye) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
cromolyn oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
cryselle (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
CUVRIOR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
cyclobenzaprine oral tablet 10 mg, 5 mg . . . . . . . . . . . . . . . . . .  31
cyclophosphamide intravenous recon soln . . . . . . . . . . . . . . . .  20
CYCLOPHOSPHAMIDE INTRAVENOUS SOLUTION
200 MG/ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
cyclophosphamide intravenous solution 500 mg/ml . . . . . . . .  20
cyclophosphamide oral capsule . . . . . . . . . . . . . . . . . . . . . . . . . .  20
cyclophosphamide oral tablet 25 mg. . . . . . . . . . . . . . . . . . . . . .  20
CYCLOPHOSPHAMIDE ORAL TABLET 50 MG . . . . . . . . . . .  20
cycloserine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
CYCLOSET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
cyclosporine intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
72

Covered Drugs Index
DRUG

PAGE

DRUG

cyclosporine modified. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
cyclosporine ophthalmic (eye). . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
cyclosporine oral capsule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
CYLTEZO(CF) PEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
CYLTEZO(CF) PEN CROHN'S-UC-HS . . . . . . . . . . . . . . . . . . .  55
CYLTEZO(CF) PEN PSORIASIS-UV . . . . . . . . . . . . . . . . . . . . .  55
CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT
10 MG/0.2 ML, 20 MG/0.4 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT
40 MG/0.8 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
CYRAMZA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
cyred eq . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
CYSTAGON. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
CYSTARAN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
cytarabine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
cytarabine (pf). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20

daunorubicin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
DAURISMO ORAL TABLET 25 MG. . . . . . . . . . . . . . . . . . . . . . .  20
DAURISMO ORAL TABLET 100 MG. . . . . . . . . . . . . . . . . . . . . .  20
daysee. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
deblitane. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
decitabine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
deferasirox oral granules in packet. . . . . . . . . . . . . . . . . . . . . . . .  45
deferasirox oral tablet 90 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
deferasirox oral tablet 180 mg, 360 mg. . . . . . . . . . . . . . . . . . . .  45
deferiprone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
DELSTRIGO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
demeclocycline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
depo-estradiol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
DEPO-MEDROL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
DEPO-SUBQ PROVERA 104 . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
DESCOVY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
desipramine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
desloratadine oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
desmopressin injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
desmopressin nasal spray,non-aerosol
10 mcg/spray (0.1 ml). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
desmopressin nasal spray with pump. . . . . . . . . . . . . . . . . . . . .  50
desmopressin oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
desog-e.estradiol/e.estradiol . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
desogestrel-ethinyl estradiol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
desonide topical cream . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
desonide topical lotion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
desonide topical ointment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
desoximetasone topical cream . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
desoximetasone topical gel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
desoximetasone topical ointment. . . . . . . . . . . . . . . . . . . . . . . . .  44
desvenlafaxine succinate oral tablet extended
release 24 hr 25 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
desvenlafaxine succinate oral tablet extended
release 24 hr 50 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
desvenlafaxine succinate oral tablet extended
release 24 hr 100 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  33
dexamethasone intensol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
dexamethasone oral elixir. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
dexamethasone oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46

D
d2.5%-0.45% sodium chloride. . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
d5%-0.45% sodium chloride. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
d5% and 0.9% sodium chloride. . . . . . . . . . . . . . . . . . . . . . . . . . .  45
D10%-0.45% SODIUM CHLORIDE. . . . . . . . . . . . . . . . . . . . . . .  45
dabigatran etexilate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
dacarbazine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
dactinomycin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
dalfampridine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
danazol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
dantrolene oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
DANYELZA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
dapsone oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
DAPTACEL (DTAP PEDIATRIC) (PF). . . . . . . . . . . . . . . . . . . . .  53
daptomycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
DAPTOMYCIN IN 0.9% SOD CHLOR . . . . . . . . . . . . . . . . . . . .  17
darifenacin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
darunavir oral tablet 600 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
darunavir oral tablet 800 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
DARZALEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
DARZALEX FASPRO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
dasetta 1/35 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
dasetta 7/7/7 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
March 2024

PAGE

73

Covered Drugs Index
DRUG

PAGE

DRUG

dexamethasone oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
dexamethasone sodium phos (pf) injection solution
10 mg/ml. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
dexamethasone sodium phosphate injection solution . . . . . .  46
dexamethasone sodium phosphate ophthalmic (eye) . . . . . .  61
dexmethylphenidate oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
dextroamphetamine-amphetamine oral capsule,
extended release 24hr. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
dextroamphetamine-amphetamine oral tablet 5 mg . . . . . . . .  34
dextroamphetamine-amphetamine oral tablet 10 mg. . . . . . .  34
dextroamphetamine-amphetamine oral tablet
12.5 mg, 30 mg, 7.5 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
dextroamphetamine-amphetamine oral tablet 15 mg. . . . . . .  34
dextroamphetamine-amphetamine oral tablet 20 mg. . . . . . .  34
dextroamphetamine sulfate oral capsule,
extended release. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
dextroamphetamine sulfate oral solution . . . . . . . . . . . . . . . . . .  34
dextroamphetamine sulfate oral tablet
10 mg, 15 mg, 20 mg, 30 mg, 5 mg. . . . . . . . . . . . . . . . . . . . . . .  34
dextrose 5%-0.2% sod chloride. . . . . . . . . . . . . . . . . . . . . . . . . . .  45
dextrose 5%-0.3% sod.chloride. . . . . . . . . . . . . . . . . . . . . . . . . . .  45
dextrose 5% in water (d5w) intravenous
parenteral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
DEXTROSE 5% IN WATER (D5W) INTRAVENOUS
PIGGYBACK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
DEXTROSE 5%-LACTATED RINGERS. . . . . . . . . . . . . . . . . . .  45
DEXTROSE 10% AND 0.2% NACL. . . . . . . . . . . . . . . . . . . . . . .  45
dextrose 10% in water (d10w). . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
DEXTROSE 25% IN WATER (D25W). . . . . . . . . . . . . . . . . . . . .  45
DEXTROSE 50% IN WATER (D50W) INTRAVENOUS
PARENTERAL SOLUTION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
dextrose 50% in water (d50w) intravenous syringe. . . . . . . . .  45
DEXTROSE 70% IN WATER (D70W). . . . . . . . . . . . . . . . . . . . .  45
DHIVY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
DIACOMIT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
diazepam injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
diazepam intensol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
diazepam oral concentrate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
diazepam oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
diazepam oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
diazepam rectal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
March 2024

PAGE

diazoxide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
diclofenac potassium oral tablet 50 mg. . . . . . . . . . . . . . . . . . . .  32
diclofenac sodium ophthalmic (eye). . . . . . . . . . . . . . . . . . . . . . .  60
diclofenac sodium oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
diclofenac sodium topical drops . . . . . . . . . . . . . . . . . . . . . . . . . .  32
diclofenac sodium topical gel 1% . . . . . . . . . . . . . . . . . . . . . . . . .  32
diclofenac sodium topical solution in metered-dose pump . .  32
dicloxacillin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
dicyclomine oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
dicyclomine oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
dicyclomine oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
DIFICID ORAL SUSPENSION FOR
RECONSTITUTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
DIFICID ORAL TABLET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
diflunisal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
difluprednate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
digoxin injection solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
digoxin oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
digoxin oral tablet 62.5 mcg (0.0625 mg). . . . . . . . . . . . . . . . . .  41
digoxin oral tablet 125 mcg (0.125 mg),
250 mcg (0.25 mg) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
dihydroergotamine nasal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
dilantin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
diltiazem hcl intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
diltiazem hcl oral capsule,extended release 12 hr. . . . . . . . . .  38
diltiazem hcl oral capsule,extended release 24 hr. . . . . . . . . .  38
diltiazem hcl oral capsule,extended release
24hr 120 mg, 180 mg, 240 mg, 300 mg . . . . . . . . . . . . . . . . . . .  38
diltiazem hcl oral capsule,ext.rel 24h degradable . . . . . . . . . .  38
diltiazem hcl oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
diltiazem hcl oral tablet extended release 24 hr. . . . . . . . . . . .  38
dilt-xr . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
dimethyl fumarate oral capsule,delayed
release(dr/ec) 120 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
dimethyl fumarate oral capsule,delayed
release(dr/ec) 120 mg (14)- 240 mg (46). . . . . . . . . . . . . . . . . .  30
dimethyl fumarate oral capsule,delayed
release(dr/ec) 240 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
diphenhydramine hcl injection solution 50 mg/ml. . . . . . . . . . .  61
diphenoxylate-atropine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
dipyridamole oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
74

Covered Drugs Index
DRUG

PAGE

DRUG

disulfiram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
divalproex oral capsule, delayed rel sprinkle. . . . . . . . . . . . . . .  27
divalproex oral tablet,delayed release (dr/ec). . . . . . . . . . . . . .  27
divalproex oral tablet extended release 24 hr. . . . . . . . . . . . . .  27
docetaxel intravenous solution 20 mg/2 ml
(10 mg/ml), 20 mg/ml (1 ml), 80 mg/4 ml (20 mg/ml) . . . . . . .  21
docetaxel intravenous solution
160 mg/16 ml (10 mg/ml), 160 mg/8 ml (20 mg/ml),
80 mg/8 ml (10 mg/ml). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  20
dofetilide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
dolishale. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
donepezil oral tablet 5 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
donepezil oral tablet 10 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
donepezil oral tablet,disintegrating 5 mg . . . . . . . . . . . . . . . . . .  30
donepezil oral tablet,disintegrating 10 mg . . . . . . . . . . . . . . . . .  30
DOPTELET (10 TAB PACK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
DOPTELET (15 TAB PACK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
DOPTELET (30 TAB PACK). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
dorzolamide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
dorzolamide-timolol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
dotti . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
DOVATO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
doxazosin oral tablet 1 mg, 2 mg, 4 mg . . . . . . . . . . . . . . . . . . .  38
doxazosin oral tablet 8 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
doxepin oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
doxepin oral concentrate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
doxepin oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
doxercalciferol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
doxorubicin intravenous recon soln 50 mg. . . . . . . . . . . . . . . . .  21
doxorubicin intravenous solution. . . . . . . . . . . . . . . . . . . . . . . . . .  21
doxorubicin, peg-liposomal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
doxy-100. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
doxycycline hyclate intravenous . . . . . . . . . . . . . . . . . . . . . . . . . .  18
doxycycline hyclate oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . .  19
doxycycline hyclate oral tablet 100 mg, 20 mg. . . . . . . . . . . . .  19
doxycycline monohydrate oral capsule 100 mg, 50 mg. . . . .  19
doxycycline monohydrate oral capsule,ir delay rel,biphase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
doxycycline monohydrate oral suspension for
reconstitution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
doxycycline monohydrate oral tablet . . . . . . . . . . . . . . . . . . . . . .  19
March 2024

PAGE

dronabinol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
DROPLET MICRON PEN NEEDLE. . . . . . . . . . . . . . . . . . . . . . .  47
DROPLET PEN NEEDLE NEEDLE 30 GAUGE X 5/16". . . .  47
DROPSAFE ALCOHOL PREP PADS . . . . . . . . . . . . . . . . . . . . .  47
DROPSAFE PEN NEEDLE NEEDLE 31 GAUGE X 3/16" . .  47
DROSPIRENONE-E.ESTRADIOL-LM.FA. . . . . . . . . . . . . . . . .  58
drospirenone-ethinyl estradiol . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
DROXIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
droxidopa oral capsule 100 mg. . . . . . . . . . . . . . . . . . . . . . . . . . .  45
droxidopa oral capsule 200 mg, 300 mg. . . . . . . . . . . . . . . . . . .  45
DUAVEE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
duloxetine oral capsule,delayed release(dr/ec)
20 mg, 60 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
duloxetine oral capsule,delayed release(dr/ec) 30 mg. . . . . .  34
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR
200 MG/1.14 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR
300 MG/2 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE
100 MG/0.67 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE
200 MG/1.14 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE
300 MG/2 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
dutasteride. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
dutasteride-tamsulosin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63

E
EC-NAPROXEN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
econazole. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
EDARBI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
EDARBYCLOR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
EDURANT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
efavirenz-emtricitabin-tenofov . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
efavirenz-lamivu-tenofov disop oral tablet
400‑300‑300 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
efavirenz-lamivu-tenofov disop oral tablet
600‑300‑300 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
efavirenz oral capsule 50 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
efavirenz oral capsule 200 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
efavirenz oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
75

Covered Drugs Index
DRUG

PAGE

DRUG

ELAPRASE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
ELECTROLYTE-48 IN D5W. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
ELIGARD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
ELIGARD (3 MONTH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
ELIGARD (4 MONTH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
ELIGARD (6 MONTH) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
elinest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
ELIQUIS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
ELIQUIS DVT-PE TREAT 30D START . . . . . . . . . . . . . . . . . . . .  40
ELITE-OB. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
ELMIRON. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
ELREXFIO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
ELZONRIS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
EMCYT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
EMPLICITI INTRAVENOUS RECON SOLN 300 MG. . . . . . .  21
EMPLICITI INTRAVENOUS RECON SOLN 400 MG. . . . . . .  21
EMSAM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
emtricitabine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
emtricitabine-tenofovir (tdf) oral tablet 100‑150 mg,
167‑250 mg, 200‑300 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
emtricitabine-tenofovir (tdf) oral tablet 133‑200 mg. . . . . . . . .  13
EMTRIVA ORAL SOLUTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
emverm. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
enalapril-hydrochlorothiazide. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
enalapril maleate oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
ENBREL MINI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
ENBREL SUBCUTANEOUS SOLUTION. . . . . . . . . . . . . . . . . .  55
ENBREL SUBCUTANEOUS SYRINGE . . . . . . . . . . . . . . . . . . .  55
ENBREL SURECLICK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
ENDARI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
endocet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
ENGERIX-B PEDIATRIC (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
ENGERIX-B (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
ENHERTU . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
enoxaparin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
enpresse. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
enskyce. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
entacapone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
entecavir. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
ENTRESTO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
March 2024

PAGE

enulose. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
ENVARSUS XR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
EPCLUSA ORAL PELLETS IN PACKET 150‑37.5 MG . . . . .  14
EPCLUSA ORAL PELLETS IN PACKET 200‑50 MG. . . . . . .  14
EPCLUSA ORAL TABLET 200‑50 MG . . . . . . . . . . . . . . . . . . . .  14
EPCLUSA ORAL TABLET 400‑100 MG. . . . . . . . . . . . . . . . . . .  14
EPIDIOLEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
epinastine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
epinephrine injection auto-injector 0.15 mg/0.3 ml,
0.3 mg/0.3 ml . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
EPINEPHRINE INJECTION AUTO-INJECTOR
0.15 MG/0.15 ML, 0.3 MG/0.3 ML . . . . . . . . . . . . . . . . . . . . . . . .  61
epinephrine injection solution 1 mg/ml . . . . . . . . . . . . . . . . . . . .  61
epirubicin intravenous solution . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
epitol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
EPKINLY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
eplerenone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
EPRONTIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ERBITUX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
ergotamine-caffeine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
ERIVEDGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
ERLEADA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
erlotinib oral tablet 25 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
erlotinib oral tablet 100 mg, 150 mg. . . . . . . . . . . . . . . . . . . . . . .  21
errin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
ertapenem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
ery pads . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
ery-tab oral tablet,delayed release (dr/ec) 250 mg,
333 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
erythrocin (as stearate) oral tablet 250 mg . . . . . . . . . . . . . . . .  16
erythrocin intravenous recon soln 500 mg. . . . . . . . . . . . . . . . .  16
erythromycin-benzoyl peroxide . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
erythromycin ethylsuccinate oral suspension for
reconstitution 200 mg/5 ml . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
erythromycin ethylsuccinate oral tablet. . . . . . . . . . . . . . . . . . . .  16
erythromycin ophthalmic (eye). . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
erythromycin oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
erythromycin oral tablet,delayed release (dr/ec) . . . . . . . . . . .  16
erythromycin with ethanol topical gel. . . . . . . . . . . . . . . . . . . . . .  43
erythromycin with ethanol topical solution . . . . . . . . . . . . . . . . .  43
76

Covered Drugs Index
DRUG

PAGE

DRUG

F

escitalopram oxalate oral solution . . . . . . . . . . . . . . . . . . . . . . . .  34
escitalopram oxalate oral tablet 10 mg, 5 mg. . . . . . . . . . . . . .  34
escitalopram oxalate oral tablet 20 mg. . . . . . . . . . . . . . . . . . . .  34
esomeprazole magnesium oral capsule,delayed
release(dr/ec) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
estarylla . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
estradiol oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
estradiol transdermal patch semiweekly. . . . . . . . . . . . . . . . . . .  57
estradiol transdermal patch weekly . . . . . . . . . . . . . . . . . . . . . . .  57
estradiol vaginal cream . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
estradiol vaginal tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
estradiol valerate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
ESTRING. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
ethacrynate sodium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
ethambutol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
ethosuximide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ethynodiol diac-eth estradiol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
etodolac . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
etonogestrel-ethinyl estradiol. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
ETOPOPHOS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
etoposide intravenous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
etravirine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
EUTHYROX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
everolimus (antineoplastic) oral tablet. . . . . . . . . . . . . . . . . . . . .  21
everolimus (antineoplastic) oral tablet for
suspension 2 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
everolimus (antineoplastic) oral tablet for
suspension 3 mg, 5 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
everolimus (immunosuppressive) oral tablet
0.5 mg, 0.75 mg, 1 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
everolimus (immunosuppressive) oral tablet 0.25 mg . . . . . .  21
EVOMELA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
EVOTAZ. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
exemestane. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
EXKIVITY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
EYLEA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
EYSUVIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
ezetimibe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
ezetimibe-simvastatin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41

March 2024

PAGE

FABRAZYME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
falmina (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
famciclovir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
famotidine oral suspension for reconstitution . . . . . . . . . . . . . .  52
famotidine oral tablet 20 mg, 40 mg. . . . . . . . . . . . . . . . . . . . . . .  52
FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG,
2 MG, 4 MG, 6 MG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
FANAPT ORAL TABLET 8 MG . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
FANAPT ORAL TABLETS, DOSE PACK . . . . . . . . . . . . . . . . . .  34
FARXIGA ORAL TABLET 5 MG . . . . . . . . . . . . . . . . . . . . . . . . . .  47
FARXIGA ORAL TABLET 10 MG . . . . . . . . . . . . . . . . . . . . . . . . .  47
FARYDAK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
FASENRA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
FASENRA PEN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
febuxostat. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
felbamate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
felodipine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
fenofibrate micronized oral capsule 134 mg,
200 mg, 67 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
fenofibrate nanocrystallized . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
fenofibrate oral tablet 160 mg, 54 mg . . . . . . . . . . . . . . . . . . . . .  41
fenofibric acid (choline) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
fentanyl. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
fentanyl citrate buccal lozenge on a handle
1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg. . . . . . .  31
fentanyl citrate buccal lozenge on a handle 200 mcg. . . . . . .  31
fentanyl citrate (pf) injection solution . . . . . . . . . . . . . . . . . . . . . .  31
FENTANYL CITRATE (PF) INJECTION SYRINGE
50 MCG/ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
FERRIPROX (2 TIMES A DAY). . . . . . . . . . . . . . . . . . . . . . . . . . .  45
FERRIPROX ORAL SOLUTION. . . . . . . . . . . . . . . . . . . . . . . . . .  45
fesoterodine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
FETZIMA ORAL CAPSULE, EXTENDED RELEASE
24 HR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
FETZIMA ORAL CAPSULE, EXT REL 24HR DOSE
PACK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
finasteride oral tablet 5 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
fingolimod. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
FINTEPLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
77

Covered Drugs Index
DRUG

PAGE

DRUG

finzala . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
FIRDAPSE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
FIRMAGON KIT W DILUENT SYRINGE
SUBCUTANEOUS RECON SOLN 80 MG. . . . . . . . . . . . . . . . .  21
FIRMAGON KIT W DILUENT SYRINGE
SUBCUTANEOUS RECON SOLN 120 MG. . . . . . . . . . . . . . . .  21
FIRVANQ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
flac otic oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
flecainide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
floxuridine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
fluconazole. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
fluconazole in nacl (iso-osm) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
flucytosine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
fludarabine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
fludrocortisone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
flunisolide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
fluocinolone acetonide oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
fluocinolone and shower cap . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
fluocinolone topical cream. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
fluocinolone topical oil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
fluocinolone topical ointment . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
fluocinolone topical solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
fluocinonide topical cream 0.1%. . . . . . . . . . . . . . . . . . . . . . . . . .  44
fluocinonide topical cream 0.05%. . . . . . . . . . . . . . . . . . . . . . . . .  44
fluocinonide topical gel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
fluocinonide topical ointment . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
fluocinonide topical solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
fluoride (sodium) dental. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
fluoride (sodium) oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
fluoride (sodium) oral tablet,chewable 1 mg
(2.2 mg sod. fluoride) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
FLUOROMETHOLONE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
fluorouracil intravenous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
fluorouracil topical cream 0.5%. . . . . . . . . . . . . . . . . . . . . . . . . . .  42
fluorouracil topical cream 5%. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
fluorouracil topical solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
fluoxetine oral capsule 10 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
fluoxetine oral capsule 20 mg, 40 mg . . . . . . . . . . . . . . . . . . . . .  34
fluoxetine oral capsule,delayed release(dr/ec). . . . . . . . . . . . .  34
fluoxetine oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
March 2024

PAGE

fluoxetine oral tablet 10 mg, 20 mg . . . . . . . . . . . . . . . . . . . . . . .  34
fluoxetine (pmdd). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
fluphenazine decanoate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
fluphenazine hcl injection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
fluphenazine hcl oral concentrate. . . . . . . . . . . . . . . . . . . . . . . . .  34
fluphenazine hcl oral elixir. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
fluphenazine hcl oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
flurbiprofen oral tablet 100 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
flurbiprofen sodium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
fluticasone propionate nasal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
fluticasone propionate topical cream. . . . . . . . . . . . . . . . . . . . . .  44
fluticasone propionate topical ointment. . . . . . . . . . . . . . . . . . . .  44
fluticasone propion-salmeterol inhalation
blister with device . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
fluvastatin oral capsule 20 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
fluvastatin oral capsule 40 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
fluvastatin oral tablet extended release 24 hr. . . . . . . . . . . . . .  41
fluvoxamine oral tablet 50 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
fluvoxamine oral tablet 100 mg, 25 mg. . . . . . . . . . . . . . . . . . . .  34
FOLIVANE-OB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
FOLOTYN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
fomepizole. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
fondaparinux subcutaneous syringe 2.5 mg/0.5 ml. . . . . . . . .  40
fondaparinux subcutaneous syringe
10 mg/0.8 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml . . . . . . . . . . . . . . . . .  40
formoterol fumarate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
FORTEO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
fosamprenavir. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
fosfomycin tromethamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
fosinopril. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
fosinopril-hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
fosphenytoin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
FOTIVDA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
FRUZAQLA ORAL CAPSULE 1 MG . . . . . . . . . . . . . . . . . . . . . .  21
FRUZAQLA ORAL CAPSULE 5 MG . . . . . . . . . . . . . . . . . . . . . .  21
fulvestrant. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
furosemide injection solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml). . .  39
FUROSEMIDE ORAL SOLUTION 40 MG/4 ML. . . . . . . . . . . .  39
furosemide oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
78

Covered Drugs Index
DRUG

PAGE

DRUG

FUZEON SUBCUTANEOUS RECON SOLN . . . . . . . . . . . . . .  14
FYARRO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
fyavolv. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
FYCOMPA ORAL SUSPENSION. . . . . . . . . . . . . . . . . . . . . . . . .  27
FYCOMPA ORAL TABLET 2 MG . . . . . . . . . . . . . . . . . . . . . . . . .  28
FYCOMPA ORAL TABLET 4 MG, 6 MG. . . . . . . . . . . . . . . . . . .  28
FYCOMPA ORAL TABLET 10 MG, 12 MG, 8 MG. . . . . . . . . .  27

GENOTROPIN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
GENOTROPIN MINIQUICK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
gentamicin injection solution 40 mg/ml. . . . . . . . . . . . . . . . . . . .  17
gentamicin in nacl (iso-osm) intravenous piggyback
100 mg/100 ml, 100 mg/50 ml, 120 mg/100 ml,
60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml . . . . . . . . . . . . . . . . .  17
gentamicin ophthalmic (eye) drops. . . . . . . . . . . . . . . . . . . . . . . .  59
gentamicin sulfate (ped) (pf). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
gentamicin topical cream. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
gentamicin topical ointment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
GENVOYA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
GILOTRIF. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
GLASSIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
glatiramer subcutaneous syringe 20 mg/ml. . . . . . . . . . . . . . . .  30
glatiramer subcutaneous syringe 40 mg/ml. . . . . . . . . . . . . . . .  30
glatopa subcutaneous syringe 20 mg/ml . . . . . . . . . . . . . . . . . .  30
glatopa subcutaneous syringe 40 mg/ml . . . . . . . . . . . . . . . . . .  30
GLEOSTINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
glimepiride oral tablet 1 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
glimepiride oral tablet 2 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
glimepiride oral tablet 4 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
glipizide-metformin oral tablet 2.5‑250 mg. . . . . . . . . . . . . . . . .  47
glipizide-metformin oral tablet 2.5‑500 mg, 5‑500 mg. . . . . . . 47
GLIPIZIDE ORAL TABLET 2.5 MG . . . . . . . . . . . . . . . . . . . . . . .  47
glipizide oral tablet 5 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
glipizide oral tablet 10 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
glipizide oral tablet extended release 24hr 2.5 mg . . . . . . . . .  47
glipizide oral tablet extended release 24hr 5 mg . . . . . . . . . . .  47
glipizide oral tablet extended release 24hr 10 mg. . . . . . . . . .  47
GLUCAGEN HYPOKIT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
glucagon emergency kit (human) . . . . . . . . . . . . . . . . . . . . . . . . .  47
GLUCAGON (HCL) EMERGENCY KIT . . . . . . . . . . . . . . . . . . .  47
glycopyrrolate injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
glycopyrrolate oral tablet 1 mg, 2 mg. . . . . . . . . . . . . . . . . . . . . .  51
glycopyrrolate (pf) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
glycopyrrolate (pf) in water injection. . . . . . . . . . . . . . . . . . . . . . .  51
glycopyrrolate (pf) in water intravenous syringe
0.4 mg/2 ml (0.2 mg/ml). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
glydo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
GLYXAMBI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47

G
gabapentin oral capsule 100 mg, 300 mg . . . . . . . . . . . . . . . . .  28
gabapentin oral capsule 400 mg. . . . . . . . . . . . . . . . . . . . . . . . . .  28
gabapentin oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
gabapentin oral tablet 600 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
gabapentin oral tablet 800 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
galantamine oral capsule,ext rel. pellets 24 hr . . . . . . . . . . . . .  30
galantamine oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
galantamine oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
GAMMAGARD LIQUID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
GAMMAKED. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
GAMMAPLEX INTRAVENOUS SOLUTION 10% . . . . . . . . . .  53
GAMMAPLEX (WITH SORBITOL). . . . . . . . . . . . . . . . . . . . . . . .  53
GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML
(10%), 10 GRAM/100 ML (10%), 20 GRAM/200 ML
(10%), 40 GRAM/400 ML (10%), 5 GRAM/50 ML (10%). . . .  53
GAMUNEX-C INJECTION SOLUTION
2.5 GRAM/25 ML (10%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
GARDASIL 9 (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
GATTEX 30-VIAL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
GATTEX ONE-VIAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
GAUZE PAD TOPICAL BANDAGE 2 X 2 " . . . . . . . . . . . . . . . .  54
gavilyte-c . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
GAVRETO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
GAZYVA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
gefitinib. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
gemcitabine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  21
gemfibrozil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
gemmily . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
GEMTESA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
generlac . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
gengraf . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
March 2024

PAGE

79

Covered Drugs Index
DRUG

PAGE

DRUG

granisetron hcl oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
griseofulvin microsize. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
griseofulvin ultramicrosize. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
guanfacine oral tablet extended release 24 hr . . . . . . . . . . . . .  34
GVOKE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
GVOKE HYPOPEN 1-PACK . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
GVOKE HYPOPEN 2-PACK . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
GVOKE PFS 1-PACK SYRINGE. . . . . . . . . . . . . . . . . . . . . . . . . . 47
GVOKE PFS 2-PACK SYRINGE. . . . . . . . . . . . . . . . . . . . . . . . . . 47

heparin (porcine) in nacl (pf). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
heparin, porcine (pf) injection syringe 5,000 unit/0.5 ml. . . . .  40
HEPARIN, PORCINE (PF) INJECTION SYRINGE
5,000 UNIT/ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
HEPLISAV-B (PF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
HIBERIX (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
HIZENTRA SUBCUTANEOUS SOLUTION
1 GRAM/5 ML (20%). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
HIZENTRA SUBCUTANEOUS SOLUTION
10 GRAM/50 ML (20%), 2 GRAM/10 ML (20%),
4 GRAM/20 ML (20%) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
HUMALOG JUNIOR KWIKPEN U-100. . . . . . . . . . . . . . . . . . . .  47
HUMALOG KWIKPEN INSULIN. . . . . . . . . . . . . . . . . . . . . . . . . .  47
HUMALOG MIX 50‑50 INSULN U-100. . . . . . . . . . . . . . . . . . . .  48
HUMALOG MIX 50‑50 KWIKPEN. . . . . . . . . . . . . . . . . . . . . . . . . 48
HUMALOG MIX 75‑25 KWIKPEN. . . . . . . . . . . . . . . . . . . . . . . . . 48
HUMALOG MIX 75‑25(U-100)INSULN. . . . . . . . . . . . . . . . . . . .  48
HUMALOG U-100 INSULIN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
HUMIRA(CF) PEDI CROHNS STARTER
SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML . . . . . . . . . .  55
HUMIRA(CF) PEDI CROHNS STARTER
SUBCUTANEOUS SYRINGE KIT
80 MG/0.8 ML-40 MG/0.4 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
HUMIRA(CF) PEN CROHNS-UC-HS . . . . . . . . . . . . . . . . . . . . .  56
HUMIRA(CF) PEN PEDIATRIC UC. . . . . . . . . . . . . . . . . . . . . . .  56
HUMIRA(CF) PEN PSOR-UV-ADOL HS . . . . . . . . . . . . . . . . . .  56
HUMIRA(CF) PEN SUBCUTANEOUS PEN
INJECTOR KIT 40 MG/0.4 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
HUMIRA(CF) PEN SUBCUTANEOUS PEN
INJECTOR KIT 80 MG/0.8 ML. . . . . . . . . . . . . . . . . . . . . . . . . . .  56
HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT
10 MG/0.1 ML, 20 MG/0.2 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT
40 MG/0.4 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
HUMIRA PEN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
HUMIRA PEN CROHNS-UC-HS START . . . . . . . . . . . . . . . . . .  55
HUMIRA PEN PSOR-UVEITS-ADOL HS. . . . . . . . . . . . . . . . . .  55
HUMIRA SUBCUTANEOUS SYRINGE KIT
40 MG/0.8 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
HUMULIN 70/30 U-100 INSULIN . . . . . . . . . . . . . . . . . . . . . . . . .  48
HUMULIN 70/30 U-100 KWIKPEN. . . . . . . . . . . . . . . . . . . . . . . .  48
HUMULIN N NPH INSULIN KWIKPEN. . . . . . . . . . . . . . . . . . . .  48

H
HAEGARDA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
hailey. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
hailey 24 fe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
hailey fe 1.5/30 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
hailey fe 1/20 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
HALAVEN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
halobetasol propionate topical cream . . . . . . . . . . . . . . . . . . . . .  44
halobetasol propionate topical ointment. . . . . . . . . . . . . . . . . . .  44
haloperidol decanoate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
haloperidol lactate injection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
haloperidol lactate oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  34
haloperidol oral tablet 0.5 mg, 1 mg, 2 mg, 5 mg. . . . . . . . . . .  35
haloperidol oral tablet 10 mg, 20 mg. . . . . . . . . . . . . . . . . . . . . .  35
HARVONI ORAL PELLETS IN PACKET 33.75‑150 MG. . . .  14
HARVONI ORAL PELLETS IN PACKET 45‑200 MG. . . . . . .  14
HARVONI ORAL TABLET 45‑200 MG . . . . . . . . . . . . . . . . . . . .  14
HARVONI ORAL TABLET 90‑400 MG . . . . . . . . . . . . . . . . . . . .  14
HAVRIX (PF) INTRAMUSCULAR SYRINGE
1,440 ELISA UNIT/ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
HAVRIX (PF) INTRAMUSCULAR SYRINGE
720 ELISA UNIT/0.5 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
heather . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
HEPARIN(PORCINE) IN 0.45% NACL INTRAVENOUS
PARENTERAL SOLUTION 25,000 UNIT/250 ML,
25,000 UNIT/500 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
HEPARIN (PORCINE) IN 5% DEX. . . . . . . . . . . . . . . . . . . . . . . .  40
heparin (porcine) injection solution. . . . . . . . . . . . . . . . . . . . . . . .  40
HEPARIN (PORCINE) INJECTION SYRINGE
5,000 UNIT/ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
March 2024

PAGE

80

Covered Drugs Index
DRUG

PAGE

DRUG

HUMULIN N NPH U-100 INSULIN. . . . . . . . . . . . . . . . . . . . . . . .  48
HUMULIN R REGULAR U-100 INSULN. . . . . . . . . . . . . . . . . . .  48
HUMULIN R U-500 (CONC) INSULIN. . . . . . . . . . . . . . . . . . . . .  48
HUMULIN R U-500 (CONC) KWIKPEN . . . . . . . . . . . . . . . . . . .  48
hydralazine injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
hydralazine oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
hydrochlorothiazide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
hydrocodone-acetaminophen oral solution
7.5‑325 mg/15 ml. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
hydrocodone-acetaminophen oral tablet
10‑300 mg, 7.5‑300 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
hydrocodone-acetaminophen oral tablet
10‑325 mg, 5‑325 mg, 7.5‑325 mg. . . . . . . . . . . . . . . . . . . . . . . .  31
hydrocodone-ibuprofen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
hydrocortisone-acetic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
hydrocortisone butyrate topical cream. . . . . . . . . . . . . . . . . . . . .  44
hydrocortisone butyrate topical ointment . . . . . . . . . . . . . . . . . .  44
hydrocortisone butyrate topical solution . . . . . . . . . . . . . . . . . . .  44
hydrocortisone butyr-emollient. . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
hydrocortisone oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
hydrocortisone rectal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
hydrocortisone topical cream 1%, 2.5% . . . . . . . . . . . . . . . . . . .  44
hydrocortisone topical cream with perineal applicator . . . . . .  51
hydrocortisone topical lotion 2.5% . . . . . . . . . . . . . . . . . . . . . . . .  44
hydrocortisone topical ointment 1%, 2.5%. . . . . . . . . . . . . . . . .  44
hydrocortisone valerate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
hydromorphone oral liquid. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
hydromorphone oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
hydroxychloroquine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
hydroxyprogesterone caproate . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
hydroxyurea. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
hydroxyzine hcl oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
HYRIMOZ(CF) PEDI CROHN STARTER
SUBCUTANEOUS SYRINGE 80 MG/0.8 ML . . . . . . . . . . . . . .  56
HYRIMOZ(CF) PEDI CROHN STARTER
SUBCUTANEOUS SYRINGE 80 MG/0.8 ML40 MG/0.4 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
HYRIMOZ(CF) PEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE
10 MG/0.1 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56

March 2024

PAGE

HYRIMOZ(CF) SUBCUTANEOUS SYRINGE
20 MG/0.2 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
HYRIMOZ(CF) SUBCUTANEOUS SYRINGE
40 MG/0.4 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
HYRIMOZ PEN CROHN'S-UC STARTER. . . . . . . . . . . . . . . . .  56
HYRIMOZ PEN PSORIASIS STARTER. . . . . . . . . . . . . . . . . . .  56

I
ibandronate oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
IBRANCE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
ibu. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
ibuprofen oral suspension. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
ibuprofen oral tablet 400 mg, 600 mg, 800 mg. . . . . . . . . . . . .  32
icatibant . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
iclevia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
ICLUSIG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
icosapent ethyl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
idarubicin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
IDHIFA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
ifosfamide intravenous recon soln 1 gram. . . . . . . . . . . . . . . . .  22
IFOSFAMIDE INTRAVENOUS RECON SOLN 3 GRAM. . . .  22
ifosfamide intravenous solution. . . . . . . . . . . . . . . . . . . . . . . . . . .  22
ILEVRO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
imatinib oral tablet 100 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
imatinib oral tablet 400 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
IMBRUVICA ORAL CAPSULE 70 MG. . . . . . . . . . . . . . . . . . . . . 22
IMBRUVICA ORAL CAPSULE 140 MG . . . . . . . . . . . . . . . . . . .  22
IMBRUVICA ORAL SUSPENSION. . . . . . . . . . . . . . . . . . . . . . . . 22
IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG. . . .  22
IMFINZI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
imipenem-cilastatin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
imipramine hcl. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
imiquimod topical cream in metered-dose pump. . . . . . . . . . .  42
imiquimod topical cream in packet 3.75% . . . . . . . . . . . . . . . . .  42
imiquimod topical cream in packet 5% . . . . . . . . . . . . . . . . . . . .  42
IMJUDO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
IMOVAX RABIES VACCINE (PF). . . . . . . . . . . . . . . . . . . . . . . . .  53
incassia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
INCRELEX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
INCRUSE ELLIPTA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
81

Covered Drugs Index
DRUG

PAGE

DRUG

indapamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE. . . . .  53
INFLECTRA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
INFUGEM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
INFUMORPH P/F. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
INGREZZA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
INGREZZA INITIATION PACK. . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
INLYTA ORAL TABLET 1 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
INLYTA ORAL TABLET 5 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
INQOVI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
INREBIC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
INSULIN LISPRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
INSULIN LISPRO PROTAMIN-LISPRO. . . . . . . . . . . . . . . . . . .  48
INSULIN SYRINGE-NEEDLE U-100 SYRINGE
0.3 ML 29 GAUGE, 1 ML 29 GAUGE X 1/2",
1/2 ML 28 GAUGE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
INTELENCE ORAL TABLET 25 MG . . . . . . . . . . . . . . . . . . . . . .  14
INTRALIPID INTRAVENOUS EMULSION 20%, 30% . . . . . .  64
INVEGA HAFYERA INTRAMUSCULAR SYRINGE
1,092 MG/3.5 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA HAFYERA INTRAMUSCULAR SYRINGE
1,560 MG/5 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE
39 MG/0.25 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE
78 MG/0.5 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE
117 MG/0.75 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE
156 MG/ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA SUSTENNA INTRAMUSCULAR SYRINGE
234 MG/1.5 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA TRINZA INTRAMUSCULAR SYRINGE
273 MG/0.88 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA TRINZA INTRAMUSCULAR SYRINGE
410 MG/1.32 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA TRINZA INTRAMUSCULAR SYRINGE
546 MG/1.75 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVEGA TRINZA INTRAMUSCULAR SYRINGE
819 MG/2.63 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
INVELTYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
IPOL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
March 2024

PAGE

ipratropium-albuterol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
ipratropium bromide inhalation . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
ipratropium bromide nasal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
irbesartan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
irbesartan-hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
irinotecan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
ISENTRESS HD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
ISENTRESS ORAL POWDER IN PACKET. . . . . . . . . . . . . . . .  14
ISENTRESS ORAL TABLET . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
ISENTRESS ORAL TABLET, CHEWABLE 25 MG . . . . . . . . .  14
ISENTRESS ORAL TABLET, CHEWABLE 100 MG. . . . . . . .  14
isibloom. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
isoniazid oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
isoniazid oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
isosorbide dinitrate oral tablet
10 mg, 20 mg, 30 mg, 5 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
isosorbide-hydralazine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
isosorbide mononitrate oral tablet. . . . . . . . . . . . . . . . . . . . . . . . .  41
isosorbide mononitrate oral tablet extended
release 24 hr. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
isotretinoin oral capsule 10 mg, 20 mg, 30 mg, 40 mg. . . . . .  43
isradipine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
itraconazole oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
itraconazole oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
ivermectin oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
IXEMPRA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
IXIARO (PF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53

J
jaimiess. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
JAKAFI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
jantoven . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
JANUMET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
JANUMET XR ORAL TABLET, ER MULTIPHASE
24 HR 50‑1,000 MG, 50‑500 MG . . . . . . . . . . . . . . . . . . . . . . . . .  48
JANUMET XR ORAL TABLET, ER MULTIPHASE
24 HR 100‑1,000 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
JANUVIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
JARDIANCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
jasmiel (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
82

Covered Drugs Index
DRUG

PAGE

DRUG

JAYPIRCA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
JEMPERLI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
JENCYCLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
JENTADUETO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC
24HR 2.5‑1,000 MG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC
24HR 5‑1,000 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
JEVTANA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
JOLESSA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
joyeaux. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
juleber. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
JULUCA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
junel 1.5/30 (21). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
junel 1/20 (21). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
junel fe 1.5/30 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
junel fe 1/20 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
junel fe 24. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
JYNNEOS (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53

KISQALI FEMARA CO-PACK ORAL TABLET
200 MG/DAY(200 MG X 1)-2.5 MG . . . . . . . . . . . . . . . . . . . . . . .  22
KISQALI FEMARA CO-PACK ORAL TABLET
400 MG/DAY(200 MG X 2)-2.5 MG . . . . . . . . . . . . . . . . . . . . . . .  22
KISQALI FEMARA CO-PACK ORAL TABLET
600 MG/DAY(200 MG X 3)-2.5 MG . . . . . . . . . . . . . . . . . . . . . . .  22
KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1). . . . . . .  22
KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2). . . . . . .  22
KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3). . . . . . .  22
KLISYRI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
klor-con. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
KLOR-CON 8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
KLOR-CON 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
klor-con m10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
klor-con m15. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
klor-con m20. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
KLOXXADO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
KORLYM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
KOSELUGO ORAL CAPSULE 10 MG . . . . . . . . . . . . . . . . . . . .  22
KOSELUGO ORAL CAPSULE 25 MG . . . . . . . . . . . . . . . . . . . .  22
kourzeq. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
K-PHOS ORIGINAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
KRAZATI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
kurvelo (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
KYPROLIS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22

K
KABIVEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
KADCYLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
kaitlib fe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
kalliga . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
KALYDECO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
kariva (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
kelnor 1/35 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
kelnor 1‑50 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
kemoplat. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
KERENDIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
KESIMPTA PEN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
ketoconazole oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
ketoconazole topical cream . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
ketoconazole topical shampoo . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
KETOROLAC OPHTHALMIC (EYE) DROPS 0.4% . . . . . . . .  60
ketorolac ophthalmic (eye) drops 0.5%. . . . . . . . . . . . . . . . . . . .  60
KEYTRUDA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
KIMMTRAK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
KINRIX (PF) INTRAMUSCULAR SYRINGE. . . . . . . . . . . . . . .  53
March 2024

PAGE

L
labetalol oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
lacosamide intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
lacosamide oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
lacosamide oral tablet 50 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
lacosamide oral tablet 100 mg, 150 mg, 200 mg. . . . . . . . . . .  28
LACRISERT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
lactated ringers intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
LACTATED RINGERS IRRIGATION . . . . . . . . . . . . . . . . . . . . . .  44
lactulose oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
LAGEVRIO (EUA). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
lamivudine oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
lamivudine oral tablet 100 mg, 300 mg. . . . . . . . . . . . . . . . . . . .  14
lamivudine oral tablet 150 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
83

Covered Drugs Index
DRUG

PAGE

DRUG

lamivudine-zidovudine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
lamotrigine oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
lamotrigine oral tablet, chewable dispersible. . . . . . . . . . . . . . .  28
lamotrigine oral tablet,disintegrating . . . . . . . . . . . . . . . . . . . . . .  28
lamotrigine oral tablet extended release 24hr. . . . . . . . . . . . . .  28
lamotrigine oral tablets,dose pack . . . . . . . . . . . . . . . . . . . . . . . .  28
LANOXIN PEDIATRIC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
lansoprazole oral capsule,delayed release(dr/ec). . . . . . . . . .  52
LANTUS SOLOSTAR U-100 INSULIN . . . . . . . . . . . . . . . . . . . .  48
LANTUS U-100 INSULIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
lapatinib . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  22
larin 1.5/30 (21) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
larin 1/20 (21) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
larin 24 fe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
larin fe 1.5/30 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
larin fe 1/20 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
latanoprost. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
LAYOLIS FE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
LEENA 28. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
leflunomide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
LENALIDOMIDE ORAL CAPSULE 2.5 MG, 20 MG. . . . . . . .  23
lenalidomide oral capsule 10 mg, 15 mg, 25 mg, 5 mg . . . . .  23
LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1),
4 MG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LENVIMA ORAL CAPSULE 12 MG/DAY (4 MG X 3),
18 MG/DAY (10 MG X 1‑4 MG X2), 24 MG/DAY
(10 MG X 2‑4 MG X 1). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LENVIMA ORAL CAPSULE 14 MG/DAY(10 MG X
1‑4 MG X 1), 20 MG/DAY (10 MG X 2), 8 MG/DAY
(4 MG X 2). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
lessina. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
letrozole . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
leucovorin calcium injection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
leucovorin calcium oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
LEUKERAN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
leuprolide (3 month) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
leuprolide subcutaneous kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
levalbuterol hcl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
LEVALBUTEROL TARTRATE . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
LEVEMIR FLEXPEN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
LEVEMIR U-100 INSULIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
March 2024

PAGE

levetiracetam in nacl (iso-os) intravenous piggyback
1,000 mg/100 ml, 1,500 mg/100 ml, 500 mg/100 ml. . . . . . . .  28
levetiracetam intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
levetiracetam oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
levobunolol ophthalmic (eye) drops 0.5%. . . . . . . . . . . . . . . . . .  60
levocarnitine oral solution 100 mg/ml . . . . . . . . . . . . . . . . . . . . .  45
LEVOCARNITINE ORAL TABLET . . . . . . . . . . . . . . . . . . . . . . . .  45
levocarnitine (with sugar). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
levocetirizine oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
levocetirizine oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
levofloxacin in d5w . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
levofloxacin oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
levofloxacin oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
levonest (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
levonorgestrel-ethinyl estrad . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
levonorg-eth estrad triphasic . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
levora-28. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
levothyroxine oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
LEVOXYL ORAL TABLET 100 MCG, 112 MCG,
125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG,
25 MCG, 50 MCG, 75 MCG, 88 MCG. . . . . . . . . . . . . . . . . . . . .  50
LEXIVA ORAL SUSPENSION. . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
LIBTAYO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
lidocaine hcl injection solution. . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
lidocaine hcl laryngotracheal . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
lidocaine hcl mucous membrane jelly in applicator. . . . . . . . .  43
lidocaine hcl mucous membrane solution 2%. . . . . . . . . . . . . .  43
lidocaine hcl mucous membrane solution 4% (40 mg/ml). . .  42
lidocaine (pf) injection solution. . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
LIDOCAINE (PF) INTRAVENOUS SOLUTION . . . . . . . . . . . .  38
lidocaine (pf) intravenous syringe. . . . . . . . . . . . . . . . . . . . . . . . .  38
lidocaine-prilocaine topical cream. . . . . . . . . . . . . . . . . . . . . . . . .  42
lidocaine topical adhesive patch,medicated 5%. . . . . . . . . . . .  42
lidocaine topical ointment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
lidocaine viscous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
lincomycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
LINEZOLID-0.9% SODIUM CHLORIDE. . . . . . . . . . . . . . . . . . .  17
linezolid in dextrose 5%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
linezolid oral suspension for reconstitution . . . . . . . . . . . . . . . .  17
linezolid oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
84

Covered Drugs Index
DRUG

PAGE

DRUG

LINZESS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
liothyronine oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
lisinopril. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
lisinopril-hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
lithium carbonate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
lithium citrate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
l norgest/e.estradiol-e.estrad . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
lojaimiess. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
LOKELMA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
LONSURF ORAL TABLET 15‑6.14 MG . . . . . . . . . . . . . . . . . . .  23
LONSURF ORAL TABLET 20‑8.19 MG . . . . . . . . . . . . . . . . . . .  23
loperamide oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
lopinavir-ritonavir oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
lopinavir-ritonavir oral tablet 100‑25 mg . . . . . . . . . . . . . . . . . . .  14
lopinavir-ritonavir oral tablet 200‑50 mg . . . . . . . . . . . . . . . . . . .  14
LOQTORZI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
lorazepam injection solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
lorazepam injection syringe 2 mg/ml . . . . . . . . . . . . . . . . . . . . . .  35
lorazepam intensol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
lorazepam oral concentrate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
lorazepam oral syringe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
lorazepam oral tablet 0.5 mg, 1 mg . . . . . . . . . . . . . . . . . . . . . . .  35
lorazepam oral tablet 2 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
LORBRENA ORAL TABLET 25 MG. . . . . . . . . . . . . . . . . . . . . . .  23
LORBRENA ORAL TABLET 100 MG. . . . . . . . . . . . . . . . . . . . . .  23
loryna (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
losartan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
losartan-hydrochlorothiazide oral tablet 50‑12.5 mg. . . . . . . .  39
losartan-hydrochlorothiazide oral tablet
100‑12.5 mg, 100‑25 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
LOTEMAX OPHTHALMIC (EYE) OINTMENT . . . . . . . . . . . . .  61
LOTEMAX SM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
loteprednol etabonate ophthalmic (eye) drops,gel. . . . . . . . . .  61
loteprednol etabonate ophthalmic (eye)
drops,suspension 0.5%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
lovastatin oral tablet 10 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
lovastatin oral tablet 20 mg, 40 mg. . . . . . . . . . . . . . . . . . . . . . . .  41
low-ogestrel (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
loxapine succinate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
lo-zumandimine (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
March 2024

PAGE

ludent fluoride oral tablet,chewable 1 mg
(2.2 mg sod. fluoride) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
LUMAKRAS ORAL TABLET 120 MG . . . . . . . . . . . . . . . . . . . . .  23
LUMAKRAS ORAL TABLET 320 MG . . . . . . . . . . . . . . . . . . . . .  23
LUMIGAN OPHTHALMIC (EYE) DROPS 0.01%. . . . . . . . . . .  60
LUMIZYME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
LUNSUMIO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LUPRON DEPOT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LUPRON DEPOT (3 MONTH). . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LUPRON DEPOT (4 MONTH). . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LUPRON DEPOT (6 MONTH). . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LUPRON DEPOT-PED (3 MONTH)
INTRAMUSCULAR SYRINGE KIT 11.25 MG. . . . . . . . . . . . . .  23
LUPRON DEPOT-PED (3 MONTH)
INTRAMUSCULAR SYRINGE KIT 30 MG. . . . . . . . . . . . . . . . .  23
LUPRON DEPOT-PED INTRAMUSCULAR KIT . . . . . . . . . . .  23
LUPRON DEPOT-PED INTRAMUSCULAR
SYRINGE KIT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
lurasidone oral tablet 80 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg . . . . . . .  35
lutera (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
LYNPARZA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LYSODREN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LYTGOBI ORAL TABLET 4 MG. . . . . . . . . . . . . . . . . . . . . . . . . . .  23
LYTGOBI ORAL TABLET 4 MG (4X 4 MG TB). . . . . . . . . . . . .  23
LYTGOBI ORAL TABLET 4 MG (5X 4 MG TB). . . . . . . . . . . . .  23
LYUMJEV KWIKPEN U-100 INSULIN. . . . . . . . . . . . . . . . . . . . .  48
LYUMJEV KWIKPEN U-200 INSULIN. . . . . . . . . . . . . . . . . . . . .  48
LYUMJEV U-100 INSULIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
lyza. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57

M
magnesium sulfate in d5w intravenous
piggyback 1 gram/100 ml . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
magnesium sulfate injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
magnesium sulfate in water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
malathion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
maraviroc oral tablet 150 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
maraviroc oral tablet 300 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
MARGENZA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
85

Covered Drugs Index
DRUG

PAGE

DRUG

marlissa (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
MARPLAN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
MATULANE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
matzim la . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
MAVYRET ORAL PELLETS IN PACKET. . . . . . . . . . . . . . . . . .  14
MAVYRET ORAL TABLET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
meclizine oral tablet 12.5 mg, 25 mg. . . . . . . . . . . . . . . . . . . . . .  51
MEDROL ORAL TABLET 2 MG. . . . . . . . . . . . . . . . . . . . . . . . . . .  46
medroxyprogesterone intramuscular. . . . . . . . . . . . . . . . . . . . . .  57
medroxyprogesterone oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
mefloquine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
megestrol oral suspension 400 mg/10 ml (10 ml),
400 mg/10 ml (40 mg/ml), 800 mg/20 ml (20 ml). . . . . . . . . . .  23
megestrol oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
MEKINIST ORAL RECON SOLN . . . . . . . . . . . . . . . . . . . . . . . . .  23
MEKINIST ORAL TABLET 0.5 MG. . . . . . . . . . . . . . . . . . . . . . . .  23
MEKINIST ORAL TABLET 2 MG. . . . . . . . . . . . . . . . . . . . . . . . . .  23
MEKTOVI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
meloxicam oral tablet 7.5 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
meloxicam oral tablet 15 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
melphalan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
melphalan hcl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
memantine oral capsule,sprinkle,er 24hr . . . . . . . . . . . . . . . . . .  30
memantine oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
memantine oral tablet 5 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
memantine oral tablet 10 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
MEMANTINE ORAL TABLETS, DOSE PACK. . . . . . . . . . . . . .  30
MENACTRA (PF) INTRAMUSCULAR SOLUTION. . . . . . . . .  53
MENQUADFI (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
MENVEO A-C-Y-W-135-DIP (PF). . . . . . . . . . . . . . . . . . . . . . . . .  54
mercaptopurine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
MEROPENEM-0.9% SODIUM CHLORIDE. . . . . . . . . . . . . . . .  17
meropenem intravenous recon soln 1 gram, 500 mg. . . . . . .  17
merzee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
mesalamine oral capsule,extended release 24hr. . . . . . . . . . .  51
mesalamine rectal enema. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
mesalamine with cleansing wipe. . . . . . . . . . . . . . . . . . . . . . . . . .  51
mesna. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
MESNEX ORAL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
metadate er. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
March 2024

PAGE

metformin oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
metformin oral tablet 1,000 mg . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
metformin oral tablet 500 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
metformin oral tablet 850 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
metformin oral tablet extended release 24hr 1,000 mg . . . . .  48
metformin oral tablet extended release 24 hr 500 mg . . . . . .  48
metformin oral tablet extended release 24hr 500 mg. . . . . . .  48
metformin oral tablet extended release 24 hr 750 mg . . . . . .  48
methadone injection solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
methadone oral solution 5 mg/5 ml . . . . . . . . . . . . . . . . . . . . . . .  31
methadone oral solution 10 mg/5 ml . . . . . . . . . . . . . . . . . . . . . .  31
methadone oral tablet 5 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
methadone oral tablet 10 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
methazolamide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
methenamine hippurate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
methimazole oral tablet 10 mg, 5 mg. . . . . . . . . . . . . . . . . . . . . .  47
methocarbamol oral tablet 500 mg, 750 mg . . . . . . . . . . . . . . .  31
methotrexate sodium injection. . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
methotrexate sodium oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
methotrexate sodium (pf). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  23
methoxsalen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
methsuximide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
methylphenidate hcl oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
methylphenidate hcl oral tablet extended release . . . . . . . . . .  35
methylphenidate hcl oral tablet extended release
24hr 18 mg, 18 mg (bx rating), 27 mg, 27 mg (bx rating),
36 mg, 36 mg (bx rating), 54 mg, 54 mg (bx rating) . . . . . . . .  35
methylpred dp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
methylprednisolone acetate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
methylprednisolone oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
methylprednisolone oral tablets,dose pack . . . . . . . . . . . . . . . .  46
methylprednisolone sodium succ injection
recon soln 125 mg, 40 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
methylprednisolone sodium succ intravenous . . . . . . . . . . . . .  46
metoclopramide hcl oral solution. . . . . . . . . . . . . . . . . . . . . . . . . .  51
metoclopramide hcl oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
metolazone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
metoprolol succinate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
metoprolol ta-hydrochlorothiaz . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
metoprolol tartrate oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
86

Covered Drugs Index
DRUG

PAGE

DRUG

METRO I.V.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
metronidazole in nacl (iso-os) . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
metronidazole oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
metronidazole topical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
metronidazole vaginal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
metyrosine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
mexiletine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
micafungin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
microgestin 1.5/30 (21) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
microgestin 1/20 (21) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
microgestin fe 1.5/30 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
microgestin fe 1/20 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
midodrine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
MIEBO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
migergot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
miglitol oral tablet 25 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
miglitol oral tablet 50 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
miglitol oral tablet 100 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
miglustat. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
mili . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
minocycline oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
minocycline oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
minoxidil oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
mirtazapine oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
mirtazapine oral tablet,disintegrating. . . . . . . . . . . . . . . . . . . . . .  35
misoprostol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
MITIGARE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
mitomycin intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
mitoxantrone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
M-M-R II (PF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
M-NATAL PLUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
modafinil oral tablet 100 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
modafinil oral tablet 200 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
moexipril. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
molindone oral tablet 5 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
molindone oral tablet 10 mg, 25 mg. . . . . . . . . . . . . . . . . . . . . . .  35
mometasone nasal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
mometasone topical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
mondoxyne nl oral capsule 100 mg. . . . . . . . . . . . . . . . . . . . . . .  19
MONJUVI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
March 2024

PAGE

mono-linyah. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
montelukast oral granules in packet. . . . . . . . . . . . . . . . . . . . . . .  62
montelukast oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
montelukast oral tablet,chewable. . . . . . . . . . . . . . . . . . . . . . . . .  62
morphine concentrate oral solution . . . . . . . . . . . . . . . . . . . . . . .  31
MORPHINE INJECTION SOLUTION . . . . . . . . . . . . . . . . . . . . .  31
MORPHINE INJECTION SYRINGE 2 MG/ML, 4 MG/ML. . .  31
morphine intravenous solution
10 mg/ml, 4 mg/ml, 8 mg/ml. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
morphine oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
morphine oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
morphine oral tablet extended release . . . . . . . . . . . . . . . . . . . .  31
morphine (pf) injection solution 0.5 mg/ml, 1 mg/ml . . . . . . . .  31
MOUNJARO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
MOVANTIK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
moxifloxacin ophthalmic (eye) . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
moxifloxacin oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
MOXIFLOXACIN-SOD.ACE, SUL-WATER . . . . . . . . . . . . . . . .  18
moxifloxacin-sod.chloride(iso) . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
mupirocin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
mupirocin calcium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
mycophenolate mofetil (hcl) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
mycophenolate mofetil oral capsule. . . . . . . . . . . . . . . . . . . . . . .  24
mycophenolate mofetil oral suspension for reconstitution. . .  24
mycophenolate mofetil oral tablet. . . . . . . . . . . . . . . . . . . . . . . . .  24
mycophenolate sodium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
MYLOTARG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
MYRBETRIQ ORAL TABLET EXTENDED
RELEASE 24 HR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63

N
nabumetone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
nadolol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
NAFCILLIN IN DEXTROSE ISO-OSM . . . . . . . . . . . . . . . . . . . .  18
nafcillin injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
nafcillin intravenous recon soln 2 gram. . . . . . . . . . . . . . . . . . . .  18
naftifine topical cream. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
naftifine topical gel 2%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
NAFTIN TOPICAL GEL 2% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
NAGLAZYME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
87

Covered Drugs Index
DRUG

PAGE

DRUG

naloxone injection solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
naloxone injection syringe 1 mg/ml . . . . . . . . . . . . . . . . . . . . . . .  32
naloxone nasal. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
naltrexone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
NAMZARIC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
naproxen oral suspension. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
naproxen oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
naproxen oral tablet,delayed release (dr/ec). . . . . . . . . . . . . . .  32
naproxen sodium oral tablet 275 mg, 550 mg. . . . . . . . . . . . . .  32
naratriptan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
NATACYN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
nateglinide oral tablet 60 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
nateglinide oral tablet 120 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . .  48
NATPARA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
NAYZILAM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
nebivolol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
necon 0.5/35 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
nefazodone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
nelarabine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
neomycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
neomycin-bacitracin-poly-hc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
neomycin-bacitracin-polymyxin. . . . . . . . . . . . . . . . . . . . . . . . . . .  59
neomycin-polymyxin b-dexameth. . . . . . . . . . . . . . . . . . . . . . . . .  60
neomycin-polymyxin b gu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
neomycin-polymyxin-gramicidin . . . . . . . . . . . . . . . . . . . . . . . . . .  59
neomycin-polymyxin-hc ophthalmic (eye) . . . . . . . . . . . . . . . . .  60
neomycin-polymyxin-hc otic (ear). . . . . . . . . . . . . . . . . . . . . . . . .  46
NERLYNX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
nevirapine oral suspension. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
nevirapine oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
nevirapine oral tablet extended release 24 hr 100 mg. . . . . .  14
nevirapine oral tablet extended release 24 hr 400 mg. . . . . .  14
NEXLETOL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
NEXLIZET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
niacin oral tablet 500 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
niacin oral tablet extended release 24 hr . . . . . . . . . . . . . . . . . .  41
niacor. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
nicardipine intravenous solution . . . . . . . . . . . . . . . . . . . . . . . . . .  39
nicardipine oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
NICOTROL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
March 2024

PAGE

NICOTROL NS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
nifedipine oral tablet extended release. . . . . . . . . . . . . . . . . . . .  39
nifedipine oral tablet extended release 24hr . . . . . . . . . . . . . . .  39
nikki (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
nilutamide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
nimodipine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
NINLARO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
NIPENT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
nisoldipine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
nitazoxanide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
nitisinone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
nitrofurantoin macrocrystal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
nitrofurantoin monohyd/m-cryst. . . . . . . . . . . . . . . . . . . . . . . . . . .  19
nitroglycerin intravenous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
nitroglycerin sublingual. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
nitroglycerin transdermal patch 24 hour . . . . . . . . . . . . . . . . . . .  41
nitroglycerin translingual . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
NIVESTYM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
NORA-BE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
noreth-ethinyl estradiol-iron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
norethindrone acetate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
norethindrone ac-eth estradiol oral tablet
0.5‑2.5 mg-mcg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
norethindrone ac-eth estradiol oral tablet
1‑20 mg-mcg, 1.5‑30 mg-mcg . . . . . . . . . . . . . . . . . . . . . . . . . . . .  58
norethindrone (contraceptive) . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
norethindrone-e.estradiol-iron oral capsule. . . . . . . . . . . . . . . .  58
norethindrone-e.estradiol-iron oral tablet . . . . . . . . . . . . . . . . . .  59
NORETHINDRONE-E.ESTRADIOL-IRON
ORAL TABLET, CHEWABLE . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
norgestimate-ethinyl estradiol . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
nortrel 0.5/35 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
nortrel 1/35 (21) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
nortrel 1/35 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
nortrel 7/7/7 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
nortriptyline oral capsule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
nortriptyline oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
NORVIR ORAL POWDER IN PACKET. . . . . . . . . . . . . . . . . . . .  14
NUBEQA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
NUCALA SUBCUTANEOUS AUTO-INJECTOR. . . . . . . . . . . .  62
88

Covered Drugs Index
DRUG

PAGE

DRUG

NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML. . . . .  62
NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML . . . . . . .  62
NUEDEXTA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
NULOJIX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
NUPLAZID. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
NURTEC ODT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
NUZYRA INTRAVENOUS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
NUZYRA ORAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
nyamyc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
nylia 1/35 (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
nylia 7/7/7 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
nymyo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
nystatin oral suspension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
nystatin oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
nystatin topical cream. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
nystatin topical ointment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
nystatin topical powder. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
nystatin-triamcinolone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
nystop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
NYVEPRIA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52

olanzapine oral tablet 15 mg, 20 mg . . . . . . . . . . . . . . . . . . . . . .  36
olanzapine oral tablet,disintegrating 10 mg, 5 mg. . . . . . . . . .  36
olanzapine oral tablet,disintegrating 15 mg, 20 mg. . . . . . . . .  36
olmesartan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
olmesartan-amlodipin-hcthiazid. . . . . . . . . . . . . . . . . . . . . . . . . . .  39
olmesartan-hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . .  39
olopatadine ophthalmic (eye) drops 0.1% . . . . . . . . . . . . . . . . .  60
omega-3 acid ethyl esters. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
omeprazole oral capsule,delayed release(dr/ec). . . . . . . . . . .  52
OMNIPOD 5 G6 INTRO KIT (GEN 5) . . . . . . . . . . . . . . . . . . . . .  48
OMNIPOD 5 G6 PODS (GEN 5). . . . . . . . . . . . . . . . . . . . . . . . . .  48
OMNIPOD CLASSIC PODS (GEN 3) . . . . . . . . . . . . . . . . . . . . .  48
OMNIPOD DASH INTRO KIT (GEN 4). . . . . . . . . . . . . . . . . . . .  48
OMNIPOD DASH PODS (GEN 4) . . . . . . . . . . . . . . . . . . . . . . . .  49
OMNIPOD GO PODS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
OMNIPOD GO PODS 10 UNITS/DAY. . . . . . . . . . . . . . . . . . . . .  49
OMNIPOD GO PODS 15 UNITS/DAY. . . . . . . . . . . . . . . . . . . . .  49
OMNIPOD GO PODS 20 UNITS/DAY. . . . . . . . . . . . . . . . . . . . .  49
OMNIPOD GO PODS 25 UNITS/DAY. . . . . . . . . . . . . . . . . . . . .  49
OMNIPOD GO PODS 30 UNITS/DAY. . . . . . . . . . . . . . . . . . . . .  49
OMNIPOD GO PODS 40 UNITS/DAY. . . . . . . . . . . . . . . . . . . . .  49
ONCASPAR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
ondansetron. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
ondansetron hcl intravenous . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
ondansetron hcl oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
ondansetron hcl oral tablet 4 mg, 8 mg. . . . . . . . . . . . . . . . . . . .  51
ondansetron hcl (pf) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
ONGENTYS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
ONIVYDE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
ONUREG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
OPDIVO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
OPDUALAG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
OPSUMIT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
oralone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
ORBACTIV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
ORENCIA CLICKJECT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML. . . .  56
ORENCIA SUBCUTANEOUS SYRINGE 87.5 MG/0.7 ML. .  56
ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML . . . . . .  56
ORENITRAM MONTH 1 TITRATION KT . . . . . . . . . . . . . . . . . .  39

O
OCALIVA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  51
OCELLA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
OCREVUS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
OCTAGAM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
octreotide acetate injection solution 1,000 mcg/ml,
100 mcg/ml, 200 mcg/ml, 50 mcg/ml. . . . . . . . . . . . . . . . . . . . . .  24
octreotide acetate injection solution 500 mcg/ml. . . . . . . . . . .  24
octreotide acetate injection syringe . . . . . . . . . . . . . . . . . . . . . . .  24
ODEFSEY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
ODOMZO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
OFEV. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
ofloxacin ophthalmic (eye) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
ofloxacin otic (ear). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
OJJAARA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
olanzapine-fluoxetine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
olanzapine intramuscular. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  35
olanzapine oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg. . . . . . . .  35
March 2024

PAGE

89

Covered Drugs Index
DRUG

PAGE

DRUG

ORENITRAM MONTH 2 TITRATION KT . . . . . . . . . . . . . . . . . .  39
ORENITRAM MONTH 3 TITRATION KT . . . . . . . . . . . . . . . . . .  39
ORENITRAM ORAL TABLET EXTENDED RELEASE
0.25 MG, 1 MG, 2.5 MG, 5 MG. . . . . . . . . . . . . . . . . . . . . . . . . . .  39
ORENITRAM ORAL TABLET EXTENDED RELEASE
0.125 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
ORGOVYX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
ORKAMBI ORAL GRANULES IN PACKET. . . . . . . . . . . . . . . .  62
ORKAMBI ORAL TABLET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
ORSERDU. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
oseltamivir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
OTEZLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
OTEZLA STARTER ORAL TABLETS, DOSE PACK
10 MG (4)-20 MG (4)-30 MG (47). . . . . . . . . . . . . . . . . . . . . . . . .  56
oxacillin injection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
oxaliplatin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
oxaprozin oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
oxazepam. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
oxcarbazepine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
OXERVATE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
oxybutynin chloride oral syrup. . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
oxybutynin chloride oral tablet 5 mg. . . . . . . . . . . . . . . . . . . . . . .  63
oxybutynin chloride oral tablet extended release 24hr. . . . . .  63
oxycodone-acetaminophen oral tablet 10‑325 mg,
2.5‑325 mg, 5‑325 mg, 7.5‑325 mg . . . . . . . . . . . . . . . . . . . . . . .  32
oxycodone oral concentrate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
oxycodone oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
oxycodone oral tablet 5 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg. . . . . . . .  31
oxymorphone oral tablet extended release 12 hr. . . . . . . . . . .  32
OZEMPIC SUBCUTANEOUS PEN INJECTOR
0.25 MG OR 0.5 MG (2 MG/3 ML), 1 MG/DOSE
(4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML). . . . . . . . . . . . . . . . . . . 49

paliperidone oral tablet extended release
24hr 1.5 mg, 9 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
paliperidone oral tablet extended release
24hr 3 mg, 6 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
palonosetron intravenous solution 0.25 mg/5 ml . . . . . . . . . . .  51
pamidronate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
PANRETIN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
pantoprazole oral tablet,delayed release (dr/ec) . . . . . . . . . . .  52
paricalcitol oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
paromomycin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
paroxetine hcl oral suspension . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
paroxetine hcl oral tablet 10 mg . . . . . . . . . . . . . . . . . . . . . . . . . .  36
paroxetine hcl oral tablet 20 mg, 40 mg . . . . . . . . . . . . . . . . . . .  36
paroxetine hcl oral tablet 30 mg . . . . . . . . . . . . . . . . . . . . . . . . . .  36
paroxetine hcl oral tablet extended release 24 hr . . . . . . . . . .  36
PAXLOVID ORAL TABLETS, DOSE PACK
150‑100 MG*. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
PAXLOVID ORAL TABLETS, DOSE PACK
300 MG (150 MG X 2)-100 MG*. . . . . . . . . . . . . . . . . . . . . . . . . .  14
pazopanib. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
PEDIARIX (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
PEDVAX HIB (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
peg 3350-electrolytes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
PEGASYS SUBCUTANEOUS SOLUTION . . . . . . . . . . . . . . . .  53
PEGASYS SUBCUTANEOUS SYRINGE . . . . . . . . . . . . . . . . .  53
peg-electrolyte soln. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
PEMAZYRE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
pemetrexed disodium intravenous recon soln. . . . . . . . . . . . . .  24
penciclovir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
penicillamine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
penicillin g potassium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
penicillin v potassium oral recon soln . . . . . . . . . . . . . . . . . . . . .  18
penicillin v potassium oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . .  18
PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2". . . . .  54
PENTACEL (PF) INTRAMUSCULAR KIT
15LF-48MCG-62DU -10 MCG/0.5ML . . . . . . . . . . . . . . . . . . . . .  54
pentamidine inhalation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
pentamidine injection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
PENTIPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
pentoxifylline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
PERFOROMIST. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62

P
pacerone oral tablet 100 mg, 400 mg . . . . . . . . . . . . . . . . . . . . .  38
pacerone oral tablet 200 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
paclitaxel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
PACLITAXEL PROTEIN-BOUND . . . . . . . . . . . . . . . . . . . . . . . . .  24
PADCEV. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
March 2024

PAGE

90

Covered Drugs Index
DRUG

PAGE

DRUG

PERIKABIVEN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
perindopril erbumine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
periogard . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
PERJETA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
permethrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
perphenazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
perphenazine-amitriptyline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
PERSERIS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
pfizerpen-g. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
phenelzine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
phenobarbital oral elixir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
phenobarbital oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
phenobarbital sodium injection solution . . . . . . . . . . . . . . . . . . .  28
phenoxybenzamine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
phenytoin oral suspension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
phenytoin oral tablet,chewable . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
phenytoin sodium extended . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
phenytoin sodium intravenous solution. . . . . . . . . . . . . . . . . . . .  28
PHESGO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
philith. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
PIFELTRO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
pilocarpine hcl ophthalmic (eye) drops 1%, 2%, 4%. . . . . . . .  60
pilocarpine hcl oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
pimecrolimus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
pimozide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
pimtrea (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
pindolol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
pioglitazone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
pioglitazone-metformin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
piperacillin-tazobactam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
PIQRAY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
pirfenidone oral tablet 267 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
pirfenidone oral tablet 534 mg, 801 mg. . . . . . . . . . . . . . . . . . . .  62
pitavastatin calcium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
plenamine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
PLERIXAFOR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
PNV-DHA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
PNV-OMEGA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
PNV-SELECT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
podofilox topical solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
March 2024

PAGE

POLIVY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
polycin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
polymyxin b sulfate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
polymyxin b sulf-trimethoprim . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
POMALYST. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
portia 28 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
PORTRAZZA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
posaconazole oral tablet,delayed release (dr/ec) . . . . . . . . . .  13
POTASSIUM CHLORID-D5‑0.45%NACL. . . . . . . . . . . . . . . . . .  63
potassium chloride-0.45% nacl . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
POTASSIUM CHLORIDE-D5‑0.2%NACL
INTRAVENOUS PARENTERAL SOLUTION 20 MEQ/L . . . .  64
POTASSIUM CHLORIDE-D5‑0.9%NACL . . . . . . . . . . . . . . . . .  64
POTASSIUM CHLORIDE IN 0.9%NACL
INTRAVENOUS PARENTERAL SOLUTION
20 MEQ/L, 40 MEQ/L. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
potassium chloride in 5% dex intravenous
parenteral solution 10 meq/l. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
POTASSIUM CHLORIDE IN 5% DEX INTRAVENOUS
PARENTERAL SOLUTION 20 MEQ/L . . . . . . . . . . . . . . . . . . . .  64
POTASSIUM CHLORIDE IN LR-D5 INTRAVENOUS
PARENTERAL SOLUTION 20 MEQ/L . . . . . . . . . . . . . . . . . . . .  64
potassium chloride intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . .  64
potassium chloride in water intravenous piggyback 10
meq/100 ml, 10 meq/50 ml, 20 meq/100 ml,
20 meq/50 ml, 40 meq/100 ml. . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
potassium chloride oral capsule, extended release. . . . . . . . .  64
potassium chloride oral liquid. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
potassium chloride oral packet . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
potassium chloride oral tablet,er particles/crystals . . . . . . . . .  64
potassium chloride oral tablet extended release . . . . . . . . . . .  64
potassium citrate oral tablet extended release. . . . . . . . . . . . .  63
POTELIGEO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
pramipexole oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
pramipexole oral tablet extended release 24 hr. . . . . . . . . . . .  29
prasugrel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
pravastatin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
praziquantel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
prazosin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
PREDNISOLONE ACETATE . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
prednisolone oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
91

Covered Drugs Index
DRUG

PAGE

DRUG

prednisolone sodium phosphate ophthalmic (eye) . . . . . . . . .  61
prednisolone sodium phosphate oral solution
15 mg/5 ml (3 mg/ml), 15 mg/5 ml (5 ml),
25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml). . . . . . .  47
prednisone intensol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
prednisone oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
prednisone oral tablet 1 mg, 10 mg, 2.5 mg,
20 mg, 5 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
prednisone oral tablet 50 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
prednisone oral tablets,dose pack . . . . . . . . . . . . . . . . . . . . . . . .  47
pregabalin oral capsule 100 mg, 150 mg,
25 mg, 50 mg, 75 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
pregabalin oral capsule 200 mg . . . . . . . . . . . . . . . . . . . . . . . . . .  28
pregabalin oral capsule 225 mg, 300 mg. . . . . . . . . . . . . . . . . .  28
pregabalin oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
PREHEVBRIO (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
PREMARIN INJECTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
PREMARIN ORAL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
PREMARIN VAGINAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
PREMASOL 10%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
PREMPRO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
PRENATAL PLUS (CALCIUM CARB). . . . . . . . . . . . . . . . . . . . .  65
PRENATAL VITAMIN PLUS LOW IRON. . . . . . . . . . . . . . . . . . .  65
prevalite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
PREVYMIS ORAL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
PREZCOBIX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
PREZISTA ORAL SUSPENSION . . . . . . . . . . . . . . . . . . . . . . . . .  14
PREZISTA ORAL TABLET 75 MG . . . . . . . . . . . . . . . . . . . . . . . .  14
PREZISTA ORAL TABLET 150 MG. . . . . . . . . . . . . . . . . . . . . . .  14
PRIFTIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
primaquine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
primidone oral tablet 125 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
primidone oral tablet 250 mg, 50 mg. . . . . . . . . . . . . . . . . . . . . .  28
PRIORIX (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
PR NATAL 400 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
PR NATAL 400 EC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
PR NATAL 430 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
PR NATAL 430 EC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
probenecid. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
probenecid-colchicine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
March 2024

PAGE

prochlorperazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
prochlorperazine edisylate injection solution
10 mg/2 ml (5 mg/ml) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
prochlorperazine maleate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
PROCRIT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
procto-med hc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
proctosol hc topical. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
proctozone-hc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
progesterone micronized. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
PROGRAF INTRAVENOUS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
PROGRAF ORAL GRANULES IN PACKET . . . . . . . . . . . . . . .  24
PROLASTIN-C INTRAVENOUS RECON SOLN . . . . . . . . . . .  45
PROLASTIN-C INTRAVENOUS SOLUTION . . . . . . . . . . . . . .  45
PROLIA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
PROMACTA ORAL POWDER IN PACKET 12.5 MG . . . . . . .  40
PROMACTA ORAL POWDER IN PACKET 25 MG. . . . . . . . .  40
PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG . . . . .  40
PROMACTA ORAL TABLET 75 MG. . . . . . . . . . . . . . . . . . . . . . .  40
promethazine oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61
promethazine rectal suppository 12.5 mg, 25 mg . . . . . . . . . .  61
promethegan rectal suppository 25 mg, 50 mg . . . . . . . . . . . .  61
propafenone oral capsule,extended release 12 hr . . . . . . . . .  38
propafenone oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
propranolol oral capsule,extended release 24 hr. . . . . . . . . . .  39
propranolol oral solution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
propranolol oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
propylthiouracil. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  47
PROQUAD (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
PROSOL 20%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
protriptyline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
PULMICORT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
PULMOZYME. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
PURIXAN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
pyrazinamide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
pyridostigmine bromide oral syrup . . . . . . . . . . . . . . . . . . . . . . . .  31
pyridostigmine bromide oral tablet 60 mg. . . . . . . . . . . . . . . . . .  31
pyridostigmine bromide oral tablet extended release. . . . . . .  31
pyrimethamine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17

92

Covered Drugs Index
DRUG

PAGE

DRUG

Q

repaglinide oral tablet 0.5 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
repaglinide oral tablet 1 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
repaglinide oral tablet 2 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
REPATHA PUSHTRONEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
REPATHA SURECLICK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
REPATHA SYRINGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
RETACRIT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
RETEVMO ORAL CAPSULE 40 MG. . . . . . . . . . . . . . . . . . . . . .  24
RETEVMO ORAL CAPSULE 80 MG. . . . . . . . . . . . . . . . . . . . . .  24
RETROVIR INTRAVENOUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  14
REVLIMID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
REXULTI ORAL TABLET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
REYATAZ ORAL POWDER IN PACKET. . . . . . . . . . . . . . . . . . . 15
REZLIDHIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
REZUROCK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
RHOPRESSA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
ribavirin oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
ribavirin oral tablet 200 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
RIDAURA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
rifabutin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
rifampin intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
rifampin oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
riluzole. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
rimantadine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
RINGER'S INTRAVENOUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
RINGER'S IRRIGATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
RINVOQ ORAL TABLET EXTENDED RELEASE
24 HR 15 MG, 30 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
RINVOQ ORAL TABLET EXTENDED RELEASE
24 HR 45 MG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
risedronate oral tablet 5 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
risedronate oral tablet 30 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
risedronate oral tablet 35 mg, 35 mg (12 pack),
35 mg (4 pack) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
risedronate oral tablet 150 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
RISPERDAL CONSTA INTRAMUSCULAR
SUSPENSION, EXTENDED REL RECON
12.5 MG/2 ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
RISPERDAL CONSTA INTRAMUSCULAR
SUSPENSION, EXTENDED REL RECON
25 MG/2 ML, 37.5 MG/2 ML, 50 MG/2 ML. . . . . . . . . . . . . . . . .  36

QINLOCK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  24
QUADRACEL (PF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
quetiapine oral tablet 100 mg, 25 mg, 50 mg . . . . . . . . . . . . . .  36
quetiapine oral tablet 150 mg, 200 mg . . . . . . . . . . . . . . . . . . . .  36
quetiapine oral tablet 300 mg, 400 mg . . . . . . . . . . . . . . . . . . . .  36
quetiapine oral tablet extended release
24 hr 150 mg, 200 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
quetiapine oral tablet extended release
24 hr 300 mg, 400 mg, 50 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
QUILLICHEW ER ORAL TABLET, CHEW, IR-ER.
BIPHASIC24HR 20 MG, 30 MG . . . . . . . . . . . . . . . . . . . . . . . . . .  36
QUILLICHEW ER ORAL TABLET, CHEW, IR-ER.
BIPHASIC24HR 40 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
quinapril . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
quinapril-hydrochlorothiazide. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
quinidine sulfate oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
quinine sulfate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17

R
RABAVERT (PF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
RADICAVA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
raloxifene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
ramelteon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
ramipril . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
ranolazine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
rasagiline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
RAYALDEE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
REBIF REBIDOSE SUBCUTANEOUS PEN
INJECTOR 8.8MCG/0.2ML-22 MCG/0.5ML (6). . . . . . . . . . . .  53
REBIF REBIDOSE SUBCUTANEOUS PEN
INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML. . . . . . . . . . . . . . 53
REBIF TITRATION PACK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
REBIF (WITH ALBUMIN). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
reclipsen (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
RECOMBIVAX HB (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
RECTIV. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
REGRANEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
REMICADE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
RENACIDIN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
March 2024

PAGE

93

Covered Drugs Index
DRUG

PAGE

DRUG

risperidone oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
risperidone oral syringe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
risperidone oral tablet 0.25 mg, 0.5 mg, 4 mg. . . . . . . . . . . . . .  36
risperidone oral tablet 1 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
risperidone oral tablet 2 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
risperidone oral tablet 3 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
risperidone oral tablet,disintegrating
0.25 mg, 0.5 mg, 4 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
risperidone oral tablet,disintegrating 1 mg. . . . . . . . . . . . . . . . .  36
risperidone oral tablet,disintegrating 2 mg. . . . . . . . . . . . . . . . .  36
risperidone oral tablet,disintegrating 3 mg. . . . . . . . . . . . . . . . .  36
ritonavir. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
rivastigmine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
rivastigmine tartrate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
RIVELSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
rizatriptan oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
rizatriptan oral tablet,disintegrating. . . . . . . . . . . . . . . . . . . . . . . .  29
ROCKLATAN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
roflumilast. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
romidepsin intravenous recon soln. . . . . . . . . . . . . . . . . . . . . . . .  25
ROMIDEPSIN INTRAVENOUS SOLUTION . . . . . . . . . . . . . . .  25
ropinirole oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
rosuvastatin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
ROTARIX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
ROTATEQ VACCINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
roweepra oral tablet 500 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
ROZLYTREK ORAL CAPSULE 100 MG . . . . . . . . . . . . . . . . . .  25
ROZLYTREK ORAL CAPSULE 200 MG . . . . . . . . . . . . . . . . . .  25
ROZLYTREK ORAL PELLETS IN PACKET . . . . . . . . . . . . . . .  25
RUBRACA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
rufinamide oral suspension. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
rufinamide oral tablet 200 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
rufinamide oral tablet 400 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
RUKOBIA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
RUXIENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
RYALTRIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
RYBELSUS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
RYBREVANT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
RYDAPT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
RYLAZE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
March 2024

PAGE

RYTARY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29

S
sajazir . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
salsalate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
SANCUSO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
SANDIMMUNE ORAL SOLUTION. . . . . . . . . . . . . . . . . . . . . . . .  25
SANDOSTATIN LAR DEPOT INTRAMUSCULAR
SUSPENSION, EXTENDED REL RECON . . . . . . . . . . . . . . . .  25
SANTYL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
sapropterin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
SARCLISA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
SCEMBLIX ORAL TABLET 20 MG. . . . . . . . . . . . . . . . . . . . . . . .  25
SCEMBLIX ORAL TABLET 40 MG. . . . . . . . . . . . . . . . . . . . . . . .  25
scopolamine base . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
SECUADO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
selegiline hcl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
selenium sulfide topical lotion . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
SELZENTRY ORAL SOLUTION. . . . . . . . . . . . . . . . . . . . . . . . . .  15
SELZENTRY ORAL TABLET 25 MG. . . . . . . . . . . . . . . . . . . . . .  15
SELZENTRY ORAL TABLET 75 MG. . . . . . . . . . . . . . . . . . . . . .  15
SE-NATAL-19 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
SE-NATAL 19 CHEWABLE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
SEREVENT DISKUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
sertraline oral concentrate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
sertraline oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
setlakin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
sevelamer carbonate oral powder in packet 0.8 gram . . . . . .  45
sevelamer carbonate oral powder in packet 2.4 gram . . . . . .  45
sevelamer carbonate oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . .  45
sharobel . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
SHINGRIX (PF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
SIGNIFOR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
sildenafil . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
sildenafil (pulm.hypertension) oral tablet . . . . . . . . . . . . . . . . . .  62
SILVER SULFADIAZINE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
SIMBRINZA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
simliya (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
simpesse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
94

Covered Drugs Index
DRUG

PAGE

DRUG

SIMULECT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
simvastatin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
sirolimus oral solution. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
sirolimus oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
SIRTURO ORAL TABLET 20 MG. . . . . . . . . . . . . . . . . . . . . . . . .  17
SIRTURO ORAL TABLET 100 MG. . . . . . . . . . . . . . . . . . . . . . . .  17
SIVEXTRO INTRAVENOUS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
SIVEXTRO ORAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
SKYRIZI INTRAVENOUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
SKYRIZI SUBCUTANEOUS PEN INJECTOR . . . . . . . . . . . . .  42
SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML. . . . . . . .  42
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR
180 MG/1.2 ML (150 MG/ML) . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR
360 MG/2.4 ML (150 MG/ML) . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
sodium bicarbonate intravenous syringe . . . . . . . . . . . . . . . . . .  64
sodium chloride 0.9% intravenous parenteral solution. . . . . .  45
SODIUM CHLORIDE 0.9% INTRAVENOUS
PIGGYBACK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  45
sodium chloride 0.45% intravenous. . . . . . . . . . . . . . . . . . . . . . .  64
sodium chloride 3% hypertonic . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
SODIUM CHLORIDE 5% HYPERTONIC. . . . . . . . . . . . . . . . . .  64
sodium chloride intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
SODIUM CHLORIDE IRRIGATION . . . . . . . . . . . . . . . . . . . . . . .  46
sodium fluoride 5000 dry mouth . . . . . . . . . . . . . . . . . . . . . . . . . .  46
sodium fluoride 5000 plus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
sodium fluoride-pot nitrate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
sodium oxybate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  36
sodium phenylbutyrate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
sodium polystyrene sulfonate oral powder. . . . . . . . . . . . . . . . .  46
SODIUM, POTASSIUM, MAG SULFATES. . . . . . . . . . . . . . . . .  52
solifenacin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
SOLIQUA 100/33. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
SOLTAMOX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
SOLU-CORTEF ACT-O-VIAL (PF). . . . . . . . . . . . . . . . . . . . . . . .  47
SOMATULINE DEPOT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
SOMAVERT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
sorafenib. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
sorine oral tablet 120 mg, 160 mg, 80 mg . . . . . . . . . . . . . . . . .  38
sotalol af. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
March 2024

PAGE

sotalol oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
SOTYLIZE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  38
spironolactone oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
spironolacton-hydrochlorothiaz . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
SPRAVATO NASAL SPRAY, NON-AEROSOL
56 MG (28 MG X 2). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
SPRAVATO NASAL SPRAY, NON-AEROSOL
84 MG (28 MG X 3). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
sprintec (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
SPRITAM. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
SPRYCEL ORAL TABLET 20 MG, 70 MG. . . . . . . . . . . . . . . . .  25
SPRYCEL ORAL TABLET 100 MG, 140 MG,
50 MG, 80 MG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
sps (with sorbitol) oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
sronyx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
SSD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
STAMARIL (PF) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
STELARA SUBCUTANEOUS SOLUTION. . . . . . . . . . . . . . . . .  42
STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML. . . .  42
STELARA SUBCUTANEOUS SYRINGE 90 MG/ML . . . . . . .  42
STIVARGA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
streptomycin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
STRIBILD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
subvenite . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
subvenite starter (blue) kit. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
subvenite starter (green) kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
subvenite starter (orange) kit. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
SUCRAID. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
sucralfate oral suspension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
sucralfate oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
SUFLAVE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
sulfacetamide-prednisolone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
sulfacetamide sodium (acne). . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
sulfacetamide sodium ophthalmic (eye) drops . . . . . . . . . . . . .  60
sulfadiazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  18
sulfamethoxazole-trimethoprim intravenous . . . . . . . . . . . . . . .  18
sulfamethoxazole-trimethoprim oral suspension . . . . . . . . . . .  18
sulfamethoxazole-trimethoprim oral tablet. . . . . . . . . . . . . . . . .  18
sulfasalazine oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52

95

Covered Drugs Index
DRUG

PAGE

DRUG

SULFASALAZINE ORAL TABLET, DELAYED
RELEASE (DR/EC). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
sulindac. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
sumatriptan nasal spray,non-aerosol 5 mg/actuation. . . . . . .  29
sumatriptan nasal spray,non-aerosol 20 mg/actuation. . . . . .  29
sumatriptan succinate oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
SUMATRIPTAN SUCCINATE SUBCUTANEOUS
CARTRIDGE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
sumatriptan succinate subcutaneous pen injector. . . . . . . . . .  29
sumatriptan succinate subcutaneous solution . . . . . . . . . . . . .  29
sunitinib malate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
SUNLENCA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
SUTAB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
syeda. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
SYMDEKO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
SYMLINPEN 60. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
SYMLINPEN 120. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
SYMPAZAN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
SYMTUZA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
SYNAREL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
SYNJARDY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC
24HR 10‑1,000 MG, 12.5‑1,000 MG, 5‑1,000 MG. . . . . . . . . .  49
SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC
24HR 25‑1,000 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
SYNTHROID. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50

TALVEY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TALZENNA ORAL CAPSULE 0.1 MG, 0.35 MG,
0.5 MG, 0.75 MG, 1 MG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TALZENNA ORAL CAPSULE 0.25 MG. . . . . . . . . . . . . . . . . . . .  25
tamoxifen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
tamsulosin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
tarina 24 fe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
tarina fe 1‑20 eq (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
TARON-C DHA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
TASIGNA ORAL CAPSULE 50 MG . . . . . . . . . . . . . . . . . . . . . . .  25
TASIGNA ORAL CAPSULE 150 MG, 200 MG . . . . . . . . . . . . .  25
tasimelteon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
taysofy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
tazarotene topical cream. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
tazarotene topical gel. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
tazicef . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
taztia xt. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
TAZVERIK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TDVAX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
TECENTRIQ. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TECHLITE INSULIN SYRINGE SYRINGE 1 ML
30 GAUGE X 1/2", 1 ML 31 GAUGE X 15/64",
1 ML 31 GAUGE X 5/16. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
TECHLITE INSULN SYR(HALF UNIT) SYRINGE
0.3 ML 31 GAUGE X 15/64", 0.3 ML 31 GAUGE X
5/16", 0.5 ML 30 GAUGE X 1/2", 0.5 ML 31 GAUGE X
15/64", 0.5 ML 31 GAUGE X 5/16". . . . . . . . . . . . . . . . . . . . . . . .  54
TECHLITE PEN NEEDLE NEEDLE 29 GAUGE X 1/2",
31 GAUGE X 3/16", 31 GAUGE X 5/16",
32 GAUGE X 1/4", 32 GAUGE X 5/32". . . . . . . . . . . . . . . . . . . .  55
TECVAYLI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TEFLARO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  16
telmisartan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39
telmisartan-amlodipine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
telmisartan-hydrochlorothiazid. . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
temazepam oral capsule 15 mg, 30 mg . . . . . . . . . . . . . . . . . . .  37
TEMODAR INTRAVENOUS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
temsirolimus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TENIVAC (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
tenofovir disoproxil fumarate . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
TEPMETKO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25

T
TABLOID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TABRECTA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
tacrolimus oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
tacrolimus topical. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
tadalafil (pulm. hypertension). . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
TADLIQ. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
TAFINLAR ORAL CAPSULE . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TAFINLAR ORAL TABLET FOR SUSPENSION . . . . . . . . . . .  25
TAGRISSO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TALICIA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
TALTZ AUTOINJECTOR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
TALTZ SYRINGE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
March 2024

PAGE

96

Covered Drugs Index
DRUG

PAGE

DRUG

terazosin oral capsule 1 mg, 2 mg, 5 mg . . . . . . . . . . . . . . . . . .  40
terazosin oral capsule 10 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
terbinafine hcl oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
terbutaline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
terconazole vaginal cream 0.4%. . . . . . . . . . . . . . . . . . . . . . . . . .  57
TERCONAZOLE VAGINAL CREAM 0.8%. . . . . . . . . . . . . . . . .  57
terconazole vaginal suppository . . . . . . . . . . . . . . . . . . . . . . . . . .  57
testosterone cypionate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
testosterone enanthate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
testosterone transdermal gel . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
testosterone transdermal gel in metered-dose
pump 12.5 mg/ 1.25 gram (1%). . . . . . . . . . . . . . . . . . . . . . . . . . .  50
testosterone transdermal gel in packet 1%
(25 mg/2.5gram), 1% (50 mg/5 gram). . . . . . . . . . . . . . . . . . . . .  50
TETANUS, DIPHTHERIA TOX PED(PF) . . . . . . . . . . . . . . . . . .  54
tetrabenazine oral tablet 12.5 mg. . . . . . . . . . . . . . . . . . . . . . . . .  30
tetrabenazine oral tablet 25 mg. . . . . . . . . . . . . . . . . . . . . . . . . . .  30
tetracycline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
THALOMID ORAL CAPSULE 100 MG, 50 MG . . . . . . . . . . . .  25
THALOMID ORAL CAPSULE 150 MG, 200 MG . . . . . . . . . . .  25
theo-24 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
theophylline oral tablet extended release 12 hr . . . . . . . . . . . .  62
theophylline oral tablet extended release 24 hr . . . . . . . . . . . .  62
thioridazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
thiotepa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
thiothixene. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
tiadylt er . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
tiagabine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
TIBSOVO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  25
TICE BCG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
TICOVAC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
tigecycline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
tilia fe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
timolol maleate ophthalmic (eye) drops . . . . . . . . . . . . . . . . . . .  60
timolol maleate ophthalmic (eye) gel forming solution . . . . . .  60
timolol maleate oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
TIS-U-SOL PENTALYTE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
TIVDAK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
TIVICAY ORAL TABLET 10 MG . . . . . . . . . . . . . . . . . . . . . . . . . .  15
TIVICAY ORAL TABLET 25 MG, 50 MG. . . . . . . . . . . . . . . . . . .  15
March 2024

PAGE

TIVICAY PD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
tizanidine oral capsule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
tizanidine oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  31
TOBRADEX ST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
tobramycin-dexamethasone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
tobramycin in 0.225% nacl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
tobramycin ophthalmic (eye) . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
tobramycin sulfate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
TOBREX OPHTHALMIC (EYE) OINTMENT. . . . . . . . . . . . . . .  60
tolcapone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
tolterodine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
TOLVAPTAN ORAL TABLET 15 MG . . . . . . . . . . . . . . . . . . . . . .  50
tolvaptan oral tablet 30 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
topiramate oral capsule,extended release 24hr. . . . . . . . . . . .  28
topiramate oral capsule, sprinkle . . . . . . . . . . . . . . . . . . . . . . . . .  28
topiramate oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
topotecan intravenous recon soln. . . . . . . . . . . . . . . . . . . . . . . . .  26
topotecan intravenous solution . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
toremifene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
torsemide oral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
TOUJEO MAX U-300 SOLOSTAR. . . . . . . . . . . . . . . . . . . . . . . .  49
TOUJEO SOLOSTAR U-300 INSULIN. . . . . . . . . . . . . . . . . . . .  49
TPN ELECTROLYTES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
TRADJENTA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
tramadol-acetaminophen. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
tramadol oral tablet 50 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
trandolapril. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
tranexamic acid oral . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
tranylcypromine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
TRAVASOL 10% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
travoprost. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
TRAZIMERA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
trazodone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
TREANDA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
TRECATOR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
TRELEGY ELLIPTA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  62
TRELSTAR INTRAMUSCULAR SUSPENSION FOR
RECONSTITUTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
TRESIBA FLEXTOUCH U-100 . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
TRESIBA FLEXTOUCH U-200 . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
97

Covered Drugs Index
DRUG

PAGE

DRUG

TRESIBA U-100 INSULIN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
tretinoin (antineoplastic). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
tretinoin microspheres . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
tretinoin topical cream . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
tretinoin topical gel 0.01%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
tretinoin topical gel 0.025%, 0.05% . . . . . . . . . . . . . . . . . . . . . . .  43
triamcinolone acetonide dental . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
triamcinolone acetonide injection suspension 40 mg/ml . . . .  47
triamcinolone acetonide topical cream 0.1%. . . . . . . . . . . . . . .  44
triamcinolone acetonide topical cream 0.025%, 0.5% . . . . . .  44
triamcinolone acetonide topical lotion . . . . . . . . . . . . . . . . . . . . .  44
triamcinolone acetonide topical ointment. . . . . . . . . . . . . . . . . .  44
triamterene-hydrochlorothiazid . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
triderm topical cream 0.1%. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  44
trientine oral capsule 250 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
tri-estarylla. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
trifluoperazine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
trifluridine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
trihexyphenidyl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC
24HR 10‑5-1,000 MG, 25‑5-1,000 MG . . . . . . . . . . . . . . . . . . . .  49
TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC
24HR 12.5‑2.5‑1,000 MG, 5‑2.5‑1,000 MG. . . . . . . . . . . . . . . .  49
TRIKAFTA ORAL GRANULES IN PACKET,
SEQUENTIAL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
TRIKAFTA ORAL TABLETS, SEQUENTIAL . . . . . . . . . . . . . . .  63
tri-legest fe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
tri-linyah . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
tri-lo-estarylla. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
tri-lo-marzia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
tri-lo-mili . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
tri-lo-sprintec. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
trimethoprim. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
tri-mili. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
trimipramine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
TRINATAL RX 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
TRINTELLIX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
tri-nymyo. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
TRIPTODUR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
tri-sprintec (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
March 2024

PAGE

TRIUMEQ. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
TRIUMEQ PD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
trivora (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
tri-vylibra. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
tri-vylibra lo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
TRIZIVIR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
TRODELVY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
TROGARZO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
TROPHAMINE 10% . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  64
TRUEPLUS INSULIN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
TRUEPLUS PEN NEEDLE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
TRULANCE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
TRULICITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
TRUMENBA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
TRUQAP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
TUKYSA ORAL TABLET 50 MG. . . . . . . . . . . . . . . . . . . . . . . . . .  26
TUKYSA ORAL TABLET 150 MG. . . . . . . . . . . . . . . . . . . . . . . . .  26
TURALIO ORAL CAPSULE 125 MG. . . . . . . . . . . . . . . . . . . . . .  26
turqoz (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
TWINRIX (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
TYBLUME . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
TYBOST. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
tydemy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
TYMLOS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55
TYPHIM VI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
TYSABRI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
TYVASO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
TYVASO INSTITUTIONAL START KIT. . . . . . . . . . . . . . . . . . . .  63
TYVASO REFILL KIT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
TYVASO STARTER KIT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
TZIELD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46

U
UNIFINE PENTIPS MAXFLOW. . . . . . . . . . . . . . . . . . . . . . . . . . .  49
UNIFINE PENTIPS NEEDLE 29 GAUGE X 1/2",
31 GAUGE X 1/4", 31 GAUGE X 3/16", 31 GAUGE X
5/16", 32 GAUGE X 1/4", 32 GAUGE X 5/32",
33 GAUGE X 5/32" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
UNIFINE PENTIPS PLUS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
UNIFINE PENTIPS PLUS MAXFLOW . . . . . . . . . . . . . . . . . . . .  49
98

Covered Drugs Index
DRUG

PAGE

DRUG

UNITHROID. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
UNITUXIN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
ursodiol oral capsule 300 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
ursodiol oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  52
UZEDY SUBCUTANEOUS SUSPENSION,
EXTENDED REL SYRING 50 MG/0.14 ML. . . . . . . . . . . . . . . .  37
UZEDY SUBCUTANEOUS SUSPENSION,
EXTENDED REL SYRING 75 MG/0.21 ML. . . . . . . . . . . . . . . .  37
UZEDY SUBCUTANEOUS SUSPENSION,
EXTENDED REL SYRING 100 MG/0.28 ML. . . . . . . . . . . . . . . 37
UZEDY SUBCUTANEOUS SUSPENSION,
EXTENDED REL SYRING 125 MG/0.35 ML. . . . . . . . . . . . . . . 37
UZEDY SUBCUTANEOUS SUSPENSION,
EXTENDED REL SYRING 150 MG/0.42 ML. . . . . . . . . . . . . . . 37
UZEDY SUBCUTANEOUS SUSPENSION,
EXTENDED REL SYRING 200 MG/0.56 ML. . . . . . . . . . . . . . . 37
UZEDY SUBCUTANEOUS SUSPENSION,
EXTENDED REL SYRING 250 MG/0.7 ML. . . . . . . . . . . . . . . .  37

VANCOMYCIN INTRAVENOUS RECON SOLN
1.5 GRAM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
vancomycin oral capsule 125 mg . . . . . . . . . . . . . . . . . . . . . . . . .  18
vancomycin oral capsule 250 mg . . . . . . . . . . . . . . . . . . . . . . . . .  18
vancomycin oral recon soln 25 mg/ml. . . . . . . . . . . . . . . . . . . . .  18
VANDAZOLE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57
VANFLYTA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
VAQTA (PF) INTRAMUSCULAR SUSPENSION
25 UNIT/0.5 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
VAQTA (PF) INTRAMUSCULAR SUSPENSION
50 UNIT/ML. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
VAQTA (PF) INTRAMUSCULAR SYRINGE
25 UNIT/0.5 ML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
VAQTA (PF) INTRAMUSCULAR SYRINGE 50 UNIT/ML . . .  54
varenicline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
VARIVAX (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
VARIZIG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
VECTIBIX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
VEKLURY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
velivet triphasic regimen (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
VELPHORO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
VELTASSA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
VEMLIDY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
VENCLEXTA ORAL TABLET 10 MG. . . . . . . . . . . . . . . . . . . . . .  26
VENCLEXTA ORAL TABLET 50 MG. . . . . . . . . . . . . . . . . . . . . .  26
VENCLEXTA ORAL TABLET 100 MG. . . . . . . . . . . . . . . . . . . . .  26
VENCLEXTA STARTING PACK . . . . . . . . . . . . . . . . . . . . . . . . . .  26
venlafaxine oral capsule,extended release 24hr 75 mg. . . . .  37
venlafaxine oral capsule,extended release
24hr 150 mg, 37.5 mg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
venlafaxine oral tablet 50 mg, 75 mg. . . . . . . . . . . . . . . . . . . . . .  37
venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg. . . . . . . . . . . .  37
VENTAVIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
VENTOLIN HFA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
verapamil intravenous solution . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
verapamil oral capsule, 24 hr er pellet ct . . . . . . . . . . . . . . . . . .  40
verapamil oral capsule,ext rel. pellets
24 hr 120 mg, 180 mg, 240 mg. . . . . . . . . . . . . . . . . . . . . . . . . . .  40
VERAPAMIL ORAL CAPSULE, EXT REL.
PELLETS 24 HR 360 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
verapamil oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40

V
valacyclovir oral tablet 1 gram. . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
valacyclovir oral tablet 500 mg . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
VALCHLOR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
valganciclovir oral recon soln. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
valganciclovir oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
valproate sodium. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
valproic acid. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
valproic acid (as sodium salt). . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
valrubicin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
valsartan-hydrochlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
valsartan oral tablet 160 mg, 40 mg, 80 mg . . . . . . . . . . . . . . .  40
valsartan oral tablet 320 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
VALTOCO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  28
VANCOMYCIN-DILUENT COMBO NO.1. . . . . . . . . . . . . . . . . .  18
VANCOMYCIN IN 0.9% SODIUM CHL INTRAVENOUS
PIGGYBACK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
VANCOMYCIN IN DEXTROSE 5% INTRAVENOUS
PIGGYBACK. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
vancomycin injection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  17
vancomycin intravenous recon soln 1,000 mg,
1.25 gram, 10 gram, 5 gram, 500 mg, 750 mg. . . . . . . . . . . . .  17
March 2024

PAGE

99

Covered Drugs Index
DRUG

PAGE

DRUG

W

verapamil oral tablet extended release. . . . . . . . . . . . . . . . . . . .  40
VERQUVO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
VERSACLOZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
VERZENIO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
vestura (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
V-GO 20 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
V-GO 30 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
V-GO 40 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49
vienva . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
vigabatrin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
vigadrone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
vilazodone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
vinblastine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
vincristine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
vinorelbine. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
viorele (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
VIRACEPT ORAL TABLET 250 MG. . . . . . . . . . . . . . . . . . . . . . .  15
VIRACEPT ORAL TABLET 625 MG. . . . . . . . . . . . . . . . . . . . . . .  15
VIREAD ORAL POWDER. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG. . . . . . . .  15
VITRAKVI ORAL CAPSULE 25 MG. . . . . . . . . . . . . . . . . . . . . . .  26
VITRAKVI ORAL CAPSULE 100 MG . . . . . . . . . . . . . . . . . . . . .  26
VITRAKVI ORAL SOLUTION. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
VIVITROL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
VIZIMPRO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
volnea (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
VONJO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
voriconazole intravenous. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
voriconazole oral suspension for reconstitution . . . . . . . . . . . .  13
voriconazole oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  13
VOSEVI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
VOTRIENT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
VRAYLAR ORAL CAPSULE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
VRAYLAR ORAL CAPSULE, DOSE PACK. . . . . . . . . . . . . . . .  37
VUMERITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
vyfemla (28). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
vylibra . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
VYNDAMAX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
VYNDAQEL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  41
VYXEOS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
March 2024

PAGE

warfarin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
WATER FOR IRRIGATION, STERILE. . . . . . . . . . . . . . . . . . . . .  46
WELIREG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
wera (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
WESCAP-PN DHA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
WESNATE DHA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
westab plus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
WESTGEL DHA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  65
wixela inhub. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
wymzya fe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59

X
XALKORI ORAL CAPSULE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
XALKORI ORAL PELLET 20 MG, 50 MG . . . . . . . . . . . . . . . . .  26
XALKORI ORAL PELLET 150 MG. . . . . . . . . . . . . . . . . . . . . . . .  26
XARELTO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  40
XARELTO DVT-PE TREAT 30D START. . . . . . . . . . . . . . . . . . .  41
XATMEP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
XCOPRI MAINTENANCE PACK ORAL TABLET
250MG/DAY(150 MG X1‑100MG X1), 350 MG/DAY
(200 MG X1‑150MG X1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
XCOPRI ORAL TABLET 50 MG . . . . . . . . . . . . . . . . . . . . . . . . . .  29
XCOPRI ORAL TABLET 100 MG. . . . . . . . . . . . . . . . . . . . . . . . .  29
XCOPRI ORAL TABLET 150 MG, 200 MG . . . . . . . . . . . . . . . .  29
XCOPRI TITRATION PACK ORAL TABLETS, DOSE
PACK 12.5 MG (14)- 25 MG (14) . . . . . . . . . . . . . . . . . . . . . . . . .  29
XCOPRI TITRATION PACK ORAL TABLETS, DOSE
PACK 150 MG (14)- 200 MG (14), 50 MG (14)100 MG (14) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
XDEMVY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
XELJANZ ORAL SOLUTION. . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
XELJANZ ORAL TABLET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
XELJANZ XR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  56
XERMELO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
XGEVA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  19
XHANCE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
XIAFLEX. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  46
XIFAXAN ORAL TABLET 550 MG . . . . . . . . . . . . . . . . . . . . . . . .  18
100

Covered Drugs Index
DRUG

PAGE

DRUG

XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC
24HR 2.5‑1,000 MG, 5‑1,000 MG, 5‑500 MG. . . . . . . . . . . . . .  49
XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC
24HR 10‑1,000 MG, 10‑500 MG. . . . . . . . . . . . . . . . . . . . . . . . . .  49
XIIDRA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
XOFLUZA ORAL TABLET 40 MG, 80 MG. . . . . . . . . . . . . . . . .  15
XOLAIR SUBCUTANEOUS RECON SOLN . . . . . . . . . . . . . . .  63
XOLAIR SUBCUTANEOUS SYRINGE 75 MG/0.5 ML. . . . . .  63
XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML. . . . . . . .  63
XOSPATA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2),
40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK
(40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE
WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2),
80MG TWICE WEEK (160 MG/WEEK). . . . . . . . . . . . . . . . . . . . 26
XTANDI ORAL CAPSULE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
XTANDI ORAL TABLET 40 MG. . . . . . . . . . . . . . . . . . . . . . . . . . .  26
XTANDI ORAL TABLET 80 MG. . . . . . . . . . . . . . . . . . . . . . . . . . .  26
XULTOPHY 100/3.6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  49

105,000 UNIT, 3,000‑10,000 -14,000-UNIT, 40,000‑
126,000- 168,000 UNIT, 5,000‑17,000- 24,000 UNIT. . . . . . .  52
ZEPOSIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  30
ZEPOSIA STARTER KIT (28-DAY) . . . . . . . . . . . . . . . . . . . . . . .  30
ZEPOSIA STARTER PACK (7-DAY) . . . . . . . . . . . . . . . . . . . . . .  30
ZEPZELCA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
zidovudine oral capsule. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
zidovudine oral syrup . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
zidovudine oral tablet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  15
ZIEXTENZO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
ZIMHI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  32
ziprasidone hcl oral capsule 20 mg . . . . . . . . . . . . . . . . . . . . . . .  37
ziprasidone hcl oral capsule 40 mg . . . . . . . . . . . . . . . . . . . . . . .  37
ziprasidone hcl oral capsule 60 mg, 80 mg . . . . . . . . . . . . . . . .  37
ziprasidone mesylate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
ZIRABEV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ZIRGAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  60
ZOLADEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
zoledronic acid intravenous solution . . . . . . . . . . . . . . . . . . . . . .  50
zoledronic acid-mannitol-water intravenous piggyback
4 mg/100 ml. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50
ZOLEDRONIC ACID-MANNITOL-WATER
INTRAVENOUS PIGGYBACK 5 MG/100 ML . . . . . . . . . . . . . .  46
ZOLEDRONIC AC-MANNITOL-0.9NACL. . . . . . . . . . . . . . . . . .  50
ZOLINZA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
zolpidem oral tablet. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
ZONISADE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
zonisamide. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
ZOSYN IN DEXTROSE (ISO-OSM) . . . . . . . . . . . . . . . . . . . . . .  18
zovia 1‑35 (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
ZTALMY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  29
ZTLIDO. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42
ZUBSOLV SUBLINGUAL TABLET 0.7‑0.18 MG,
1.4‑0.36 MG, 11.4‑2.9 MG, 2.9‑0.71 MG, 5.7‑1.4 MG . . . . . .  32
ZUBSOLV SUBLINGUAL TABLET 8.6‑2.1 MG. . . . . . . . . . . . . 32
zumandimine (28) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  59
ZURZUVAE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
ZYDELIG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ZYKADIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ZYLET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  61

Y
YERVOY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  26
YF-VAX (PF). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  54
YONDELIS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
YUPELRI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
yuvafem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  57

Z
zafirlukast. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  63
zaleplon oral capsule 5 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
zaleplon oral capsule 10 mg. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
ZALTRAP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ZANOSAR. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ZARXIO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  53
ZEJULA ORAL CAPSULE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ZEJULA ORAL TABLET. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ZELBORAF . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
zenatane. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43
ZENPEP ORAL CAPSULE, DELAYED RELEASE
(DR/EC) 10,000‑32,000 -42,000 UNIT, 15,000‑47,000
-63,000 UNIT, 20,000‑63,000- 84,000 UNIT, 25,000‑79,000March 2024

PAGE

101

Covered Drugs Index
DRUG

PAGE

DRUG

ZYNLONTA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ZYNYZ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  27
ZYPREXA RELPREVV INTRAMUSCULAR
SUSPENSION FOR RECONSTITUTION
210 MG, 300 MG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  37
ZYPREXA RELPREVV INTRAMUSCULAR
SUSPENSION FOR RECONSTITUTION 405 MG . . . . . . . . .  37

March 2024

102

PAGE

1-800-668-3813 (TTY 711)
October 1 – March 31,
8 a.m. – 8 p.m. local time, 7 days a week.
April 1 – September 30,
Monday – Friday 8 a.m. – 8 p.m. local time.
CignaMedicare.com

Contract/PBP Numbers
H0439-003-001
H0439-003-002
H0439-006-000
H0439-007-000
H0439-008-000
H0439-009-000
H0439-010-000
H0439-011-000
H0439-013-000
H0672-001-000
H0672-003-000
H0672-004-000
H0672-005-000
H0672-006-000
H0672-007-000
H0672-008-000
H0672-011-000
H0672-013-000
H0672-014-000
H0672-016-000
H0672-017-000
H2108-022-000
H2108-036-000
H2108-040-000
H2108-042-001
H2108-042-002
H3949-030-000
H3949-031-000
H3949-032-000
H3949-034-000
H3949-035-000

H3949-045-000
H3949-046-000
H3949-047-000
H3949-048-000
H3949-049-000
H3949-050-000
H4407-027-000
H4407-028-000
H4407-030-001
H4407-030-002
H4407-030-003
H4513-026-000
H4513-030-000
H4513-036-000
H4513-037-000
H4513-038-000
H4513-049-001
H4513-049-002
H4513-049-003
H4513-049-004
H4513-049-005
H4513-050-000
H4513-051-000
H4513-052-000
H4513-059-000
H4513-061-001
H4513-061-002
H4513-061-003
H4513-061-004
H4513-061-005
H4513-064-000

H4513-068-001
H4513-068-002
H4513-068-003
H4513-073-000
H4513-074-000
H4513-083-001
H4513-083-002
H4513-083-003
H4513-083-004
H4513-083-005
H4513-083-006
H4513-083-007
H4513-084-000
H4513-085-000
H4513-086-000
H5410-018-000
H5410-024-000
H5410-026-000
H5410-027-000
H5410-028-000
H5410-029-000
H5410-030-000
H5410-037-000
H5410-039-000
H5410-040-000
H5410-041-000
H5410-043-000
H5410-044-000
H5410-048-000
H5410-050-000
H5410-051-000

H5410-052-000
H5410-053-000
H5410-054-000
H7020-004-000
H7020-006-000
H7020-008-000
H7020-009-000
H7389-001-000
H7389-002-000
H7389-003-000
H7389-004-000
H7389-008-000
H7389-011-000
H7787-001-000
H7849-001-000
H7849-002-000
H7849-003-000
H7849-006-000
H7849-013-000
H7849-014-000
H7849-015-000
H7849-017-000
H7849-018-000
H7849-020-000
H7849-021-000
H7849-022-000
H7849-023-000
H7849-024-000
H7849-026-000
H7849-027-000
H7849-029-000

H7849-030-000
H7849-031-000
H7849-033-000
H7849-034-000
H7849-037-000
H7849-038-000
H7849-039-000
H7849-041-000
H7849-042-000
H7849-044-000
H7849-045-000
H7849-047-000
H7849-048-000
H7849-050-000
H7849-051-000
H7849-052-000
H7849-054-000
H7849-055-000
H7849-056-000
H7849-057-000
H7849-058-000
H7849-059-000
H7849-060-000
H7849-064-001
H7849-064-002
H7849-064-003
H7849-064-004
H7849-065-000
H7849-066-000
H7849-067-000
H7849-068-000

H7849-070-000
H7849-071-000
H7849-076-000
H7849-077-000
H7849-080-000
H7849-081-000
H7849-082-000
H7849-083-000
H7849-084-000
H7849-085-000
H7849-087-000
H7849-088-000
H7849-101-000
H7849-102-001
H7849-102-002
H7849-102-003
H7849-102-004
H7849-103-000
H7849-104-000
H7849-105-000
H7849-106-000
H7849-107-000
H7849-108-000
H7849-109-000
H7849-110-000
H7849-111-000
H7849-112-001
H7849-112-002
H7849-113-001
H7849-113-002
H7849-113-003

H7849-113-004
H7849-114-000
H7849-115-000
H7849-116-000
H7849-117-001
H7849-117-002
H7849-118-000
H7849-119-000
H7849-120-000
H7849-121-000
H7849-123-000
H7849-124-001
H7849-124-002
H7849-125-000
H7849-127-000
H7849-128-000
H7849-129-000
H7849-130-000
H7849-131-000
H7849-132-000
H7849-133-001
H7849-133-002
H7849-133-003
H7849-134-001
H7849-134-002
H9460-001-000
H9725-008-000
H9725-010-000
H9725-011-000

This formulary was updated on 3/1/2024. For more recent information or other questions, please contact Cigna Healthcare Customer
Service, at 1-800-668-3813 (TTY users should call 711), October 1 – March 31, 8 a.m. – 8 p.m. local time, 7 days a week. From
April 1 – September 30, Monday – Friday 8 a.m. – 8 p.m. local time, or visit CignaMedicare.com. Cigna Healthcare products and services
are provided exclusively by or through operating subsidiaries of The Cigna Group. The Cigna names, logos, and marks, including THE
CIGNA GROUP and CIGNA HEALTHCARE are owned by Cigna Intellectual Property, Inc. © 2024 Cigna Healthcare.
March 2024
975467 c

